0001428336-19-000021.txt : 20190909 0001428336-19-000021.hdr.sgml : 20190909 20190909162202 ACCESSION NUMBER: 0001428336-19-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20190731 FILED AS OF DATE: 20190909 DATE AS OF CHANGE: 20190909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 191083283 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-2019x7x3110q.htm 10-Q Document
false--01-31Q2202000014283360.0500.1024.3663.640.100.1044.5344.5373.6182.3982.391250001050000.00010.00019000000009000000006244600070603000624460007060300022517000450940001936600061188000P5YP5Y0.1840000.00010.00011000000001000000000000P4YP4Y0.36530.35980.02680.02430.02520.02210P6Y3MP5Y2M1DP5Y1M2DP4Y11M12D 0001428336 2019-02-01 2019-07-31 0001428336 2019-08-30 0001428336 2019-07-31 0001428336 2019-01-31 0001428336 2018-02-01 2018-07-31 0001428336 2018-05-01 2018-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-05-01 2019-07-31 0001428336 2019-05-01 2019-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-02-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-05-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-05-01 2018-07-31 0001428336 us-gaap:ServiceMember 2018-05-01 2018-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-02-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-02-01 2018-07-31 0001428336 us-gaap:ServiceMember 2019-05-01 2019-07-31 0001428336 us-gaap:ServiceMember 2019-02-01 2019-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-05-01 2018-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-02-01 2018-07-31 0001428336 us-gaap:ServiceMember 2018-02-01 2018-07-31 0001428336 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2019-04-30 0001428336 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2018-07-31 0001428336 us-gaap:CommonStockMember 2018-02-01 2018-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-07-31 0001428336 us-gaap:CommonStockMember 2018-01-31 0001428336 us-gaap:RetainedEarningsMember 2018-04-30 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:RetainedEarningsMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001428336 us-gaap:CommonStockMember 2018-04-30 0001428336 us-gaap:CommonStockMember 2019-05-01 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-02-01 2018-07-31 0001428336 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-30 0001428336 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-05-01 2018-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0001428336 us-gaap:CommonStockMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-07-31 0001428336 us-gaap:CommonStockMember 2019-07-31 0001428336 us-gaap:CommonStockMember 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001428336 us-gaap:CommonStockMember 2018-05-01 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-02-01 2019-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-05-01 2018-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001428336 2018-04-30 0001428336 us-gaap:CommonStockMember 2019-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2018-01-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-05-01 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-02-01 2019-07-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-02-01 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-02-01 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-02-01 2018-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2018-02-01 2018-07-31 0001428336 hqy:WageWorksMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember 2019-02-01 2019-07-31 0001428336 hqy:FollowOnEquityOfferingMember 2019-07-12 0001428336 us-gaap:AccountingStandardsUpdate201602Member 2019-02-01 0001428336 srt:MaximumMember 2019-07-31 0001428336 hqy:FollowOnEquityOfferingMember 2019-07-12 2019-07-12 0001428336 srt:MaximumMember 2019-02-01 2019-07-31 0001428336 srt:MinimumMember 2019-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-07-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-07-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-07-31 0001428336 us-gaap:OtherIntangibleAssetsMember 2019-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-01-31 0001428336 us-gaap:OtherIntangibleAssetsMember 2019-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-05-01 2019-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-07-31 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-09-30 2015-09-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2015-09-30 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 2018-02-01 2019-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-05-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2018-05-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-02-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-05-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-05-01 2018-07-31 0001428336 us-gaap:RestrictedStockMember 2019-05-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-02-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-02-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-05-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2019-02-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-05-01 2018-07-31 0001428336 us-gaap:RestrictedStockMember 2018-05-01 2018-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-05-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-02-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-05-01 2018-07-31 0001428336 hqy:SalesandMarketingMember 2018-02-01 2018-07-31 0001428336 us-gaap:CostOfSalesMember 2019-02-01 2019-07-31 0001428336 hqy:SalesandMarketingMember 2019-05-01 2019-07-31 0001428336 us-gaap:CostOfSalesMember 2018-05-01 2018-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-05-01 2018-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-02-01 2019-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-05-01 2019-07-31 0001428336 hqy:SalesandMarketingMember 2018-05-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-02-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-05-01 2019-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2019-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-02-01 2018-07-31 0001428336 hqy:SalesandMarketingMember 2019-02-01 2019-07-31 0001428336 us-gaap:CostOfSalesMember 2018-02-01 2018-07-31 0001428336 us-gaap:CostOfSalesMember 2019-05-01 2019-07-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember 2018-02-01 2018-07-31 0001428336 srt:MinimumMember 2018-02-01 2018-07-31 0001428336 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 hqy:DebtCovenantPeriodOneMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 hqy:WageWorksMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 hqy:DebtInstrumentAmortizationPeriodFourMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2022-08-30 0001428336 hqy:DebtCovenantPeriodFourMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 hqy:DebtCovenantPeriodFourMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 hqy:DebtInstrumentAmortizationPeriodOneMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 hqy:DebtInstrumentAmortizationPeriodFiveMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2023-08-30 0001428336 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 hqy:DebtCovenantPeriodTwoMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 hqy:DebtCovenantPeriodThreeMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 hqy:DebtInstrumentAmortizationPeriodTwoMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2020-08-30 0001428336 hqy:DebtInstrumentAmortizationPeriodThreeMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2021-08-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
 
 
 
HEALTHEQUITY, INC.
 
 
 
(Exact name of registrant as specified in its charter)
Delaware
 
7389
 
52-2383166
(State or other jurisdiction of
incorporation or organization)
 
(Primary Standard Industrial
Classification Code Number)
 
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
HQY
The NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 
 
Emerging growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 30, 2019, there were 70,621,252 shares of the registrant's common stock outstanding.
 



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
 
 
Page
Part I. FINANCIAL INFORMATION
 
Item 1.
 
 
 
 
 
 
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
 
Item 1.
Item 1A.
Item 2.
Item 6.
 
 



-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)
July 31, 2019


January 31, 2019

 
(unaudited)

 
 
Assets



Current assets



Cash and cash equivalents
$
815,160


$
361,475

Accounts receivable, net of allowance for doubtful accounts as of July 31, 2019 and January 31, 2019 of $105 and $125, respectively
27,357


25,668

Other current assets
10,999


7,534

Total current assets
853,516


394,677

Investments
81,839

 
709

Property and equipment, net
9,873


8,223

Operating lease right-of-use assets
36,716

 

Intangible assets, net
88,768


79,666

Goodwill
4,651


4,651

Deferred tax asset
666


1,677

Other assets
22,311


20,413

Total assets
$
1,098,340


$
510,016

Liabilities and stockholders’ equity



Current liabilities



Accounts payable
$
2,740


$
3,520

Accrued compensation
11,055


16,981

Accrued liabilities
19,392


8,552

Operating lease liabilities
3,954

 

Total current liabilities
37,141


29,053

Operating lease liabilities, non-current
35,660

 

Deferred tax liability
7,773


916

Other long-term liabilities
735


2,968

Total liabilities
81,309


32,937

Commitments and contingencies (see note 6)



Stockholders’ equity



Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively



Common stock, $0.0001 par value, 900,000 shares authorized, 70,603 and 62,446 shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively
7


6

Additional paid-in capital
783,986


305,223

Accumulated earnings
233,038


171,850

Total stockholders’ equity
1,017,031


477,079

Total liabilities and stockholders’ equity
$
1,098,340


$
510,016

See accompanying notes to condensed consolidated financial statements.


-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (unaudited)

(in thousands, except per share data)
Three months ended July 31,
 

Six months ended July 31,
 
2019


2018


2019


2018

Revenue:



 
 
 
 
Service revenue
$
26,282

 
$
24,935

 
$
53,090

 
$
49,756

Custodial revenue
43,614

 
30,715

 
85,566

 
59,149

Interchange revenue
16,727

 
15,417

 
35,019

 
32,066

Total revenue
86,623

 
71,067

 
173,675

 
140,971

Cost of revenue:
 
 
 
 

 
 
Service costs
19,745

 
17,199

 
40,394

 
35,246

Custodial costs
4,209

 
3,502

 
8,332

 
6,941

Interchange costs
4,229

 
3,791

 
8,756

 
7,853

Total cost of revenue
28,183

 
24,492

 
57,482

 
50,040

Gross profit
58,440

 
46,575

 
116,193

 
90,931

Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
8,391

 
7,243

 
17,361

 
14,103

Technology and development
11,645

 
8,398

 
22,550

 
16,377

General and administrative
9,262

 
7,893

 
17,971

 
15,400

Amortization of acquired intangible assets
1,494

 
1,478

 
2,985

 
2,948

Merger integration
2,784

 

 
2,784

 

Total operating expenses
33,576

 
25,012

 
63,651

 
48,828

Income from operations
24,864

 
21,563

 
52,542

 
42,103

Other income (expense), net
(1,128
)
 
(75
)
 
22,472

 
(76
)
Income before income taxes
23,736

 
21,488

 
75,014

 
42,027

Income tax provision (benefit)
4,370

 
(1,029
)
 
13,826

 
(3,067
)
Net income and comprehensive income
$
19,366


$
22,517


$
61,188


$
45,094

Net income per share:



 
 
 
 
Basic
$
0.30

 
$
0.36

 
$
0.97

 
$
0.73

Diluted
$
0.30

 
$
0.36

 
$
0.94

 
$
0.72

Weighted-average number of shares used in computing net income per share:
 
 
 
 
 
 
 
Basic
64,220

 
61,880

 
63,289

 
61,531

Diluted
65,583

 
63,397

 
64,785

 
63,060

See accompanying notes to condensed consolidated financial statements.

-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)

(in thousands)
Three months ended July 31,
 
 
Six months ended July 31,
 
2019

 
2018

 
2019

 
2018

Total stockholders' equity, beginning balances
$
529,299

 
$
396,974

 
$
477,079

 
$
346,274

 
 
 
 
 
 
 
 
Common stock:
 
 
 
 
 
 
 
Beginning balance
6

 
6

 
6

 
6

Issuance of common stock upon exercise of stock options, and for restricted stock

 

 

 

Issuance of common stock
1

 

 
1

 

Ending balance
7

 
6

 
7

 
6

Additional paid-in capital:
 
 
 
 
 
 
 
Beginning balance
315,621

 
276,440

 
305,223

 
261,237

Issuance of common stock upon exercise of stock options, and for restricted stock
2,281

 
7,640

 
6,651

 
18,604

Other issuance of common stock
458,494

 

 
458,494

 

Stock-based compensation
7,590

 
5,488

 
13,618

 
9,727

Ending balance
783,986

 
289,568

 
783,986

 
289,568

Accumulated comprehensive loss:
 
 
 
 
 
 
 
Beginning balance

 

 

 
(269
)
Cumulative effect from adoption of ASU 2016-01

 

 

 
269

Ending balance

 

 

 

Accumulated earnings:
 
 
 
 
 
 
 
Beginning balance
213,672

 
120,528

 
171,850

 
85,300

Net income
19,366

 
22,517

 
61,188

 
45,094

Cumulative effect from adoption of ASC 606

 

 

 
13,007

Cumulative effect from adoption of ASU 2016-01

 

 

 
(356
)
Ending balance
$
233,038

 
$
143,045

 
$
233,038

 
$
143,045

 
 
 
 
 
 
 
 
Total stockholders' equity, ending balances
$
1,017,031

 
$
432,619

 
$
1,017,031

 
$
432,619

See accompanying notes to condensed consolidated financial statements.


-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)


Six months ended July 31,
 
(in thousands)
2019


2018

Cash flows from operating activities:



Net income
$
61,188


$
45,094

Adjustments to reconcile net income to net cash provided by operating activities:



Depreciation and amortization
9,722


8,916

Unrealized (gains) losses on marketable equity securities and other
(27,180
)

86

Deferred taxes
7,868


2,351

Stock-based compensation
13,618


9,727

Changes in operating assets and liabilities:





Accounts receivable
(1,689
)

(3,304
)
Other assets
(5,036
)

(6,921
)
Operating lease right-of-use assets
1,286

 

Accounts payable
(1,083
)

(837
)
Accrued compensation
(5,926
)

(2,826
)
Accrued liabilities and other current liabilities
4,942


56

Operating lease liabilities, non-current
(1,210
)
 

Other long-term liabilities
331


298

Net cash provided by operating activities
56,831


52,640

Cash flows from investing activities:



Purchases of intangible member assets
(1,736
)

(1,014
)
Purchases of marketable equity securities and other
(53,845
)

(368
)
Purchases of property and equipment
(3,492
)

(2,690
)
Purchases of software and capitalized software development costs
(9,518
)

(4,701
)
Net cash used in investing activities
(68,591
)

(8,773
)
Cash flows from financing activities:



Proceeds from follow-on equity offering, net of payments for offering costs
458,881

 

Proceeds from exercise of common stock options
6,564


18,469

Net cash provided by financing activities
465,445


18,469

Increase in cash and cash equivalents
453,685


62,336

Beginning cash and cash equivalents
361,475


199,472

Ending cash and cash equivalents
$
815,160


$
261,808

Supplemental cash flow data:
 
 
 
Interest expense paid in cash
$
101

 
$
101

Income taxes paid in cash, net of refunds received
9,119

 
554

Supplemental disclosures of non-cash investing and financing activities:



Purchases of property and equipment included in accounts payable or accrued liabilities at period end
$
3


$
14

Purchases of software and capitalized software development costs included in accounts payable or accrued liabilities at period end
487


175

Purchases of intangible member assets accrued during the period
6,500

 
181

Exercise of common stock options receivable
87


135

Follow-on equity offering costs accrued during the period
386

 

Debt issuance costs accrued during the period
345

 

See accompanying notes to condensed consolidated financial statements.

-6-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)



Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. The Company offers a full range of innovative solutions for managing health care accounts (Health Savings Accounts ("HSAs"), Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.
Merger with WageWorks, Inc.
On June 26, 2019, HealthEquity, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”) with WageWorks, Inc., a Delaware corporation (“WageWorks”), and a wholly owned subsidiary of HealthEquity, Inc. (“Merger Sub”), pursuant to which, on the terms and subject to the conditions therein, Merger Sub would merge with and into WageWorks (the “Merger”), with WageWorks surviving the Merger and becoming a wholly owned subsidiary of HealthEquity, Inc. On August 30, 2019, the Merger closed and HealthEquity, Inc. paid approximately $2.0 billion in cash to WageWorks stockholders.
The Merger is expected to give HealthEquity, Inc. access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and consumer-directed benefits ("CDBs"), including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, and HealthEquity Retirement Services, LLC (collectively referred to as the "Company").
As of July 31, 2019, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all unrealized gains on the investment were recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. The investment was valued at $81.1 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2019 and for the three and six months ended July 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report

-7-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 1. Summary of business and significant accounting policies (continued)

on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
For the three and six months ended July 31, 2019, the Company added a new expense line item (Merger integration) on the condensed consolidated statements of operations and comprehensive income, which includes professional fees and all other internal and external costs directly related to the integration activities as a result of the Merger.
Follow-on equity offering
On July 12, 2019, the Company closed a follow-on public offering of 7,762,500 shares of common stock at a public offering price of $61.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $458.5 million after deducting underwriting discounts and commissions of approximately $14.1 million and other offering expenses payable by the Company of approximately $0.9 million.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases and investments in equity securities, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019.
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space and data storage facilities with remaining lease terms of approximately 3 to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.

-8-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 1. Summary of business and significant accounting policies (continued)

Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in investments on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding charge through other income (expense), net in the condensed consolidated statements of operations and comprehensive income. See Note 3—Supplemental financial statement information for additional information.
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and six-month period ended July 31, 2019.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.

-9-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 1. Summary of business and significant accounting policies (continued)

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU allows the capitalization of implementation costs incurred in a hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
Note 2. Net income per share
The following table sets forth the computation of basic and diluted net income per share:
(in thousands, except per share data)
 
Three months ended July 31,
 
 
Six months ended July 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income
 
$
19,366

 
$
22,517

 
$
61,188

 
$
45,094

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Weighted-average dilutive effect of stock options and restricted stock units
 
1,363

 
1,517

 
1,496

 
1,529

Diluted weighted-average common shares outstanding
 
65,583

 
63,397

 
64,785

 
63,060

Net income per share:
 
 
 
 
 
 
 
 
Basic
 
$
0.30

 
$
0.36

 
$
0.97

 
$
0.73

Diluted
 
$
0.30

 
$
0.36

 
$
0.94

 
$
0.72


For the three months ended July 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options, restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
Note 3. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:
Property and equipment
Property and equipment consisted of the following as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
4,288

 
$
3,583

Furniture and fixtures
 
5,201

 
4,476

Computer equipment
 
11,279

 
9,242

Property and equipment, gross
 
20,768

 
17,301

Accumulated depreciation
 
(10,895
)
 
(9,078
)
Property and equipment, net
 
$
9,873

 
$
8,223


Depreciation expense for the three months ended July 31, 2019 and 2018 was $1.0 million and $0.8 million, respectively, and $1.8 million and $1.7 million for the six months ended July 31, 2019 and 2018, respectively.

-10-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 3. Supplemental financial statement information (continued)

Investments
Investments consisted of the following equity investments as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Marketable equity securities, at fair value
 
$
81,130

 
$

Non-marketable equity securities
 
500

 
500

Equity method investments
 
209

 
209

Total equity investments
 
$
81,839

 
$
709


Unrealized gain recognized during the six months ended July 31, 2019 for equity investments held as of July 31, 2019 was $27.3 million, which was attributable to an increase in fair value of WageWorks common stock. In connection with the closing of the Merger on August 30, 2019, the Company's investment in WageWorks common stock was canceled.
Other income (expense), net
Other income (expense), net, consisted of the following:
 
 
Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income, net
 
$
1,817

 
$
234

 
$
3,097

 
$
425

Unrealized gain on marketable equity securities
 
3,774

 

 
27,285

 

Acquisition costs
 
(6,596
)
 
(224
)
 
(7,780
)
 
(225
)
Other
 
(123
)
 
(85
)
 
(130
)
 
(276
)
Total other income (expense), net
 
$
(1,128
)
 
$
(75
)
 
$
22,472

 
$
(76
)

Note 4. Leases
The Company has entered into various non-cancelable operating lease agreements for office space and data storage facilities with remaining lease terms of approximately 3 to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Six months ended

(in thousands, except for term and percentages)
 
July 31, 2019

 
July 31, 2019

Operating lease expense
 
$
1,086

 
$
2,160

 
 
 
 
 
Weighted average remaining lease term
 
11.24 years

Weighted average discount rate
 
4.37
%


-11-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 4. Leases (continued)

Maturities of operating lease liabilities as of July 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
2,013

2021
 
4,105

2022
 
4,205

2023
 
4,233

2024
 
4,288

Thereafter
 
31,930

Total lease payments
 
50,774

Less imputed interest
 
(11,160
)
Present value of lease liabilities
 
$
39,614

 
 
 
Current
 
$
3,954

Non-current
 
35,660

Total lease liabilities
 
$
39,614


As of July 31, 2019, the Company had an additional operating lease for office space that has not yet commenced with undiscounted lease payments of $17.1 million. This operating lease will commence in fiscal year 2021 with a lease term of approximately 11 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Six months ended

(in thousands)
 
July 31, 2019

 
July 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
852

 
$
1,829

ROU assets obtained in exchange for new operating lease obligations
 
$

 
$
199


Note 5. Intangible assets and goodwill
Intangible assets
During the three months ended July 31, 2019, the Company acquired the right to act as custodian of a portfolio of HSA Members for $6.5 million, which is expected to be paid in October 2019 upon conversion of the accounts to the Company's proprietary platform. The cost was recorded in accrued liabilities on the condensed consolidated balance sheet and allocated to acquired intangible member assets as of July 31, 2019. The Company has determined the acquired intangible member assets to have a useful life of 15 years. The assets will be amortized using the straight-line amortization method, which has been determined appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.
During the three months ended July 31, 2019 and 2018, the Company capitalized software development costs of $4.0 million and $2.1 million, respectively, and $7.7 million and $4.2 million for the six months ended July 31, 2019 and 2018, respectively, related to significant enhancements and upgrades to its proprietary system.

-12-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 5. Intangible assets and goodwill (continued)


The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2019 and January 31, 2019:
(in thousands)

July 31, 2019


January 31, 2019

Amortized intangible assets:

 
 
 
Capitalized software development costs

$
48,410

 
$
40,583

Software

6,430

 
4,252

Other intangible assets

2,882

 
2,882

Acquired intangible member assets

92,084

 
85,110

Intangible assets, gross

149,806

 
132,827

Accumulated amortization

(61,038
)
 
(53,161
)
Intangible assets, net

$
88,768

 
$
79,666


During the three months ended July 31, 2019 and 2018, the Company expensed a total of $3.8 million and $3.4 million, respectively, and $7.7 million and $6.6 million for the six months ended July 31, 2019 and 2018, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
Amortization expense for the three months ended July 31, 2019 and 2018 was $4.0 million and $3.5 million, respectively, and $7.9 million and $7.2 million for the six months ended July 31, 2019 and 2018, respectively.
Goodwill
There were no changes to the goodwill carrying value during the three and six months ended July 31, 2019 and 2018.
Note 6. Commitments and contingencies
The Company’s principal commitments consist of operating lease obligations for office space and data storage facilities, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of January 31, 2019 are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended January 31, 2019, and except for the entry into the Merger Agreement with WageWorks, providing for the acquisition of WageWorks for approximately $2.0 billion in cash, did not change materially during the three and six months ended July 31, 2019.
Note 7. Indebtedness
On September 30, 2015, the Company entered into a credit facility (the "Prior Credit Agreement") that provided for a secured revolving credit facility in the aggregate principal amount of $100.0 million for a term of five years. No amounts were drawn under the Prior Credit Agreement as of July 31, 2019.
Borrowings under the Prior Credit Agreement bore interest equal to, at the Company's option, a) an adjusted LIBOR rate or b) a customary base rate, in each case with an applicable spread determined based on the Company's leverage ratio as of the most recent fiscal quarter. The applicable spread for borrowing under the Prior Credit Agreement ranged from 1.50% to 2.00% with respect to adjusted LIBOR rate borrowings and 0.50% to 1.00% with respect to customary base rate borrowings. The Company paid a commitment fee of 0.20% on the daily amount of the unused commitments under the Prior Credit Agreement in arrears at the end of each fiscal quarter.
The Company's material subsidiaries were required to guarantee the obligations of the Company under the Prior Credit Agreement. The obligations of the Company and the guarantors under the Prior Credit Agreement and the guarantees were secured by substantially all assets of the Company and the guarantors, subject to customary exclusions and exceptions.

Note 7. Indebtedness (continued)

-13-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

The Prior Credit Agreement required the Company to maintain a total leverage ratio of not more than 3.00 to 1.00 as of the end of each fiscal quarter and a minimum interest coverage ratio of at least 3.00 to 1.00 as of the end of each fiscal quarter. In addition, the Prior Credit Agreement included customary representations and warranties, affirmative and negative covenants, and events of default. The restrictive covenants included customary restrictions on the Company's ability to incur additional indebtedness; make investments, loans or advances; grant or incur liens on assets; engage in mergers, consolidations, liquidations or dissolutions; engage in transactions with affiliates; and make dividend payments. The Company was in compliance with these covenants as of July 31, 2019.
In connection with the closing of the Merger on August 30, 2019, the Company entered into a new $1.6 billion credit agreement (the "Credit Agreement"), which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million. For a description of the terms of the Credit Agreement, refer to Note 11—Subsequent events of the Notes to condensed consolidated financial statements.
Note 8. Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and six months ended July 31, 2019, the Company recorded income tax expense of $4.4 million and $13.8 million, respectively. This resulted in an effective income tax expense rate of 18.4% for each of the three and six months ended July 31, 2019, compared with an effective income tax benefit rate of 4.8% and 7.3% for the three and six months ended July 31, 2018, respectively. For the three and six months ended July 31, 2019 and 2018, the net impact of discrete tax items caused a 4.8 and 4.6 percentage point decrease and a 27.0 and 29.5 percentage point decrease, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income. The increase in the effective income tax rate from the same period last year is primarily due to a decrease in excess tax benefits on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income.
As of July 31, 2019 and January 31, 2019, the Company’s total gross unrecognized tax benefit was $2.0 million and $1.7 million, respectively. Certain unrecognized tax benefits have been netted against their related deferred tax assets. As of July 31, 2019, an unrecognized tax benefit of $0.4 million was recorded. As of January 31, 2019, no unrecognized tax benefit had been recorded. If recognized, $1.9 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2019.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.
Note 9. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,010


$
807

 
$
1,869

 
$
1,220

Sales and marketing

1,158


891

 
2,166

 
1,596

Technology and development

1,930


1,300

 
3,429

 
2,291

General and administrative

3,492


2,490

 
6,154

 
4,620

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727



-14-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 9. Stock-based compensation (continued)


The following table shows stock-based compensation by award type:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,727


$
1,983

 
$
3,510

 
$
3,747

Performance stock options



172

 

 
325

Restricted stock units

3,694


2,045

 
6,619

 
3,587

Performance restricted stock units

1,393


536

 
2,044

 
1,050

Restricted stock awards

164


171

 
327

 
226

Performance restricted stock awards

612


581

 
1,118

 
792

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727


Stock options
The Company currently grants stock options under the 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock options to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors.
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended July 31,
 
Six months ended July 31,
 
  

2019
 
2018
 
2019

 
2018

Expected dividend yield

*

*
 
%
 
%
Expected stock price volatility

*

*
 
35.98% - 36.53%

 
37.84
%
Risk-free interest rate

*

*
 
2.21% - 2.43%

 
2.52% - 2.68%

Expected life of options

*

*
 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended July 31, 2019 and 2018.

-15-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 9. Stock-based compensation (continued)


The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(283
)

$0.10 - 44.53

$
23.49





Forfeited

(31
)

$24.36 - 44.53

$
30.96





Outstanding as of July 31, 2019

2,238


$0.10 - 82.39

$
30.03


6.45

$
116,288

Vested and expected to vest as of July 31, 2019

2,238




$
30.03


6.45

$
116,288

Exercisable as of July 31, 2019

1,429




$
22.14


5.75

$
85,503


The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
As of July 31, 2019, the weighted-average vesting period of non-vested awards expected to vest is approximately 1.6 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $10.5 million.
Restricted stock units and restricted stock awards
The Company grants restricted stock units ("RSUs") and restricted stock awards ("RSAs") to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 150% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals.
In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from 0% to 200%

-16-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 9. Stock-based compensation (continued)


based on the level of achievement of the performance goals. The PRSAs were issued at the 200% level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.
In March 2019, the Company awarded 129,963 PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 200% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals.
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

527


70.84





Released

(122
)

54.49


(11
)

62.75

Forfeited

(42
)

55.77


(10
)

61.72

Outstanding as of July 31, 2019

1,010


$
63.41


235


$
61.91


For the six months ended July 31, 2019, the aggregate intrinsic value of RSUs and RSAs released was $8.8 million and $0.8 million, respectively. For the six months ended July 31, 2018, the aggregate intrinsic value of RSUs released was $4.6 million.
Total unrecorded stock-based compensation expense as of July 31, 2019 associated with RSUs and PRSUs was $52.1 million, which is expected to be recognized over a weighted-average period of 2.7 years. Total unrecorded stock-based compensation expense as of July 31, 2019 associated with RSAs and PRSAs was $5.4 million, which is expected to be recognized over a weighted-average period of 1.8 years.
Note 10. Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of marketable equity securities.





-17-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 10. Fair value (continued)
The following table summarizes the assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy reflecting the valuation techniques utilized to determine fair value:


July 31, 2019
 
(in thousands)

Level 1


Level 2


Level 3

Other investments:







Marketable equity securities

$
81,130


$


$


The Company did not have any assets measured at fair value on a recurring basis as of January 31, 2019. The Company has classified cash and cash equivalents and marketable equity securities as Level 1 in the fair value hierarchy.
Note 11. Subsequent events
Merger with WageWorks
On August 30, 2019, the Company closed the Merger with WageWorks for $51.35 per share in cash, or approximately $2.0 billion in the aggregate. As a result of the Merger, the Company's investment in the common stock of WageWorks was canceled. In addition, the Company assumed and converted into Company equity awards approximately 0.5 million outstanding equity awards to WageWorks employees. The Company financed the cash transaction through a combination of $805.4 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.0 million, under the term loan facility described below.
New Credit Agreement
In connection with the closing of the Merger on August 30, 2019, the Company entered into a new $1.6 billion Credit Agreement, which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company's pro forma secured net leverage ratio would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Borrowings under the Credit Agreement will bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the term loan facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the term loan facility: (i) 2.5% for the year commencing August 30, 2019; (ii) 5.0% for each of the years during the two-year period commencing August 30, 2020; (iii) 7.5% for the year commencing August 30, 2022; and (iv) 10.0% for the year commencing August 30, 2023.
The Credit Agreement contains customary affirmative and negative covenants, including covenants related to the following subjects: mergers, and sales of assets; limitations on the incurrence of certain liens; limitations on certain indebtedness; limitations on the ability to pay dividends; and certain affiliate transactions, in each case, subject to customary exceptions and “baskets.”
In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to

-18-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 11. Subsequent events (continued)
1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.






-19-


Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning the anticipated benefits of the Merger with WageWorks, market opportunity, our future financial and operating results, investment and acquisition strategy, sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, use of non-GAAP financial measures, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in our Annual Report on Form 10-K for the year ended January 31, 2019, as updated by this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC, and the WageWorks Annual Report on Form 10-K for the year ended December 31, 2018 and its other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in the high-growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. Our platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow their tax-advantaged healthcare savings.
The core of our ecosystem is the HSA, a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. As of July 31, 2019, we were the integrated HSA platform for 141 Health Plan and Administrator Partners and over 45,000 employer clients. Our Health Plan and Administrator Partners and Employer Partners constitute our Network Partners.
Since our inception in 2002, we have been committed to developing technology solutions that empower healthcare consumers. We have a proprietary cloud-based technology platform, developed and refined during more than a decade of operations, which we believe is highly differentiated in the marketplace. Key platform differentiators include purpose-built technology that offers greater functionality and flexibility than the technologies used by our competitors, more than 3,000 data integrations with our Network Partner and other benefits provider systems, and configurability solutions with more than 1,700 uniquely tailored configurations serving our Network Partners. We work closely with our Network Partners to educate and provide personalized guidance regarding the benefits of HSAs and our other products.
We earn revenue primarily from three sources: service revenue, custodial revenue and interchange revenue. We earn service revenue by providing monthly account services on our platform, primarily through contracts with our Network Partners, and custodial agreements with individual members. We earn custodial revenue from custodial cash assets deposited with our federally-insured custodial depository partners and with our insurance company partner, and recordkeeping fees we earn in respect of mutual funds in which our members invest. We also earn interchange revenue from interchange fees that we earn on payments that our members make using our physical and virtual payment cards.

-20-


Merger with WageWorks
On June 26, 2019, we entered into a Merger Agreement with WageWorks, and Merger Sub, pursuant to which, on the terms and subject to the conditions therein, Merger Sub would merge with and into WageWorks (the “Merger”), with WageWorks surviving the Merger and becoming a wholly owned subsidiary of HealthEquity. On August 30, 2019, the Merger closed and we paid approximately $2.0 billion in cash to WageWorks stockholders, financed through net borrowings of approximately $1.22 billion under our new term loan facility and approximately $805.4 million of cash on hand.
The Merger is expected to give us access to more of the fast-growing HSA market by expanding our direct distribution to employers and benefits advisors as a single source, premier provider of HSAs and complementary consumer-directed benefits ("CDBs"), including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts. WageWorks' focus on member engagement and client service enables us to more fully meet the needs of employers, partners and a broader range of consumers along the continuum of health savings.
We expect that the Merger will significantly impact the number of our HSA Members, custodial and other HSA assets, Adjusted EBITDA, total revenue, total cost of revenue and operating expenses, and materially impact our other financial results.
Key factors affecting our performance
We believe that our performance and future success are driven by a number of factors, including our acquisition of WageWorks and those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See the section entitled “Risk factors” included in our Annual Report on Form 10-K, as updated by this Quarterly Report on Form 10-Q and our other reports filed with the SEC.
Structural change in U.S. private health insurance
Substantially all of our revenue is derived from healthcare-related saving and spending by consumers in the United States, which is impacted by changes affecting the broader healthcare industry in the U.S. The healthcare industry has changed significantly in recent years, and we expect that significant changes will continue to occur that will result in increased participation in high deductible healthcare plans, or HDHPs, and other consumer-centric health plans. In particular, we believe that continued growth in healthcare costs, and related factors will spur HDHP and HSA growth; however, the timing and impact of these and other developments in the healthcare industry are difficult to predict, and changes in U.S. healthcare policy could adversely affect our business.
Attracting and penetrating network partners
We created our business model to take advantage of the changing dynamics of the U.S. private health insurance market. Our model is based on a B2B2C distribution strategy, meaning that we rely on our Employer Partners and Health Plan and Administrator Partners to reach potential members to increase the number of our HSA Members. Our success depends in large part on our ability to further penetrate our existing Network Partners by adding new HSA Members from these partners and adding new Network Partners.
Our innovative technology platform
We believe that innovations incorporated in our technology that enable consumers to make healthcare saving and spending decisions differentiate us from our competitors and drive our growth in revenue, HSA Members, Network Partners and custodial assets. Similarly, these innovations underpin our ability to provide a differentiated consumer experience in a cost-effective manner. We intend to continue to invest in our technology development to enhance our platform’s capabilities and infrastructure. For example, we are currently undertaking a significant update of our proprietary platform’s architecture, which will allow us to improve our transaction processing capabilities and related platform infrastructure to support continued account and transaction growth.
Broad product offering
Our Employer Partners and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs, including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts.  We believe that the combination of our HSA platform with WageWorks' complementary CDB offerings as a result of the Merger will strengthen and broaden our product offerings, enabling us to better meet the needs of our clients and prospective clients. As a market-leading, single-source provider, we believe we will be better positioned to attract new Employer Partners as well as sell additional complementary services to our existing clients. 


-21-


Our “DEEP Purple” culture
The new healthcare consumer needs education and guidance delivered by people as well as technology. We believe that our "DEEP Purple" culture which we define as driving excellence, ethics, and process while providing remarkable service, is a significant factor in our ability to attract and retain customers and to address nimbly, opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster DEEP Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development and advancement opportunities.
Interest rates
As a non-bank custodian, we contract with federally-insured custodial depository partners and an insurance company partner to hold custodial cash assets on behalf of our members, and we earn a significant portion of our total revenue from interest rates offered to us by these partners. The contract terms range from three to five years and have either fixed or variable interest rates. As our custodial assets increase and existing agreements expire, we seek to enter into new contracts with federally-insured custodial depository partners, the terms of which are impacted by the then-prevailing interest rate environment. The diversification of deposits among partners and varied contract terms substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we can realize. Conversely, a sustained increase in prevailing interest rates without a corresponding increase in what we pay on our members' deposits can increase our yield over time. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, as our yield increases, we expect the spread to grow between the interest offered to us by our custodial depository partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Our competition and industry
Our direct competitors are HSA custodians. Many of these are state or federally chartered banks and other financial institutions for which we believe technology-based healthcare services are not a core business. Certain of our direct competitors have chosen to exit the market despite increased demand for these services. This has created, and we believe will continue to create, opportunities for us to leverage our technology platform and capabilities to increase our market share. However, some of our direct competitors (including well-known mutual fund companies such as Fidelity) are in a position, should they choose, to devote more resources to the development, sale and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration technology and service providers, partner with banks and other HSA custodians to compete with us. Our Health Plan and Administrator Partners may also choose to offer technology-based healthcare services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code and IRS regulations, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
Our acquisition strategy
We have a successful history of acquiring complementary assets and businesses that strengthen our platform, including our recent acquisition of WageWorks. We seek to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate and integrate

-22-


acquisitions that have created value for shareholders. We intend to continue to pursue acquisitions of complementary assets and businesses that we believe will strengthen our platform.
Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
HSA Members
The following table sets forth our HSA Members as of and for the periods indicated:
(in thousands, except percentages)

July 31, 2019


July 31, 2018


% Change


January 31, 2019

HSA Members

4,163


3,574


16
 %

3,994

Average HSA Members - Year-to-date

4,073


3,488


17
 %

3,608

Average HSA Members - Quarter-to-date

4,119


3,533


17
 %

3,813

New HSA Members - Year-to-date

215


219


(2
)%

679

New HSA Members - Quarter-to-date

126


121


4
 %

341

Active HSA Members

3,300


2,933


13
 %

3,241

HSA Members with investments

187


143


31
 %

163

The number of our HSA Members is a key metric because our revenue is driven by the amount we earn from our HSA Member's accounts, balances and spend. The number of our HSA Members increased by approximately 589,000, or 16%, from July 31, 2018 to July 31, 2019, primarily driven by further penetration into existing Network Partners and the addition of new Network Partners.
HSAs are individually owned portable healthcare accounts. As HSA Members transition between employers or health plans, they may no longer be enrolled in an HDHP that qualifies them to continue to make contributions to their HSA. If these HSA Members deplete their custodial balance, we may consider them no longer an Active HSA Member. We define an Active HSA Member as an HSA Member that (i) is associated with a Health Plan and Administrator Partner or an Employer Partner, in each case as of the end of the applicable period; or (ii) has held a custodial balance at any point during the previous twelve month period. Active HSA Members increased 13% from 2.9 million as of July 31, 2018 to 3.3 million as of July 31, 2019.
During the three months ended July 31, 2019, we acquired the rights to be custodian of a portfolio of HSA members for $6.5 million. None of these HSA Members had transitioned to our platform as of July 31, 2019, and accordingly are not included in our total HSA Members as of July 31, 2019. We expect the HSA Members to convert to our proprietary platform in October 2019.
Custodial assets
The following table sets forth our HSA Member custodial assets as of and for the periods indicated:
(in millions, except percentages)

July 31, 2019


July 31, 2018


% Change


January 31, 2019

Custodial cash

$
6,460


$
5,537


17
%

$
6,428

Custodial investments

2,056


1,494


38
%

1,670

Total custodial assets

$
8,516


$
7,031


21
%

$
8,098

Average daily custodial cash - Year-to-date

$
6,404


$
5,478


17
%

$
5,586

Average daily custodial cash - Quarter-to-date

$
6,402


$
5,489


17
%

$
5,837

Our custodial assets, which are our HSA Members' assets for which we are the custodian, consist of the following components: (i) custodial cash deposits, which are deposits with our federally-insured custodial depository partners, (ii) custodial cash deposits invested in an annuity contract with our insurance company partner, and (iii) investments in mutual funds through our custodial investment fund partner. Measuring our custodial assets is important because our custodial revenue is directly affected by average daily custodial balances.
Our total custodial assets increased by $1.5 billion, or 21%, from July 31, 2018 to July 31, 2019, primarily driven by additional custodial assets from our existing HSA Members and new custodial assets from our new HSA Members.

-23-


Importantly, our custodial investment assets increased by $562 million, or 38%, from July 31, 2018 to July 31, 2019, reflecting our strategy to help our HSA Members build wealth and invest for retirement.
During the three months ended July 31, 2019, we acquired the rights to be custodian of a portfolio of HSA members for $6.5 million. None of the custodial assets had transitioned to our platform as of July 31, 2019, and accordingly are not included in our total custodial assets as of July 31, 2019. We expect the custodial assets to convert to our proprietary platform in October 2019.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, unrealized gains and losses on marketable equity securities, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income, the most comparable GAAP financial measure, to Adjusted EBITDA for each of the periods indicated:
 
 
Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Net income
 
$
19,366

 
$
22,517

 
$
61,188

 
$
45,094

Interest income
 
(1,884
)
 
(303
)
 
(3,227
)
 
(561
)
Interest expense
 
67

 
69

 
130

 
136

Income tax provision (benefit)
 
4,370

 
(1,029
)
 
13,826

 
(3,067
)
Depreciation and amortization
 
3,455

 
2,918

 
6,737

 
5,968

Amortization of acquired intangible assets
 
1,494

 
1,478

 
2,985

 
2,948

Stock-based compensation expense
 
7,590

 
5,488

 
13,618

 
9,727

Merger integration expenses
 
2,784

 

 
2,784

 

Acquisition costs
 
6,596

 
224

 
7,780

 
225

Unrealized gain on marketable equity securities
 
(3,774
)
 

 
(27,285
)
 

Other (1)
 
579

 
439

 
1,030

 
958

Adjusted EBITDA
 
$
40,643

 
$
31,801

 
$
79,566

 
$
61,428

(1)
For the three months ended July 31, 2019 and 2018, Other consisted of non-income-based taxes of $108 and $116, other (income)/costs of $15 and $(32), and amortization of incremental costs to obtain a contract of $456 and $355, respectively. For the six months ended July 31, 2019 and 2018, Other consisted of non-income-based taxes of $121 and $220, other costs of $9 and $56, and amortization of incremental costs to obtain a contract of $900 and $682, respectively.
The following table further sets forth our Adjusted EBITDA:

Three months ended July 31,
 


Six months ended July 31,
 
 
 
(in thousands, except percentages)
2019

2018

$ Change

% Change

2019

2018

$ Change

% Change

Adjusted EBITDA
$
40,643

$
31,801

$
8,842

28
%
$
79,566

$
61,428

$
18,138

30
%
As a percentage of revenue
47
%
45
%
 
 
46
%
44
%
 
 
Our Adjusted EBITDA increased by $8.8 million, or 28%, from $31.8 million for the three months ended July 31, 2018 to $40.6 million for the three months ended July 31, 2019. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a 22% increase in total revenue.
Our Adjusted EBITDA increased by $18.1 million, or 30%, from $61.4 million for the six months ended July 31, 2018 to $79.6 million for the six months ended July 31, 2019. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a 23% increase in total revenue.
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.





-24-


Key components of our results of operations
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, employer clients and individual members for the administration services we provide in connection with the HSAs and RAs we offer. With respect to our Network Partners, our fees are generally based on a fixed tiered structure for the duration of our agreement with the relevant Network Partner and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered under our written service agreements.
Custodial revenue.    We earn custodial revenue, an increasing component of our overall revenue, primarily from our HSA Member custodial cash assets deposited with our federally-insured custodial depository partners and with our insurance company partner, Employer Partner custodial cash assets, and recordkeeping fees we earn in respect of mutual funds in which our members invest. As a non-bank custodian, we deposit our custodial cash with our various depository partners pursuant to contracts that (i) have terms up to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant depository partner, and (iii) have minimum and maximum required deposit balances. We earn custodial revenue on our custodial cash that is based on the interest rates offered to us by these depository partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA assets in mutual funds through our custodial investment partner. We earn a recordkeeping fee, calculated as a percentage of custodial investments.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our payment cards to make a qualified purchase. This revenue is collected each time a member “swipes” our payment card to pay a healthcare-related expense. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing bank and the card processor.
Cost of revenue
Cost of revenue includes costs related to servicing member accounts, managing customer and partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members. Other components of cost of revenue include interest retained by members on custodial cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards and costs of marketing materials that we produce for our Network Partners.
Custodial costs.    Custodial costs are comprised of interest retained by our HSA Members and fees we pay to banking consultants whom we use to help secure agreements with our federally-insured custodial depository partners. Interest retained by HSA Members is calculated on a tiered basis. The interest rates retained by HSA Members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on RA-linked payment card transactions, payment card costs are higher for RA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our partners and members, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.

-25-


Technology and development.    Technology and development expenses include personnel and related expenses for software engineering, information technology, and product development. Technology and development expenses also include software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, compliance, and people departments. They also include depreciation, amortization, stock-based compensation and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from our acquisition of intangible member assets. We acquired these intangible member assets from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We also acquired other intangible assets, which are 401(k) customer relationships, in connection with an acquisition of a business. We amortize these assets over the assets' estimated useful life of 10 years. We evaluate our acquired intangible assets for impairment at least each year, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, and technology-related expenses directly related to the integration activities as a result of the Merger.
Other income (expense), net
Other income (expense) primarily consists of unrealized holding gains and losses on mark-to-market investments, less interest expense associated with our credit agreement, non-income-based taxes and acquisition costs, plus interest income earned on corporate cash.
Income tax provision
We are subject to federal and state income taxes in the United States based on a calendar tax year which differs from our fiscal year-end for financial reporting purposes. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. As of July 31, 2019, we recorded a net deferred tax liability in most jurisdictions except Utah and three other states for which a net deferred tax asset has been recorded. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Due to the positive evidence of current taxable income coupled with forecasted profitability, no valuation allowance was required as of July 31, 2019 for most of our deferred tax assets. However, we recorded a valuation allowance of $0.1 million as of July 31, 2019 and January 31, 2019 with respect to unrealized capital losses for which we do not expect to generate taxable capital gains in order to utilize the capital losses in the future.
Comparison of the three and six months ended July 31, 2019 and 2018
Our net income decreased 14% to $19.4 million during the three months ended July 31, 2019 from $22.5 million during the three months ended July 31, 2018, due to a $5.4 million increase in our income tax provision and an increase of $1.0 million in other expense, net, partially offset by a $3.3 million increase in income from operations.
Our net income increased 36% to $61.2 million during six months ended July 31, 2019 from $45.1 million during the six months ended July 31, 2018, primarily due to a $22.5 million increase in other income, net, which was primarily due to a $27.3 million unrealized gain on our equity investment in WageWorks, and a $10.4 million increase in income from operations, partially offset by a $16.9 million increase in our income tax provision.

-26-


The following table sets forth our revenue for the periods indicated:


Three months ended July 31,
 




Six months ended July 31,
 
 
 
 
 
(in thousands, except percentages)

2019

 
2018


$ Change


% Change

2019

 
2018

 
$ Change

 
% Change

Service revenue
 
$
26,282

 
$
24,935

 
$
1,347

 
5
%
$
53,090

 
$
49,756

 
$
3,334

 
7
%
Custodial revenue
 
43,614

 
30,715

 
12,899

 
42
%
85,566

 
59,149

 
26,417

 
45
%
Interchange revenue

16,727


15,417


1,310


8
%
35,019

 
32,066

 
2,953

 
9
%
Total revenue

$
86,623


$
71,067


$
15,556


22
%
$
173,675

 
$
140,971

 
$
32,704

 
23
%
Service revenue
The $1.3 million, or 5%, increase in service revenue from the three months ended July 31, 2018 to the three months ended July 31, 2019 was primarily due to an increase in the number of our HSA Members, partially offset by lower service revenue per average HSA Members. The $3.3 million, or 7%, increase in service revenue from the six months ended July 31, 2018 to the six months ended July 31, 2019 was primarily due to an increase in the number of our HSA Members, partially offset by lower service revenue per average HSA Members. The number of our HSA Members increased by approximately 589,000, or 16%, from July 31, 2018 to July 31, 2019. The growth in the number of our HSA Members was primarily due to growth from our existing and new Network Partners.
Service revenue as a percentage of our total revenue continued to decrease primarily due to the higher growth rate of custodial revenue.
Service revenue per average HSA Members decreased by approximately 10% and 9% from the three and six months ended July 31, 2018 to the three and six months ended July 31, 2019. Our service fee tiered pricing structure incentivizes our Network Partners to add HSA Members because we charge a lower rate for higher volumes of HSA Members. As Network Partners add more HSA Members, the account fee per average HSA Members will continue to decrease.
Custodial revenue
The $12.9 million, or 42%, increase in custodial revenue from the three months ended July 31, 2018 to the three months ended July 31, 2019 was primarily due to an increase in the yield on average custodial cash assets from 2.11% for the three months ended July 31, 2018 to 2.54% and an increase in average daily custodial cash assets of $0.9 billion, or 17%.
The $26.4 million, or 45%, increase in custodial revenue from the six months ended July 31, 2018 to the six months ended July 31, 2019 was primarily due to an increase in the yield on average custodial cash assets from 2.07% for the six months ended July 31, 2018 to 2.54% and an increase in average daily custodial cash assets of $0.9 billion, or 17%.
Custodial revenue as a percentage of our total revenue continued to increase primarily due to new custodial depository agreements with higher interest rates payable on average cash balances deposited thereunder, and also due to average daily custodial cash asset growth.
Custodial revenue per average HSA Members increased by approximately 22% and 24% from the three and six months ended July 31, 2018 to the three and six months ended July 31, 2019 primarily due to the increase in the yield on and balances of average daily custodial cash assets.
Interchange revenue
The $1.3 million, or 8%, increase in interchange revenue from the three months ended July 31, 2018 to the three months ended July 31, 2019 was primarily due to an overall increase in the number of average HSA Members partially offset by lower card spend per average HSA Members.
The $3.0 million, or 9%, increase in interchange revenue from the six months ended July 31, 2018 to the six months ended July 31, 2019 was primarily due to an overall increase in the number of average HSA Members partially offset by lower card spend per average HSA Members.
Interchange revenue per average HSA Members decreased by approximately 7% and 6% from the three and six months ended July 31, 2018 to the three and six months ended July 31, 2019, primarily due to a decrease in card spend per average HSA Members.



-27-


Total revenue
Total revenue per average HSA Members increased by 5% and 6% from the three and six months ended July 31, 2018 to the three and six months ended July 31, 2019, due to the increase in custodial revenue per average HSA Members, partially offset by the decreases in service and interchange revenue per average HSA Members.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
(in thousands, except percentages)

Three months ended July 31,
 




Six months ended July 31,
 
 
 
 
 

2019

 
2018


$ Change


% Change

2019

 
2018

 
$ Change

 
% Change

Service costs

$
19,745


$
17,199


$
2,546


15
%
$
40,394

 
$
35,246

 
$
5,148

 
15
%
Custodial costs

4,209


3,502


707


20
%
8,332

 
6,941

 
1,391

 
20
%
Interchange costs

4,229


3,791


438


12
%
8,756

 
7,853

 
903

 
11
%
Total cost of revenue

$
28,183


$
24,492


$
3,691


15
%
$
57,482

 
$
50,040

 
$
7,442

 
15
%
Service costs
The $2.5 million, or 15%, increase in service costs from the three months ended July 31, 2018 to the three months ended July 31, 2019 was due to the higher volume of accounts being serviced. The $2.5 million increase is due to increases of $1.2 million due to hiring of additional personnel to implement and support our new Network Partners and HSA Members, increases in other expense of $0.8 million, and increases in activation and processing costs of $0.5 million. Service costs per average HSA Members decreased by 2% from the three months ended July 31, 2018 to the three months ended July 31, 2019 due to planned efficiency measures.
The $5.1 million, or 15%, increase in service costs from the six months ended July 31, 2018 to the six months ended July 31, 2019 was due to the higher volume of accounts being serviced. The $5.1 million increase is due to increases in activation and processing costs of $1.8 million, increases of $1.8 million related to the hiring of additional personnel to implement and support our new Network Partners and HSA Members, increases in other expense of $0.9 million, and increases in stock-based compensation expense of $0.6 million. Service costs per average HSA Members decreased by 2% from the six months ended July 31, 2018 to the six months ended July 31, 2019 due to planned efficiency measures.
Custodial costs
The $0.7 million, or 20%, increase in custodial costs from the three months ended July 31, 2018 to the three months ended July 31, 2019 was due to an increase in average daily custodial cash assets, which increased from $5.5 billion for the three months ended July 31, 2018 to $6.4 billion for the three months ended July 31, 2019. Custodial interest costs on average custodial cash assets decreased slightly from 0.24% for the three months ended July 31, 2018 to 0.23% for the three months ended July 31, 2019.
The $1.4 million, or 20%, increase in custodial costs from the six months ended July 31, 2018 to the six months ended July 31, 2019 was due to an increase in average daily custodial cash assets, which increased from $5.5 billion for the six months ended July 31, 2018 to $6.4 billion for the six months ended July 31, 2019. Custodial interest costs on average custodial cash assets decreased slightly from 0.24% for the six months ended July 31, 2018 to 0.23% for the six months ended July 31, 2019.
Interchange costs
The $0.4 million, or 12%, and $0.9 million, or 11%, increase in interchange costs for the three and six months ended July 31, 2018 compared to the three and six months ended July 31, 2019 was due to an overall increase in average HSA Members, partially offset by decreased card spend per average HSA Members.
Cost of revenue
As we continue to add HSA Members, we expect that our cost of revenue will increase in dollar amount to support our Network Partners and members. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our Member Education Center, Network Partner implementation and account management functions.

-28-


Operating expenses
The following table sets forth our operating expenses for the periods indicated:
(in thousands, except percentages)

Three months ended July 31,
 
 
 
 
 
Six months ended July 31,
 
 
 
 
 

2019

 
2018

 
$ Change

 
% Change

2019

 
2018

 
$ Change

 
% Change

Sales and marketing

$
8,391


$
7,243


$
1,148


16
%
$
17,361

 
$
14,103

 
$
3,258

 
23
%
Technology and development

11,645


8,398


3,247


39
%
22,550

 
16,377

 
6,173

 
38
%
General and administrative

9,262


7,893


1,369


17
%
17,971

 
15,400

 
2,571

 
17
%
Merger integration
 
2,784

 

 
2,784

 
n/a

2,784

 

 
2,784

 
n/a

Amortization of acquired intangible assets

1,494


1,478


16


1
%
2,985

 
2,948

 
37

 
1
%
Total operating expenses

$
33,576


$
25,012


$
8,564


34
%
$
63,651

 
$
48,828

 
$
14,823

 
30
%
Sales and marketing
The $1.1 million, or 16%, increase in sales and marketing expense from the three months ended July 31, 2018 to the three months ended July 31, 2019 was due to increased staffing of $0.8 million and higher stock-based compensation expense of $0.3 million.
The $3.3 million, or 23%, increase in sales and marketing expense from the six months ended July 31, 2018 to the six months ended July 31, 2019 was due to increased staffing of $2.3 million, higher stock-based compensation expense of $0.6 million, and increases in other expenses of $0.4 million.
Technology and development
The $3.2 million, or 39%, increase in technology and development expense from the three months ended July 31, 2018 to the three months ended July 31, 2019 was due to increased personnel-related expense of $2.0 million, increases in professional fees of $1.7 million, increased stock-based compensation of $0.6 million, increases in amortization and depreciation of $0.3 million, and other increases of $0.5 million, which were partially offset by increases in capitalized development of $1.9 million.
The $6.2 million, or 38%, increase in technology and development expense from the six months ended July 31, 2018 to the six months ended July 31, 2019 was due to increased personnel-related expense of $3.7 million, increases in professional fees of $3.4 million, increases in amortization, depreciation and stock-based compensation of $1.8 million, and other increases of $0.8 million, which were partially offset by increases in capitalized development of $3.5 million.
General and administrative
The $1.4 million, or 17%, increase in general and administrative expense from the three months ended July 31, 2018 to the three months ended July 31, 2019 was due to increased personnel-related expense of $0.2 million, increases in stock-based compensation of $1.0 million, and increases in other expenses of $0.2 million.
The $2.6 million, or 17%, increase in general and administrative expense from the six months ended July 31, 2018 to the six months ended July 31, 2019 was due to increased personnel-related expense of $1.0 million, increases in stock-based compensation of $1.5 million, and increases in other expenses of $0.1 million.
Merger integration
The $2.8 million in merger integration expense for the three and six months ended July 31, 2019 was due to integration activities directly related to the Merger. We expect merger integration expenses to continue for the next 24 to 36 months as we integrate WageWorks.
Other income (expense), net
The change in other income (expense), net, from the three months ended July 31, 2018 to the three months ended July 31, 2019 was primarily due to acquisition costs of $6.6 million, partially offset by an unrealized gain of $3.8 million in connection with our equity investment in WageWorks and interest income, net, on corporate cash of $1.8 million.
The change in other income (expense), net, from the six months ended July 31, 2018 to the six months ended July 31, 2019 was primarily due to an unrealized gain of $27.3 million in connection with our equity investment in WageWorks, as well as interest income, net, on corporate cash of $3.1 million, partially offset by acquisition costs of $7.8 million.

-29-


In connection with the closing of the Merger on August 30, 2019, our equity investment in WageWorks common stock was canceled.
Income tax provision (benefit)
Income tax provision for the three and six months ended July 31, 2019 was $4.4 million and $13.8 million as compared to an income tax benefit of $1.0 million and $3.1 million for the three and six months ended July 31, 2018. The increase in the tax provision for the three and six months ended July 31, 2019 compared to the three and six months ended July 31, 2018 was $5.4 million and $16.9 million, respectively. The change during the six months ended July 31, 2019 was primarily due to an unrealized gain of $27.3 million in connection with our equity investment in WageWorks coupled with a decrease in excess tax benefits from stock-based compensation.
Our effective income tax rate for the three and six months ended July 31, 2019 was a provision of 18.4%, compared to a benefit of 4.8% and 7.3% for the three and six months ended July 31, 2018. The change to an income tax provision from an income tax benefit for the three and six months ended July 31, 2019 compared to the three and six months ended July 31, 2018 is primarily due to a decrease in excess tax benefits related to stock-based compensation recognized in the provision for income taxes relative to pre-tax book income.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. A significant number of new and existing Network Partners bring us new HSA Members beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new HSA Members, we incur costs related to implementing and supporting our new Network Partners and new HSA Members. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter with the majority of expenses incurred in our fourth fiscal quarter.
Liquidity and capital resources
Cash and cash equivalents overview
As of July 31, 2019, our principal source of liquidity was our current cash and cash equivalents balances, collections from our service, custodial and interchange revenue activities, and availability under our prior credit facility. In connection with the closing of the Merger on August 30, 2019, we entered into a new credit facility with Wells Fargo Bank, N.A., which includes a $350.0 million revolving credit facility which is now a source of liquidity for the Company. We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, and capital expenditures.
As of July 31, 2019 and January 31, 2019, cash and cash equivalents were $815.2 million and $361.5 million, respectively. Cash and cash equivalents as of July 31, 2019 included approximately $458.5 million of net proceeds we received from our follow-on offering in July 2019 from the sale of 7,762,500 shares of our common stock. We used approximately $805.4 million of our cash to help fund the Merger on August 30, 2019.
Capital resources
We have a “shelf” registration statement on Form S-3 on file with the SEC. This shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters and capital expenditures, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
On July 12, 2019, the Company closed a follow-on public offering of 7,762,500 shares of common stock at a public offering price of $61.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $458.5 million after deducting underwriting discounts and commissions of approximately $14.1 million and other offering expenses payable by the Company of approximately $0.9 million.
As of July 31, 2019, we were party to the Prior Credit Agreement with $100.0 million of available borrowings. There were no borrowings under the Prior Credit Agreement as of July 31, 2019. We were in compliance with all covenants as of July 31, 2019.

-30-


In connection with the closing of the Merger on August 30, 2019, the Company entered into a new $1.6 billion Credit Agreement, which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the Credit Agreement, refer to Note 11—Subsequent events of the Notes to condensed consolidated financial statements.
Use of cash
From February 1, 2019 to April 4, 2019, we acquired approximately 1.6 million common shares of WageWorks for $53.8 million in open market purchases. On August 30, 2019, the Merger closed and we paid approximately $2.0 billion in cash to WageWorks stockholders, which was funded with net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.0 million, under the above term loan and $805.4 million of cash on hand.
Capital expenditures for the six months ended July 31, 2019 and 2018 were $13.0 million and $7.4 million, respectively. We expect our capital expenditures to increase for the remainder of the year ending January 31, 2020 as we continue to devote capital expenditures to improve the architecture and functionality of our proprietary system. Costs to improve the architecture of our proprietary system include computer hardware, personnel and related costs for software engineering and outsourced software engineering services. In addition, we plan to devote further resources to leasehold improvements and furniture and fixtures for our office space.
We believe our existing cash and cash equivalents will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
The following table shows our cash flows from operating activities, investing activities and financing activities for the stated periods:


Six months ended July 31,
 
(in thousands)

2019

 
2018

Net cash provided by operating activities

$
56,831


$
52,640

Net cash used in investing activities

(68,591
)

(8,773
)
Net cash provided by financing activities

465,445


18,469

Increase in cash and cash equivalents

453,685


62,336

Beginning cash and cash equivalents

361,475


199,472

Ending cash and cash equivalents

$
815,160


$
261,808

Cash flows provided by operating activities. Net cash provided by operating activities during the six months ended July 31, 2019 resulted primarily from our net income of $61.2 million, adjusted for the following non-cash items: depreciation and amortization of $9.7 million, stock-based compensation of $13.6 million, and changes in deferred taxes of $7.9 million, operating lease right-of-use assets of $1.3 million, and accrued liabilities and other current and long-term liabilities of $5.3 million. These items were offset by unrealized gains on marketable equity securities and other of $27.2 million, a decrease in accrued compensation of $5.9 million resulting from the payment of bonuses and commissions subsequent to year-end, an increase in accounts receivable of $1.7 million, an increase in other assets of $5.0 million, and a decrease in operating lease liabilities and accounts payable of $2.3 million.
Net cash provided by operating activities during the six months ended July 31, 2018 resulted primarily from our net income of $45.1 million, adjusted for the following non-cash items: depreciation and amortization of $8.9 million, stock-based compensation of $9.7 million, and changes in deferred taxes of $2.4 million, and changes in inventories, accrued liabilities, other long-term liabilities, and unrealized losses on marketable securities and other totaling $0.5 million. These items were offset by an increase in other assets of $7.0 million, a decrease in accrued compensation of $2.8 million resulting from the payment of bonuses and commissions subsequent to year-end, an increase in accounts receivable of $3.3 million, and a decrease in accounts payable of $0.8 million.
Cash flows used in investing activities. Net cash used in investing activities for the six months ended July 31, 2019 was primarily the result of purchases of marketable equity securities of $53.8 million. We also continued

-31-


development of our proprietary system and other software necessary to support our continued account growth. Purchases of software and capitalized software development costs for the six months ended July 31, 2019 were $9.5 million, compared to purchases of software and capitalized software development costs of $4.7 million for the six months ended July 31, 2018. Our purchases of property and equipment increased from $2.7 million for the six months ended July 31, 2018 to $3.5 million for the six months ended July 31, 2019, primarily as a result of increases in tenant improvements. In addition, during the six months ended July 31, 2019, purchases of intangible member assets resulted in cash outflows of $1.7 million, compared to $1.0 million for the six months ended July 31, 2018.
Cash flows provided by financing activities. Cash flow provided by financing activities during the six months ended July 31, 2019 resulted primarily from our follow-on offering where we received net proceeds of $458.9 million from the sale of 7,762,500 shares of our common stock and the exercise of stock options of $6.6 million compared to $18.5 million for the six months ended July 31, 2018.
Contractual obligations
Except for the entry into the Merger Agreement with WageWorks, providing for the acquisition of WageWorks for approximately $2.0 billion in cash, there were no material changes during the three months ended July 31, 2019, outside of the ordinary course of business, in our contractual obligations from those disclosed in our Annual Report on Form 10-K for the year ended January 31, 2019.
Off-balance sheet arrangements
During the three months ended July 31, 2019 and 2018, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements.
Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended January 31, 2019. Other than the adoption of ASU 2016-02 and related subsequent amendments, Leases, and updates to our Investment policies described in Note 1 of the accompanying unaudited condensed consolidated financial statements, there have been no significant or material changes in our critical accounting policies during the six months ended July 31, 2019, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the year ended January 31, 2019. We do not expect any significant changes to our critical accounting policies as a result of the Merger with WageWorks.
Recent accounting pronouncements
See Note 1. Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Qualitative and quantitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the three months ended July 31, 2019, no one customer accounted for

-32-


greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of July 31, 2019 were $815.2 million, of which $1 million was covered by federal depository insurance. We have not experienced any material losses in such accounts and believe we are not exposed to any significant credit risk with respect to our cash and cash equivalents. Our accounts receivable balance as of July 31, 2019 was $27.4 million. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable. We continue to monitor our credit risk and place our cash, cash equivalents, and marketable securities with reputable financial institutions.
Interest rate risk
Custodial assets. As of July 31, 2019, we had custodial cash assets of approximately $6.5 billion. We have entered into depository agreements with financial institutions for our cash custodial assets. The contracted interest rates were negotiated at the time the depository agreements were executed. A significant reduction in prevailing market interest rates may make it difficult for us to continue to place custodial deposits at the current contracted rates.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of July 31, 2019, we had unrestricted cash and cash equivalents of $815.2 million. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Equity investment risk
Marketable equity securities. Our marketable equity securities are subject to a variety of market-related risks that could substantially reduce or increase the carrying value of our holdings. As of July 31, 2019, we had marketable equity securities of $81.1 million, comprised of investments in WageWorks common stock. We are required to record all adjustments to the carrying value of our marketable equity securities through our condensed consolidated statements of operations and comprehensive income. In connection with the closing of the Merger on August 30, 2019, the Company's investment in WageWorks common stock was canceled.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures included, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

-33-


Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

-34-


Part II—Other Information
Item 1. Legal Proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. As of July 31, 2019, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows, financial position or brand. As a result of the Merger, we have inherited all legal proceedings of WageWorks, and we are continuing to evaluate these legal proceedings and the expected impact on the combined company. For a description of WageWorks' legal proceedings, see Note 10 to the Condensed Consolidated Financial Statements in WageWorks’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.
Item 1A. Risk factors
The risks described in “Risk factors,” in our Annual Report on Form 10-K for the year ended January 31, 2019 could materially and adversely affect our business, financial condition and results of operations. Other than indicated below, there have been no material changes in such risks. These risk factors do not identify all risks that we face - our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. In addition, due to the closing of the Merger, we are now subject to the risks described in WageWorks's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on Form 10-Q for the three months ended March 31, 2019 and June 30, 2019, as well as in Exhibit 99.5 to our Form 8-K filed July 8, 2019.
We may experience difficulties in integrating the operations of WageWorks into our business and in realizing the expected benefits of the Merger.
The success of the Merger will depend in part on our ability to realize the anticipated business opportunities from combining the operations of WageWorks with our business in an efficient and effective manner. The integration process could take longer than anticipated and could result in the loss of key employees, the disruption of each company's ongoing businesses, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with customers, employees or other third parties, or our ability to achieve the anticipated benefits of the Merger, and could harm our financial performance. If we are unable to successfully or timely integrate the operations of WageWorks with our business, we may incur unanticipated liabilities and be unable to realize the revenue growth, synergies and other anticipated benefits resulting from the Merger, and our business, results of operations and financial condition could be materially and adversely affected.
The synergies attributable to the Merger may vary from expectations.
We may fail to realize our anticipated benefits and synergies expected from the Merger, which could adversely affect our business, financial condition and operating results. The success of the Merger will depend, in significant part, on our ability to successfully integrate the acquired business, grow the revenue of the combined company and realize the anticipated strategic benefits and synergies from the combination. We believe that the addition of WageWorks will complement our strategy by giving us access to more of the fast-growing HSA market by expanding our direct distribution to employers and benefits advisors as a single source, premier provider of HSAs and complementary CDBs, including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts. However, achieving these goals requires growth of the revenue of the combined company and realization of the targeted cost synergies expected from the Merger. This growth and the anticipated benefits of the transaction may not be realized fully or at all, or may take longer to realize than expected. Actual operating, technological, strategic and revenue opportunities, if achieved at all, may be less significant than expected or may take longer to achieve than anticipated. If we are not able to achieve these objectives and realize the anticipated benefits and synergies expected from the Merger within the anticipated timing or at all, our business, financial condition and operating results may be adversely affected.
WageWorks may have liabilities that are not known, probable or estimable at this time.
As a result of the Merger, WageWorks became our subsidiary and it will remain subject to all of its liabilities, including the class action and derivative lawsuits and SEC investigation described in the filings referenced in the first paragraph under Item 1A above, and in the WageWorks' Supplement to Proxy Statement filed August 21, 2019. There could be unasserted claims or assessments that we failed or were unable to discover or identify in the course of performing due diligence investigations of WageWorks. In addition, there may be liabilities that are neither

-35-


probable nor estimable at this time that may become probable or estimable in the future. Any such liabilities, individually or in the aggregate, could have a material adverse effect on our financial results. We may learn additional information about WageWorks that adversely affects us, such as unknown, unasserted or contingent liabilities and issues relating to compliance with applicable laws.
Without limitation to the generality of the foregoing, WageWorks is subject to various rules, regulations, laws and other legal requirements, enforced by governments or other public authorities. Misconduct, fraud, non-compliance with applicable laws and regulations, or other improper activities by any of WageWorks's directors, officers, employees or agents could have a significant impact on WageWorks's business and reputation and could subject WageWorks to fines and penalties, criminal, civil and administrative legal sanctions and suspension from contracting (including with public bodies), resulting in reduced revenues and profits. Such misconduct could include the failure to comply with regulations prohibiting bribery, regulations on lobbying or similar activities, control over financial reporting, environmental laws and any other applicable laws or regulations.
The complexity of the integration and transition associated with the Merger, together with the resulting increased scale and national presence, may affect our internal control over financial reporting and ability to effectively and timely report financial results.
The additional scale of the combined company's operations, together with the complexity of the integration effort, including changes to or implementation of critical information technology systems, may adversely affect our ability to report financial results on a timely basis. In addition, we will have to train new employees and third-party providers. The Merger may necessitate significant modifications to our internal control systems, processes and information systems, both on a transition basis and over the longer-term as we fully integrate the combined company. Due to the complexity of the Merger, we cannot be certain that changes to our internal control over financial reporting will be effective for any period, or on an ongoing basis. If we are unable to accurately report our financial results in a timely manner, or are unable to assert that our internal controls over financial reporting are effective, our business, financial condition and results of operations, and the market perception thereof, may be materially adversely affected.
The terms of our credit facility require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility.
On August 30, 2019, we entered into a new $1.6 billion Credit Agreement, which consists of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million. The Credit Agreement is secured by a lien covering substantially all of our assets. The Credit Agreement contains customary affirmative and negative covenants, including covenants related to the following subjects: mergers, and sales of assets; limitations on the incurrence of certain liens; limitations on certain indebtedness; limitations on the ability to pay dividends; certain affiliate transactions; and financial performance covenants. If we default under the Credit Agreement, the lenders will be able to declare all obligations immediately due and payable and take control of our pledged assets, potentially requiring us to renegotiate the Credit Agreement on terms less favorable to us or to immediately cease operations. The lenders' rights to repayment would be senior to the rights of the holders of our common stock to receive any proceeds.
We may be adversely affected by interest rate changes due to the floating interest rate under our Credit Agreement.
Borrowings under the Credit Agreement bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As such, our financial position may be adversely affected by fluctuations in interest rates.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) Unregistered Sale of Equity Securities
None.
(b) Use of Proceeds from Public Offering of Common Stock
On August 5, 2014, we closed our initial public offering of 10,465,000 shares of common stock sold by us. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to a registration statement

-36-


on Form S-1 (File No. 333-196645), which was declared effective by the SEC on July 30, 2014. JP Morgan & Chase Co. and Wells Fargo acted as the lead underwriters. The public offering price of the shares sold in the offering was $14.00 per share. The total gross proceeds from the offering to us were $146.5 million. After deducting underwriting discounts and commissions of approximately $10.2 million and offering expenses payable by us of approximately $3.7 million, we received approximately $132.6 million. There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus (dated July 30, 2014) filed with the SEC on August 1, 2014 pursuant to Rule 424(b) of the Securities Act. We paid a previously declared cash dividend of $50.0 million on shares of our common stock outstanding on August 4, 2014. In addition, we paid a cash dividend of $347,000 on shares of our outstanding series D-3 redeemable convertible preferred stock accrued through the date of conversion of such shares into common stock, which occurred on August 4, 2014. Other than the foregoing dividends, we made no payments directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates.
During the year ended January 31, 2016, the Company used funds received from the offerings to acquire the rights to be the custodian of the Bancorp and M&T Bank HSA portfolios for approximately $34.2 million and approximately $6.2 million, respectively.
During the year ended January 31, 2018, the Company used funds received from the offerings to acquire the rights to be custodian of two HSA portfolios for approximately $6.4 million and $8.0 million in cash, respectively, the assets of BenefitGuard LLC, a 401(k) provider that offers plan administrator and named fiduciary services for 401(k) employer sponsors, for approximately $2.9 million, and the rights to be the sole administrator of a portfolio of HSA Members for $3.3 million.
During the year ended January 31, 2019, the Company used funds received from the offerings to acquire the rights to be custodian of an HSA portfolio for approximately $1.2 million in cash.
On August 30, 2019, the Merger closed and HealthEquity, Inc. paid approximately $2.0 billion in cash to WageWorks stockholders, using approximately $805.4 million of cash on hand. Accordingly, all remaining proceeds from the offerings described above have been used.



-37-


Item 6. Exhibits
 
 
 
Incorporate by reference
Exhibit
no.
 
Description
Form
File No.
Exhibit
Filing Date
10.1
 

8-K
001-36568
2.1
June 27, 2019
10.2
 


8-K
001-36568
10.1
August 30, 2019
31.1+
 
 
 
 
 
31.2+
 
 
 
 
 
32.1*#
 
 
 
 
 
32.2*#
 
 
 
 
 
101.INS
 
XBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
 
101.SCH
 
Inline XBRL Taxonomy schema linkbase document
 
 
 
 
101.CAL
 
Inline XBRL Taxonomy calculation linkbase document
 
 
 
 
101.DEF
 
Inline XBRL Taxonomy definition linkbase document
 
 
 
 
101.LAB
 
Inline XBRL Taxonomy labels linkbase document
 
 
 
 
101.PRE
 
Inline XBRL Taxonomy presentation linkbase document
 
 
 
 
104
 
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2019, formatted in Inline XBRL.

 
 
 
 
+
 
Filed herewith.
*
 
Furnished herewith.
#
 
These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.

-38-


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
HEALTHEQUITY, INC.
Date: September 9, 2019
By:
 
/s/ Darcy Mott

 
Name:
 
Darcy Mott
 
Title:
 
Executive Vice President and Chief Financial Officer

-39-
EX-31.1 2 exhibit311-ceo302x2019.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: September 9, 2019
 
 
 
 
By:
 
/s/ Jon Kessler

Name:
 
Jon Kessler
Title:
 
Chief Executive Officer
 (Principal Executive Officer)



EX-31.2 3 exhibit312-cfo302x2019.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Darcy Mott, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 9, 2019
 
 
 
By:
 
/s/ Darcy Mott

Name:
 
Darcy Mott
Title:
 
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)



EX-32.1 4 exhibit321-ceo906x2019.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.
Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2019 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: September 9, 2019
 
 
 
 
By:
 
/s/ Jon Kessler

Name:
 
Jon Kessler
Title:
 
Chief Executive Officer
(Principal Executive Officer)



EX-32.2 5 exhibit322-cfo906x2019.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Darcy Mott, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.
Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2019 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: September 9, 2019
 
 
 
 
By:
 
/s/ Darcy Mott

Name:
 
Darcy Mott
Title:
 
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 



EX-101.SCH 6 hqy-20190731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2125100 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2425401 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2138100 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 2438402 - Disclosure - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink 2338301 - Disclosure - Fair value (Tables) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2434401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2428401 - Disclosure - Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Leases (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Net income per share link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Net income per share (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Net income per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2437405 - Disclosure - Stock-based compensation (Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2437404 - Disclosure - Stock-based compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2437407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2437403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) link:presentationLink link:calculationLink link:definitionLink 2437406 - Disclosure - Stock-based compensation (Stock option activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2437402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2337301 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 2440401 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Supplemental financial statement information (Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hqy-20190731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hqy-20190731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hqy-20190731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenue Cost of Sales [Member] Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Technology and development Technology and Development [Member] Technology and Development [Member] General and administrative General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total stock-based compensation expense Share-based Payment Arrangement, Expense Fair Value Disclosures [Abstract] Fair value Fair Value Disclosures [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period Debt amortization commencing August 30, 2019 Debt Instrument, Amortization Period One [Member] Debt Instrument, Amortization Period One Debt amortization commencing August 30, 2020 Debt Instrument, Amortization Period Two [Member] Debt Instrument, Amortization Period Debt amortization commencing August 30, 2021 Debt Instrument, Amortization Period Three [Member] Debt Instrument, Amortization Period Three [Member] Debt amortization commencing August 30, 2022 Debt Instrument, Amortization Period Four [Member] Debt Instrument, Amortization Period Four [Member] Debt amortization commencing August 30, 2023 Debt Instrument, Amortization Period Five [Member] Debt Instrument, Amortization Period Five [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] WageWorks, Inc Wage Works [Member] Wage Works [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent events Subsequent Event [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Base Rate Base Rate [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Term Loan Secured Debt [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Debt covenant, beginning August 30, 2019 Debt Covenant Period One [Member] Debt Covenant Period One Debt covenant, beginning July 31, 2020 Debt Covenant Period Two [Member] Debt Covenant Period Two Debt covenant, beginning July 31, 2021 Debt Covenant Period Three [Member] Debt Covenant Period Three Debt covenant, acquisition holiday provision Debt Covenant Period Four [Member] Debt Covenant Period Four Subsequent Event [Line Items] Subsequent Event [Line Items] Merger related costs, price per share Business Acquisition, Share Price Consideration paid for merger Business Combination, Consideration Transferred Equity awards assumed Business Combination, Consideration Transferred, Share Based Payment Arrangement Assumed Business Combination, Consideration Transferred, Share Based Payment Arrangement Assumed Cash paid Payments to Acquire Businesses, Gross Borrowing pursuant to term loan facility Business Combination, Consideration Transferred, Liabilities Incurred Lender fees Debt Issuance Costs, Gross Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Facility term Debt Instrument, Term Possible additional future loans to incur amount Line Of Credit Facility, Potential Increase In Maximum Borrowing Capacity Line Of Credit Facility, Potential Increase In Maximum Borrowing Capacity Pro forma maximum leverage ratio Debt Instrument, Covenant Description, Increase In Maximum Borrowing Capacity, Pro Forma Secured Leverage Ratio Debt Instrument, Covenant Description, Increase In Maximum Borrowing Capacity, Pro Forma Secured Leverage Ratio Variable rate borrowing spread Debt Instrument, Basis Spread on Variable Rate Amortization percentage of original principle amount Debt Instrument, Covenant Description, Amortization, Percentage Of Original Principal Amount Debt Instrument, Covenant Description, Amortization, Percentage Of Original Principal Amount Maximum leverage ratio Debt Instrument, Covenant Description, Leverage Ratio Debt Instrument, Covenant Description, Leverage Ratio Acquisition threshold for maximum total net leverage ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Minimum interest coverage ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock options Share-based Payment Arrangement, Option [Member] Performance stock options Performance Shares [Member] Restricted stock units Restricted Stock Units (RSUs) [Member] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Restricted stock awards Restricted Stock [Member] Performance restricted stock awards Performance Restricted Stock Awards [Member] Performance Restricted Stock Awards [Member] Stock-based compensation Share-based Payment Arrangement [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Capitalized software development costs Software and Software Development Costs [Member] Software Computer Software, Intangible Asset [Member] Other intangible assets Other Intangible Assets [Member] Acquired intangible member assets Customer Relationships [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Intangible assets, gross Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Intangible assets, net Finite-Lived Intangible Assets, Net Earnings Per Share [Abstract] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Prior Credit Agreement Prior Credit Agreement [Member] Prior Credit Agreement [Member] Secured Revolving Credit Facility Customary Base Rate Subsequent Event Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term Line of Credit Long-term Line of Credit Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag RSUs and PRSUs RSAs and PRSAs Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, ending balance (in shares) Weighted-average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Released (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, ending balance (usd per share) Leases [Abstract] Operating lease expense Operating Lease, Expense Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Summary of share based compensation recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense by award type Share-based Payment Arrangement, Cost by Plan [Table Text Block] Summary of assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of restricted stock unit activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Net income Net Income (Loss) Attributable to Parent Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average common shares outstanding (in shares) Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Net income per share: Earnings Per Share, Basic and Diluted [Abstract] Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Assets measured at fair value on a recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Income Tax Disclosure [Abstract] Income tax provision (benefit) Income Tax Expense (Benefit) Effective tax rate - (benefit) expense Effective Income Tax Rate Reconciliation, Percent Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Gross unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefit Unrecognized Tax Benefit, Net Unrecognized Tax Benefit, Net Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net of allowance for doubtful accounts as of July 31, 2019 and January 31, 2019 of $105 and $125, respectively Accounts Receivable, after Allowance for Credit Loss, Current Other current assets Other Assets, Current Total current assets Assets, Current Investments Long-term Investments Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Goodwill Deferred tax asset Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued liabilities Accrued Liabilities, Current Operating lease liabilities Operating Lease, Liability, Current Total current liabilities Liabilities, Current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Deferred tax liability Deferred Income Tax Liabilities, Net Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (see note 6) Commitments and Contingencies Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively Preferred Stock, Value, Issued Common stock, $0.0001 par value, 900,000 shares authorized, 70,603 and 62,446 shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated earnings Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Income taxes Income Tax Disclosure [Text Block] Lease cost Lease, Cost [Table Text Block] Operating lease liability maturity schedule Lessee, Operating Lease, Liability, Maturity [Table Text Block] Indebtedness Debt Disclosure [Text Block] Intangible member assets Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Purchase price adjustment of acquired intangible members assets Finite-lived Intangible Assets Acquired Useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Capitalized software development costs Capitalized Computer Software, Additions Software development costs incurred and expensed Research and Development Expense, Software (Excluding Acquired in Process Cost) Amortization expense Amortization of Intangible Assets Change in goodwill Goodwill, Period Increase (Decrease) Organization, Consolidation and Presentation of Financial Statements [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Follow-on equity offering Follow On Equity Offering [Member] Follow On Equity Offering [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Equity securities investment ownership percentage Equity Securities Investment, Ownership Percentage Equity Securities Investment, Ownership Percentage Marketable equity securities, at fair value Equity Securities, FV-NI Equity method investment ownership percentage Equity Method Investment, Ownership Percentage Equity method investments Equity Method Investments Cost method investment ownership percentage Cost Method Investment, Ownership Percentage Cost Method Investment, Ownership Percentage Non-marketable equity securities Equity Securities without Readily Determinable Fair Value, Amount Common stock, shares (in shares) Sale of Stock, Number of Shares Issued in Transaction Offering price per share (in usd per share) Sale of Stock, Price Per Share Net proceeds from follow on offering Sale of Stock, Consideration Received on Transaction Underwriting discounts and commissions Payments of Stock Issuance Costs Other offering expenses payable Stock Issuance Costs Payable Stock Issuance Costs Payable Remaining operating lease terms Lessee, Operating Lease, Remaining Lease Term Lessee, Operating Lease, Remaining Lease Term Lease renewal terms extension Lessee, Operating Lease, Renewal Term Operating lease liabilities Operating Lease, Liability Operating lease right of use asset Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Unrealized (gains) losses on marketable equity securities and other Gain (Loss) on Disposition of Intangible Assets Deferred taxes Deferred Income Tax Expense (Benefit) Stock-based compensation Share-based Payment Arrangement, Noncash Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Other assets Increase (Decrease) in Prepaid Expense Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Employee Related Liabilities Accrued liabilities and other current liabilities Increase (Decrease) in Accrued Liabilities Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of intangible member assets Payments to Acquire Intangible Assets Purchases of marketable equity securities and other Payments to Acquire Investments Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of software and capitalized software development costs Payments for Software Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from follow-on equity offering, net of payments for offering costs Proceeds from Issuance of Common Stock Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Beginning cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Ending cash and cash equivalents Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes paid in cash, net of refunds received Income Taxes Paid, Net Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Purchases of property and equipment included in accounts payable or accrued liabilities at period end Capital Expenditures Incurred but Not yet Paid Purchases of intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable Follow-on equity offering costs accrued during the period Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Debt issuance costs accrued during the period Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Operating lease not yet commenced term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued (in shares) Preferred Stock, Shares Issued Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Subsequent events Subsequent Events [Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Investments Investment, Policy [Policy Text Block] Recent adopted and issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Property and equipment Property, Plant and Equipment [Table Text Block] Investments Investment [Table Text Block] Other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Non-marketable equity securities Total equity investments Unrealized gain on marketable equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Service revenue Service [Member] Custodial revenue Financial Service, Other [Member] Interchange revenue Credit and Debit Card [Member] Revenue: Revenues [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Cost of revenue: Cost of Revenue [Abstract] Total cost of revenue Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Sales and marketing Selling and Marketing Expense Technology and development Research and Development Expense General and administrative General and Administrative Expense Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Merger integration Business Combination, Integration Related Costs Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net income and comprehensive income Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net income per share: Weighted-average number of shares used in computing net income per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Basic (in shares) Diluted (in shares) Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Opening balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Ending balance (shares) Range of exercise prices (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Beginning balance, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Beginning balance, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Granted, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted Granted, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted Exercised, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Exercised, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Forfeited, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Forfeited, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Ending balance, minimum (usd per share) Ending balance, maximum (usd per share) Weighted- average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Opening balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Ending balance (usd per share) Weighted- average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and expected to vest as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest as of year end, weighted average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest as of year end, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercisable as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable as of year end, weighted-average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable as of year end, weighted-average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable as of year end, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Cumulative effect from adoption of ASC 606 Accounting Standards Update 2014-09 [Member] Cumulative effect from adoption of ASU 2016-01 Accounting Standards Update 2016-01 [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common stock Common Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated comprehensive loss AOCI Attributable to Parent [Member] Accumulated earnings Retained Earnings [Member] Beginning balance Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Issuance of common stock Stock Issued During Period, Value, New Issues Other issuance of common stock Stock Issued During Period, Value, Other Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Cumulative effect from adoption of accounting standard updates Cumulative Effect of New Accounting Principle in Period of Adoption Ending balance Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Computer equipment Computer Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Depreciation expense Depreciation Net income per share Earnings Per Share [Text Block] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Percentage of capital stock Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Forfeiture period Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period Weighted-average vesting period of non-vested awards expected to vest Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock compensation expense to be recognized in future Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Performance units awards (in shares) Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Interest income, net Interest Income (Expense), Net Acquisition costs Business Combination, Acquisition Related Costs Other Other Nonoperating Expense Total other income (expense), net Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Operating cash flows from operating leases Operating Lease, Payments ROU assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Remaining 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease liabilities Operating lease liabilities, Current Operating lease liabilities, Non-current Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Investment Type [Axis] Investment Type [Axis] Investment [Domain] Investments [Domain] Marketable equity securities Equity Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other investments Investments, Fair Value Disclosure Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Leases Lessee, Operating Leases [Text Block] EX-101.PRE 10 hqy-20190731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and contingencies
6 Months Ended
Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
The Company’s principal commitments consist of operating lease obligations for office space and data storage facilities, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of January 31, 2019 are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended January 31, 2019, and except for the entry into the Merger Agreement with WageWorks, providing for the acquisition of WageWorks for approximately $2.0 billion in cash, did not change materially during the three and six months ended July 31, 2019.
XML 12 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Fair value
6 Months Ended
Jul. 31, 2019
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of marketable equity securities.




Note 10. Fair value (continued)
The following table summarizes the assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy reflecting the valuation techniques utilized to determine fair value:


July 31, 2019
 
(in thousands)

Level 1


Level 2


Level 3

Other investments:







Marketable equity securities

$
81,130


$


$


The Company did not have any assets measured at fair value on a recurring basis as of January 31, 2019. The Company has classified cash and cash equivalents and marketable equity securities as Level 1 in the fair value hierarchy.
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Jul. 31, 2019
Jan. 31, 2019
Current assets    
Cash and cash equivalents $ 815,160 $ 361,475
Accounts receivable, net of allowance for doubtful accounts as of July 31, 2019 and January 31, 2019 of $105 and $125, respectively 27,357 25,668
Other current assets 10,999 7,534
Total current assets 853,516 394,677
Investments 81,839 709
Property and equipment, net 9,873 8,223
Operating lease right-of-use assets 36,716  
Intangible assets, net 88,768 79,666
Goodwill 4,651 4,651
Deferred tax asset 666 1,677
Other assets 22,311 20,413
Total assets 1,098,340 510,016
Current liabilities    
Accounts payable 2,740 3,520
Accrued compensation 11,055 16,981
Accrued liabilities 19,392 8,552
Operating lease liabilities 3,954  
Total current liabilities 37,141 29,053
Operating lease liabilities, non-current 35,660  
Deferred tax liability 7,773 916
Other long-term liabilities 735 2,968
Total liabilities 81,309 32,937
Commitments and contingencies (see note 6)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 70,603 and 62,446 shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively 7 6
Additional paid-in capital 783,986 305,223
Accumulated earnings 233,038 171,850
Total stockholders’ equity 1,017,031 477,079
Total liabilities and stockholders’ equity $ 1,098,340 $ 510,016
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed consolidated statements of cash flows (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Cash flows from operating activities:    
Net income $ 61,188 $ 45,094
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 9,722 8,916
Unrealized (gains) losses on marketable equity securities and other (27,180) 86
Deferred taxes 7,868 2,351
Stock-based compensation 13,618 9,727
Changes in operating assets and liabilities:    
Accounts receivable (1,689) (3,304)
Other assets (5,036) (6,921)
Operating lease right-of-use assets 1,286  
Accounts payable (1,083) (837)
Accrued compensation (5,926) (2,826)
Accrued liabilities and other current liabilities 4,942 56
Operating lease liabilities, non-current (1,210)  
Other long-term liabilities 331 298
Net cash provided by operating activities 56,831 52,640
Cash flows from investing activities:    
Purchases of intangible member assets (1,736) (1,014)
Purchases of marketable equity securities and other (53,845) (368)
Purchases of property and equipment (3,492) (2,690)
Purchases of software and capitalized software development costs (9,518) (4,701)
Net cash used in investing activities (68,591) (8,773)
Cash flows from financing activities:    
Proceeds from follow-on equity offering, net of payments for offering costs 458,881 0
Proceeds from exercise of common stock options 6,564 18,469
Net cash provided by financing activities 465,445 18,469
Increase in cash and cash equivalents 453,685 62,336
Beginning cash and cash equivalents 361,475 199,472
Ending cash and cash equivalents 815,160 261,808
Supplemental cash flow data:    
Interest expense paid in cash 101 101
Income taxes paid in cash, net of refunds received 9,119 554
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable or accrued liabilities at period end 3 14
Exercise of common stock options receivable 87 135
Follow-on equity offering costs accrued during the period 386 0
Debt issuance costs accrued during the period 345 0
Software    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets 487 175
Intangible member assets    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets $ 6,500 $ 181
XML 15 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) - USD ($)
$ in Thousands
Jul. 31, 2019
Jan. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 149,806 $ 132,827
Accumulated amortization (61,038) (53,161)
Intangible assets, net 88,768 79,666
Capitalized software development costs    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 48,410 40,583
Software    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 6,430 4,252
Other intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross 2,882 2,882
Acquired intangible member assets    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 92,084 $ 85,110
EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 17 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Lease Cost) (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
USD ($)
Jul. 31, 2019
USD ($)
Leases [Abstract]    
Operating lease expense $ 1,086 $ 2,160
Weighted average remaining lease term 11 years 2 months 26 days 11 years 2 months 26 days
Weighted average discount rate 4.37% 4.37%
XML 18 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Summary of share based compensation recognized) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 7,590 $ 5,488 $ 13,618 $ 9,727
Cost of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,010 807 1,869 1,220
Sales and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,158 891 2,166 1,596
Technology and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,930 1,300 3,429 2,291
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 3,492 $ 2,490 $ 6,154 $ 4,620
XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 180 340 1 false 55 0 false 4 false false R1.htm 0001000 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/CondensedConsolidatedBalanceSheets Condensed consolidated balance sheets Statements 2 false false R3.htm 1001001 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited Condensed consolidated statements of operations and comprehensive income (unaudited) Statements 4 false false R5.htm 1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 1006000 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 2104100 - Disclosure - Net income per share Sheet http://healthequity.com/role/NetIncomePerShare Net income per share Notes 8 false false R9.htm 2106100 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/SupplementalFinancialStatementInformation Supplemental financial statement information Notes 9 false false R10.htm 2107100 - Disclosure - Leases Sheet http://healthequity.com/role/Leases Leases Notes 10 false false R11.htm 2122100 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 11 false false R12.htm 2125100 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 12 false false R13.htm 2128100 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 13 false false R14.htm 2134100 - Disclosure - Income taxes Sheet http://healthequity.com/role/IncomeTaxes Income taxes Notes 14 false false R15.htm 2137100 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/StockBasedCompensation Stock-based compensation Notes 15 false false R16.htm 2138100 - Disclosure - Fair value Sheet http://healthequity.com/role/FairValue Fair value Notes 16 false false R17.htm 2140100 - Disclosure - Subsequent events Sheet http://healthequity.com/role/SubsequentEvents Subsequent events Notes 17 false false R18.htm 2201201 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 18 false false R19.htm 2304301 - Disclosure - Net income per share (Tables) Sheet http://healthequity.com/role/NetIncomePerShareTables Net income per share (Tables) Tables http://healthequity.com/role/NetIncomePerShare 19 false false R20.htm 2306301 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/SupplementalFinancialStatementInformation 20 false false R21.htm 2307301 - Disclosure - Leases (Tables) Sheet http://healthequity.com/role/LeasesTables Leases (Tables) Tables http://healthequity.com/role/Leases 21 false false R22.htm 2322301 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/IntangibleAssetsAndGoodwill 22 false false R23.htm 2337301 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockBasedCompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/StockBasedCompensation 23 false false R24.htm 2338301 - Disclosure - Fair value (Tables) Sheet http://healthequity.com/role/FairValueTables Fair value (Tables) Tables http://healthequity.com/role/FairValue 24 false false R25.htm 2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details) Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails Summary of business and significant accounting policies (Narrative) (Details) Details http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies 25 false false R26.htm 2404402 - Disclosure - Net income per share (Details) Sheet http://healthequity.com/role/NetIncomePerShareDetails Net income per share (Details) Details http://healthequity.com/role/NetIncomePerShareTables 26 false false R27.htm 2406402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails Supplemental financial statement information (Property and equipment) (Details) Details http://healthequity.com/role/SupplementalFinancialStatementInformationTables 27 false false R28.htm 2406403 - Disclosure - Supplemental financial statement information (Investments) (Details) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails Supplemental financial statement information (Investments) (Details) Details http://healthequity.com/role/SupplementalFinancialStatementInformationTables 28 false false R29.htm 2406404 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails Supplemental financial statement information (Other income (expense), net) (Details) Details http://healthequity.com/role/SupplementalFinancialStatementInformationTables 29 false false R30.htm 2407402 - Disclosure - Leases (Narrative) (Details) Sheet http://healthequity.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://healthequity.com/role/LeasesTables 30 false false R31.htm 2407403 - Disclosure - Leases (Lease Cost) (Details) Sheet http://healthequity.com/role/LeasesLeaseCostDetails Leases (Lease Cost) (Details) Details http://healthequity.com/role/LeasesTables 31 false false R32.htm 2407404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) Sheet http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails Leases (Maturities of Operating Lease Liabilities) (Details) Details http://healthequity.com/role/LeasesTables 32 false false R33.htm 2407405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails Leases (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/LeasesTables 33 false false R34.htm 2422402 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleAssetsAndGoodwillTables 34 false false R35.htm 2422403 - Disclosure - Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) Details http://healthequity.com/role/IntangibleAssetsAndGoodwillTables 35 false false R36.htm 2425401 - Disclosure - Commitments and contingencies (Details) Sheet http://healthequity.com/role/CommitmentsAndContingenciesDetails Commitments and contingencies (Details) Details http://healthequity.com/role/CommitmentsAndContingencies 36 false false R37.htm 2428401 - Disclosure - Indebtedness (Details) Sheet http://healthequity.com/role/IndebtednessDetails Indebtedness (Details) Details http://healthequity.com/role/Indebtedness 37 false false R38.htm 2434401 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncomeTaxesDetails Income taxes (Details) Details http://healthequity.com/role/IncomeTaxes 38 false false R39.htm 2437402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) Sheet http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails Stock-based compensation (Summary of share based compensation recognized) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 39 false false R40.htm 2437403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) Sheet http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails Stock-based compensation (Stock-based compensation expense by award type) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 40 false false R41.htm 2437404 - Disclosure - Stock-based compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockBasedCompensationNarrativeDetails Stock-based compensation (Narrative) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 41 false false R42.htm 2437405 - Disclosure - Stock-based compensation (Assumptions) (Details) Sheet http://healthequity.com/role/StockBasedCompensationAssumptionsDetails Stock-based compensation (Assumptions) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 42 false false R43.htm 2437406 - Disclosure - Stock-based compensation (Stock option activity) (Details) Sheet http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails Stock-based compensation (Stock option activity) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 43 false false R44.htm 2437407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) Sheet http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails Stock-based compensation (Restricted stock unity activity) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 44 false false R45.htm 2438402 - Disclosure - Fair value (Details) Sheet http://healthequity.com/role/FairValueDetails Fair value (Details) Details http://healthequity.com/role/FairValueTables 45 false false R46.htm 2440401 - Disclosure - Subsequent events (Details) Sheet http://healthequity.com/role/SubsequentEventsDetails Subsequent events (Details) Details http://healthequity.com/role/SubsequentEvents 46 false false R9999.htm Uncategorized Items - hqy-2019x7x3110q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - hqy-2019x7x3110q.htm Cover 47 false false All Reports Book All Reports hqy-2019x7x3110q.htm exhibit311-ceo302x2019.htm exhibit312-cfo302x2019.htm exhibit321-ceo906x2019.htm exhibit322-cfo906x2019.htm hqy-20190731.xsd hqy-20190731_cal.xml hqy-20190731_def.xml hqy-20190731_lab.xml hqy-20190731_pre.xml http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 20 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Fair value (Details) - Recurring - Marketable equity securities
$ in Thousands
Jul. 31, 2019
USD ($)
Level 1  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Other investments $ 81,130
Level 2  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Other investments 0
Level 3  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Other investments $ 0
XML 21 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 6 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2017
Jul. 31, 2019
Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares authorized (in shares)       2,600,000  
Percentage of capital stock       3.00%  
Expected dividend yield       0.00% 0.00%
Unrecognized stock compensation expense to be recognized in future       $ 10.5  
Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period       10 years  
Forfeiture period       90 days  
Weighted-average vesting period of non-vested awards expected to vest       1 year 7 months 6 days  
Restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted-average vesting period of non-vested awards expected to vest       2 years 8 months 12 days  
Award vesting period       4 years  
Performance units awards (in shares)       527,000  
Aggregate intrinsic value       $ 8.8 $ 4.6
Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future       $ 52.1  
Performance restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Performance units awards (in shares) 129,963   146,964    
Performance restricted stock units | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting rights percentage 0.00%   0.00%    
Performance restricted stock units | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting rights percentage 200.00%   150.00%    
Performance restricted stock awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Performance units awards (in shares)   227,760      
Performance restricted stock awards | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting rights percentage   0.00%      
Performance restricted stock awards | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting rights percentage   200.00%      
Restricted stock awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted-average vesting period of non-vested awards expected to vest       1 year 9 months 18 days  
Award vesting period       4 years  
Performance units awards (in shares)       0  
Aggregate intrinsic value       $ 0.8  
Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future       $ 5.4  
XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental financial statement information (Investments) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Marketable equity securities, at fair value $ 81,130   $ 81,130   $ 0
Non-marketable equity securities 500   500   500
Equity method investments 209   209   209
Total equity investments 81,839   81,839   $ 709
Unrealized gain on marketable equity securities $ 3,774 $ 0 $ 27,285 $ 0  
XML 24 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental financial statement information (Tables)
6 Months Ended
Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and equipment
Property and equipment consisted of the following as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
4,288

 
$
3,583

Furniture and fixtures
 
5,201

 
4,476

Computer equipment
 
11,279

 
9,242

Property and equipment, gross
 
20,768

 
17,301

Accumulated depreciation
 
(10,895
)
 
(9,078
)
Property and equipment, net
 
$
9,873

 
$
8,223


Investments
Investments consisted of the following equity investments as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Marketable equity securities, at fair value
 
$
81,130

 
$

Non-marketable equity securities
 
500

 
500

Equity method investments
 
209

 
209

Total equity investments
 
$
81,839

 
$
709


Other income (expense), net
Other income (expense), net, consisted of the following:
 
 
Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income, net
 
$
1,817

 
$
234

 
$
3,097

 
$
425

Unrealized gain on marketable equity securities
 
3,774

 

 
27,285

 

Acquisition costs
 
(6,596
)
 
(224
)
 
(7,780
)
 
(225
)
Other
 
(123
)
 
(85
)
 
(130
)
 
(276
)
Total other income (expense), net
 
$
(1,128
)
 
$
(75
)
 
$
22,472

 
$
(76
)

XML 25 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Fair value (Tables)
6 Months Ended
Jul. 31, 2019
Fair Value Disclosures [Abstract]  
Assets measured at fair value on a recurring basis
The following table summarizes the assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy reflecting the valuation techniques utilized to determine fair value:


July 31, 2019
 
(in thousands)

Level 1


Level 2


Level 3

Other investments:







Marketable equity securities

$
81,130


$


$


XML 26 hqy-2019x7x3110q_htm.xml IDEA: XBRL DOCUMENT 0001428336 2019-02-01 2019-07-31 0001428336 2019-08-30 0001428336 2019-07-31 0001428336 2019-01-31 0001428336 2018-02-01 2018-07-31 0001428336 2018-05-01 2018-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-05-01 2019-07-31 0001428336 2019-05-01 2019-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-02-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-05-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-05-01 2018-07-31 0001428336 us-gaap:ServiceMember 2018-05-01 2018-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-02-01 2019-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-02-01 2018-07-31 0001428336 us-gaap:ServiceMember 2019-05-01 2019-07-31 0001428336 us-gaap:ServiceMember 2019-02-01 2019-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-05-01 2018-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-02-01 2018-07-31 0001428336 us-gaap:ServiceMember 2018-02-01 2018-07-31 0001428336 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2019-04-30 0001428336 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2018-07-31 0001428336 us-gaap:CommonStockMember 2018-02-01 2018-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-07-31 0001428336 us-gaap:CommonStockMember 2018-01-31 0001428336 us-gaap:RetainedEarningsMember 2018-04-30 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:RetainedEarningsMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001428336 us-gaap:CommonStockMember 2018-04-30 0001428336 us-gaap:CommonStockMember 2019-05-01 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-02-01 2018-07-31 0001428336 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-30 0001428336 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-05-01 2018-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0001428336 us-gaap:CommonStockMember 2018-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-07-31 0001428336 us-gaap:CommonStockMember 2019-07-31 0001428336 us-gaap:CommonStockMember 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001428336 us-gaap:CommonStockMember 2018-05-01 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-02-01 2019-07-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-05-01 2018-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001428336 2018-04-30 0001428336 us-gaap:CommonStockMember 2019-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2018-01-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-05-01 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-02-01 2019-07-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-02-01 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-02-01 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-02-01 2018-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2018-02-01 2018-07-31 0001428336 hqy:WageWorksMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember 2019-02-01 2019-07-31 0001428336 hqy:FollowOnEquityOfferingMember 2019-07-12 0001428336 us-gaap:AccountingStandardsUpdate201602Member 2019-02-01 0001428336 srt:MaximumMember 2019-07-31 0001428336 hqy:FollowOnEquityOfferingMember 2019-07-12 2019-07-12 0001428336 srt:MaximumMember 2019-02-01 2019-07-31 0001428336 srt:MinimumMember 2019-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-07-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-07-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-07-31 0001428336 us-gaap:OtherIntangibleAssetsMember 2019-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-01-31 0001428336 us-gaap:OtherIntangibleAssetsMember 2019-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-05-01 2019-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-07-31 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-09-30 2015-09-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2015-09-30 2015-09-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 2019-08-30 0001428336 2018-02-01 2019-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-05-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2018-05-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-02-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-05-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-05-01 2018-07-31 0001428336 us-gaap:RestrictedStockMember 2019-05-01 2019-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-02-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-02-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-05-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-02-01 2018-07-31 0001428336 us-gaap:PerformanceSharesMember 2019-02-01 2019-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-05-01 2018-07-31 0001428336 us-gaap:RestrictedStockMember 2018-05-01 2018-07-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-05-01 2019-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-05-01 2018-07-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-02-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-05-01 2018-07-31 0001428336 hqy:SalesandMarketingMember 2018-02-01 2018-07-31 0001428336 us-gaap:CostOfSalesMember 2019-02-01 2019-07-31 0001428336 hqy:SalesandMarketingMember 2019-05-01 2019-07-31 0001428336 us-gaap:CostOfSalesMember 2018-05-01 2018-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-05-01 2018-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-02-01 2019-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-05-01 2019-07-31 0001428336 hqy:SalesandMarketingMember 2018-05-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-02-01 2018-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-05-01 2019-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2019-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-02-01 2018-07-31 0001428336 hqy:SalesandMarketingMember 2019-02-01 2019-07-31 0001428336 us-gaap:CostOfSalesMember 2018-02-01 2018-07-31 0001428336 us-gaap:CostOfSalesMember 2019-05-01 2019-07-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember 2018-02-01 2018-07-31 0001428336 srt:MinimumMember 2018-02-01 2018-07-31 0001428336 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-07-31 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember hqy:DebtCovenantPeriodOneMember 2019-08-30 0001428336 hqy:WageWorksMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember hqy:DebtInstrumentAmortizationPeriodFourMember 2022-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember hqy:DebtCovenantPeriodFourMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember hqy:DebtCovenantPeriodFourMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember hqy:DebtInstrumentAmortizationPeriodOneMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember hqy:DebtInstrumentAmortizationPeriodFiveMember 2023-08-30 0001428336 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember hqy:DebtCovenantPeriodTwoMember 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember hqy:DebtCovenantPeriodThreeMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember hqy:DebtInstrumentAmortizationPeriodTwoMember 2020-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember hqy:DebtInstrumentAmortizationPeriodThreeMember 2021-08-30 shares iso4217:USD iso4217:USD shares pure false --01-31 Q2 2020 0001428336 0.050 0.10 24.36 63.64 0.10 0.10 44.53 44.53 73.61 82.39 82.39 125000 105000 0.0001 0.0001 900000000 900000000 62446000 70603000 62446000 70603000 22517000 45094000 19366000 61188000 P5Y P5Y 0.184 0 0 0 0.0001 0.0001 100000000 100000000 0 0 0 0 P4Y P4Y 0.3653 0.3598 0.0268 0.0243 0.0252 0.0221 0 P6Y3M P5Y2M1D P5Y1M2D P4Y11M12D 10-Q true 2019-07-31 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 70621252 815160000 361475000 27357000 25668000 10999000 7534000 853516000 394677000 81839000 709000 9873000 8223000 36716000 88768000 79666000 4651000 4651000 666000 1677000 22311000 20413000 1098340000 510016000 2740000 3520000 11055000 16981000 19392000 8552000 3954000 37141000 29053000 35660000 7773000 916000 735000 2968000 81309000 32937000 0 0 7000 6000 783986000 305223000 233038000 171850000 1017031000 477079000 1098340000 510016000 26282000 24935000 53090000 49756000 43614000 30715000 85566000 59149000 16727000 15417000 35019000 32066000 86623000 71067000 173675000 140971000 19745000 17199000 40394000 35246000 4209000 3502000 8332000 6941000 4229000 3791000 8756000 7853000 28183000 24492000 57482000 50040000 58440000 46575000 116193000 90931000 8391000 7243000 17361000 14103000 11645000 8398000 22550000 16377000 9262000 7893000 17971000 15400000 1494000 1478000 2985000 2948000 2784000 0 2784000 0 33576000 25012000 63651000 48828000 24864000 21563000 52542000 42103000 -1128000 -75000 22472000 -76000 23736000 21488000 75014000 42027000 4370000 -1029000 13826000 -3067000 19366000 22517000 61188000 45094000 0.30 0.36 0.97 0.73 0.30 0.36 0.94 0.72 64220000 61880000 63289000 61531000 65583000 63397000 64785000 63060000 529299000 396974000 477079000 346274000 6000 6000 6000 6000 0 0 0 0 1000 0 1000 0 7000 6000 7000 6000 315621000 276440000 305223000 261237000 2281000 7640000 6651000 18604000 458494000 0 458494000 0 7590000 5488000 13618000 9727000 783986000 289568000 783986000 289568000 0 0 0 -269000 269000 0 0 0 0 213672000 120528000 171850000 85300000 19366000 22517000 61188000 45094000 13007000 -356000 233038000 143045000 233038000 143045000 1017031000 432619000 1017031000 432619000 61188000 45094000 9722000 8916000 27180000 -86000 7868000 2351000 13618000 9727000 1689000 3304000 5036000 6921000 -1286000 -1083000 -837000 -5926000 -2826000 4942000 56000 -1210000 331000 298000 56831000 52640000 1736000 1014000 53845000 368000 3492000 2690000 9518000 4701000 -68591000 -8773000 458881000 0 6564000 18469000 465445000 18469000 453685000 62336000 361475000 199472000 815160000 261808000 101000 101000 9119000 554000 3000 14000 487000 175000 6500000 181000 87000 135000 386000 0 345000 0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Summary of business and significant accounting policies</span><span style="font-family:Arial;font-size:12pt;font-weight:bold;"> </span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Business</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. The Company offers a full range of innovative solutions for managing health care accounts (Health Savings Accounts ("HSAs"), Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Merger with WageWorks, Inc.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 26, 2019, HealthEquity, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”) with WageWorks, Inc., a Delaware corporation (“WageWorks”), and a wholly owned subsidiary of HealthEquity, Inc. (“Merger Sub”), pursuant to which, on the terms and subject to the conditions therein, Merger Sub would merge with and into WageWorks (the “Merger”), with WageWorks surviving the Merger and becoming a wholly owned subsidiary of HealthEquity, Inc. On August 30, 2019, the Merger closed and HealthEquity, Inc. paid approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> in cash to WageWorks stockholders. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Merger is expected to give HealthEquity, Inc. access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and consumer-directed benefits ("CDBs"), including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principles of consolidation</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, and HealthEquity Retirement Services, LLC (collectively referred to as the "Company"). </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of July 31, 2019, the Company held a </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in WageWorks. The Company measured the investment at fair value, and all unrealized gains on the investment were recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$81.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>22%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisitions of businesses are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of presentation </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying condensed consolidated financial statements as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and for the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company added a new expense line item (Merger integration) on the condensed consolidated statements of operations and comprehensive income, which includes professional fees and all other internal and external costs directly related to the integration activities as a result of the Merger. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Follow-on equity offering</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On July 12, 2019, the Company closed a follow-on public offering of </span><span style="font-family:Arial;font-size:10pt;"><span>7,762,500</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock at a public offering price of </span><span style="font-family:Arial;font-size:10pt;"><span>$61.00</span></span><span style="font-family:Arial;font-size:10pt;"> per share, less the underwriters' discount. The Company received net proceeds of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$458.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> after deducting underwriting discounts and commissions of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$14.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and other offering expenses payable by the Company of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Significant accounting policies </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases and investments in equity securities, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases. </span><span style="font-family:Arial;font-size:10pt;">The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various operating leases consisting of office space and data storage facilities with remaining lease terms of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments. </span><span style="font-family:Arial;font-size:10pt;">Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in investments on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding charge through other income (expense), net in the condensed consolidated statements of operations and comprehensive income. See Note 3—Supplemental financial statement information for additional information.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">(codified as "ASC 842"), </span><span style="font-family:Arial;font-size:10pt;">which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of </span><span style="font-family:Arial;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and ROU assets of </span><span style="font-family:Arial;font-size:10pt;"><span>$38.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;">-month period ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent issued accounting pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:Arial;font-size:10pt;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Simplifying the Test for Goodwill Impairment,</span><span style="font-family:Arial;font-size:10pt;"> which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Arial;font-size:10pt;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Arial;font-size:10pt;">. This ASU allows the capitalization of implementation costs incurred in a hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div> 2000000000.0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principles of consolidation</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, and HealthEquity Retirement Services, LLC (collectively referred to as the "Company"). </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of July 31, 2019, the Company held a </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in WageWorks. The Company measured the investment at fair value, and all unrealized gains on the investment were recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$81.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>22%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisitions of businesses are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.</span></div> 0.04 81100000 0.22 200000 0.01 500000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of presentation </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying condensed consolidated financial statements as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and for the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div> Certain reclassifications have been made to prior year amounts to conform to the current year presentation. 7762500 61.00 458500000 14100000 900000 <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases. </span><span style="font-family:Arial;font-size:10pt;">The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various operating leases consisting of office space and data storage facilities with remaining lease terms of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019. </span></div> P3Y P11Y P3Y P10Y <div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments. </span><span style="font-family:Arial;font-size:10pt;">Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in investments on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding charge through other income (expense), net in the condensed consolidated statements of operations and comprehensive income. See Note 3—Supplemental financial statement information for additional information.</span></div> <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">(codified as "ASC 842"), </span><span style="font-family:Arial;font-size:10pt;">which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of </span><span style="font-family:Arial;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and ROU assets of </span><span style="font-family:Arial;font-size:10pt;"><span>$38.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;">-month period ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent issued accounting pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:Arial;font-size:10pt;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Simplifying the Test for Goodwill Impairment,</span><span style="font-family:Arial;font-size:10pt;"> which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Arial;font-size:10pt;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Arial;font-size:10pt;">. This ASU allows the capitalization of implementation costs incurred in a hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div> 40600000 38000000.0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Net income per share</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator (basic and diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (basic):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average dilutive effect of stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, respectively, attributable to stock options, restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator (basic and diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,094</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (basic):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average dilutive effect of stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 19366000 22517000 61188000 45094000 64220000 61880000 63289000 61531000 64220000 61880000 63289000 61531000 1363000 1517000 1496000 1529000 65583000 63397000 64785000 63060000 0.30 0.36 0.97 0.73 0.30 0.36 0.94 0.72 300000 100000 300000 100000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Supplemental financial statement information</span><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Property and equipment</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment consisted of the following as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,873</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the six months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Investments consisted of the following equity investments as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities, at fair value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total equity investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>709</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gain recognized during the six months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> for equity investments held as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$27.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, which was attributable to an increase in fair value of WageWorks common stock. In connection with the closing of the Merger on August 30, 2019, the Company's investment in WageWorks common stock was canceled. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Other income (expense), net</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other income (expense), net, consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gain on marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,472</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment consisted of the following as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11,279</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>20,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(10,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,873</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4288000 3583000 5201000 4476000 11279000 9242000 20768000 17301000 10895000 9078000 9873000 8223000 1000000.0 800000 1800000 1700000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Investments consisted of the following equity investments as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Marketable equity securities, at fair value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total equity investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81,839</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>709</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 81130000 0 500000 500000 209000 209000 81839000 709000 27300000 <div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other income (expense), net, consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,817</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Unrealized gain on marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(6,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(7,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(123</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,472</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1817000 234000 3097000 425000 3774000 0 27285000 0 6596000 224000 7780000 225000 123000 85000 130000 276000 -1128000 -75000 22472000 -76000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Leases</span><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various non-cancelable operating lease agreements for office space and data storage facilities with remaining lease terms of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of operating lease costs, lease term and discount rate are as follows:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except for term and percentages)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.24 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of operating lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>31,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company had an additional operating lease for office space that has not yet commenced with undiscounted lease payments of </span><span style="font-family:Arial;font-size:10pt;"><span>$17.1 million</span></span><span style="font-family:Arial;font-size:10pt;">. This operating lease will commence in fiscal year 2021 with a lease term of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>11 years</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ROU assets obtained in exchange for new operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P3Y P11Y P3Y P10Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of operating lease costs, lease term and discount rate are as follows:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except for term and percentages)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,086</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>11.24 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,829</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ROU assets obtained in exchange for new operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1086000 2160000 P11Y2M26D 0.0437 <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of operating lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>31,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>50,774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(11,160</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2013000 4105000 4205000 4233000 4288000 31930000 50774000 11160000 39614000 3954000 35660000 39614000 17100000 P11Y 852000 1829000 0 199000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Intangible assets and goodwill</span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Intangible assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company acquired the right to act as custodian of a portfolio of HSA Members for </span><span style="font-family:Arial;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be paid in October 2019 upon conversion of the accounts to the Company's proprietary platform. The cost was recorded in accrued liabilities on the condensed consolidated balance sheet and allocated to acquired intangible member assets as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. The Company has determined the acquired intangible member assets to have a useful life of </span><span style="font-family:Arial;font-size:10pt;"><span>15 years</span></span><span style="font-family:Arial;font-size:10pt;">. The assets will be amortized using the straight-line amortization method, which has been determined appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the Company capitalized software development costs of </span><span style="font-family:Arial;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the six months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively, related to significant enhancements and upgrades to its proprietary system.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortized intangible assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Capitalized software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>48,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>40,583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired intangible member assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>92,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>149,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,827</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(61,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(53,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>88,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the Company expensed a total of </span><span style="font-family:Arial;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There were </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> changes to the goodwill carrying value during the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div> 6500000 P15Y 4000000.0 2100000 7700000 4200000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortized intangible assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Capitalized software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>48,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>40,583</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired intangible member assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>92,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>149,806</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,827</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(61,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(53,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>88,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 48410000 40583000 6430000 4252000 2882000 2882000 92084000 85110000 149806000 132827000 61038000 53161000 88768000 79666000 3800000 3400000 7700000 6600000 4000000.0 3500000 7900000 7200000 0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Commitments and contingencies</span><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company’s principal commitments consist of operating lease obligations for office space</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;">and</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">data storage facilities, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, and except for the entry into the Merger Agreement with WageWorks, providing for the acquisition of WageWorks for approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> in cash, did not change materially during the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div> 2000000000.0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On September 30, 2015, the Company entered into a credit facility (the "Prior Credit Agreement") that provided for a secured revolving credit facility in the aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> for a term of </span><span style="font-family:Arial;font-size:10pt;"><span>five years</span></span><span style="font-family:Arial;font-size:10pt;">. </span><span style="font-family:Arial;font-size:10pt;"><span>No</span></span><span style="font-family:Arial;font-size:10pt;"> amounts were drawn under the Prior Credit Agreement as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Borrowings under the Prior Credit Agreement bore interest equal to, at the Company's option, a) an adjusted LIBOR rate or b) a customary base rate, in each case with an applicable spread determined based on the Company's leverage ratio as of the most recent fiscal quarter. The applicable spread for borrowing under the Prior Credit Agreement ranged from </span><span style="font-family:Arial;font-size:10pt;"><span>1.50%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>2.00%</span></span><span style="font-family:Arial;font-size:10pt;"> with respect to adjusted LIBOR rate borrowings and </span><span style="font-family:Arial;font-size:10pt;"><span>0.50%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>1.00%</span></span><span style="font-family:Arial;font-size:10pt;"> with respect to customary base rate borrowings. The Company paid a commitment fee of </span><span style="font-family:Arial;font-size:10pt;"><span>0.20%</span></span><span style="font-family:Arial;font-size:10pt;"> on the daily amount of the unused commitments under the Prior Credit Agreement in arrears at the end of each fiscal quarter.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company's material subsidiaries were required to guarantee the obligations of the Company under the Prior Credit Agreement. The obligations of the Company and the guarantors under the Prior Credit Agreement and the guarantees were secured by substantially all assets of the Company and the guarantors, subject to customary exclusions and exceptions.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Note 7. </span><span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness (continued)</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Prior Credit Agreement required the Company to maintain a total leverage ratio of not more than </span><span style="font-family:Arial;font-size:10pt;"><span>3.00</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;">1.00</span><span style="font-family:Arial;font-size:10pt;"> as of the end of each fiscal quarter and a minimum interest coverage ratio of at least </span><span style="font-family:Arial;font-size:10pt;"><span>3.00</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;">1.00</span><span style="font-family:Arial;font-size:10pt;"> as of the end of each fiscal quarter. In addition, the Prior Credit Agreement included customary representations and warranties, affirmative and negative covenants, and events of default. The restrictive covenants included customary restrictions on the Company's ability to incur additional indebtedness; make investments, loans or advances; grant or incur liens on assets; engage in mergers, consolidations, liquidations or dissolutions; engage in transactions with affiliates; and make dividend payments. The Company was in compliance with these covenants as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the closing of the Merger on August 30, 2019, the Company entered into a new </span><span style="font-family:Arial;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Arial;font-size:10pt;"> credit agreement (the "Credit Agreement"), which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:Arial;font-size:10pt;">, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$350 million</span></span><span style="font-family:Arial;font-size:10pt;">. For a description of the terms of the Credit Agreement, refer to Note 11—Subsequent events of the Notes to condensed consolidated financial statements.</span></div> 100000000.0 P5Y 0 0.0150 0.0200 0.0050 0.0100 0.0020 3.00 3.00 1600000000 1250000000 350000000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Income taxes</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company follows FASB Accounting Standards Codification 740-270, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes - Interim Reporting</span><span style="font-family:Arial;font-size:10pt;">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company recorded income tax expense of </span><span style="font-family:Arial;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. This resulted in an effective income tax expense rate of </span><span style="font-family:Arial;font-size:10pt;"><span>18.4%</span></span><span style="font-family:Arial;font-size:10pt;"> for each of the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, compared with an effective income tax benefit rate of </span><span style="font-family:Arial;font-size:10pt;"><span>4.8%</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>7.3%</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. For the </span><span style="font-family:Arial;font-size:10pt;">three and six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the net impact of discrete tax items caused a </span><span style="font-family:Arial;font-size:10pt;"><span>4.8</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>4.6</span></span><span style="font-family:Arial;font-size:10pt;"> percentage point decrease and a </span><span style="font-family:Arial;font-size:10pt;"><span>27.0</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>29.5</span></span><span style="font-family:Arial;font-size:10pt;"> percentage point decrease, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income. The increase in the effective income tax rate from the same period last year is primarily due to a decrease in excess tax benefits on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company’s total gross unrecognized tax benefit was </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. Certain unrecognized tax benefits have been netted against their related deferred tax assets. As of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, an unrecognized tax benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> was recorded. As of </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> unrecognized tax benefit had been recorded. If recognized, </span><span style="font-family:Arial;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.</span></div> 4400000 13800000 0.184 -0.048 -0.073 -0.048 -0.046 -0.270 -0.295 2000000.0 1700000 400000 0 1900000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Stock-based compensation</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sales and marketing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Technology and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows stock-based compensation by award type: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock options</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company currently grants stock options under the 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock options to the directors and team members of the Company to purchase up to an aggregate of </span><span style="font-family:Arial;font-size:10pt;"><span>2.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by </span><span style="font-family:Arial;font-size:10pt;"><span>3%</span></span><span style="font-family:Arial;font-size:10pt;"> of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of issuance, or are forfeited </span><span style="font-family:Arial;font-size:10pt;"><span>90 days</span></span><span style="font-family:Arial;font-size:10pt;"> after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Valuation assumptions.</span><span style="font-family:Arial;font-size:10pt;"> The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">35.98% - 36.53%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.21% - 2.43%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.52% - 2.68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life of options</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.95 - 5.09 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.17 - 6.25 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">* </span><span style="font-family:Arial;font-size:7pt;"><span>No</span></span><span style="font-family:Arial;font-size:7pt;"> stock options were granted during the three months ended July 31, 2019 and 2018. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of </span><span style="font-family:Arial;font-size:10pt;"><span>zero</span></span><span style="font-family:Arial;font-size:10pt;"> is based on the fact that the Company expects to invest cash in operations. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of stock option activity is as follows:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except for exercise prices and term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of<br/>options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Range of<br/>exercise<br/>prices</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$63.64 - 73.61</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 44.53</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$24.36 - 44.53</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of July 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested and expected to vest as of July 31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.45</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of July 31, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted-average vesting period of non-vested awards expected to vest is approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1.6 years</span></span><span style="font-family:Arial;font-size:10pt;">; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Restricted stock units and restricted stock awards</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company grants restricted stock units ("RSUs") and restricted stock awards ("RSAs") to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a </span><span style="font-family:Arial;font-size:10pt;">four</span><span style="font-family:Arial;font-size:10pt;">-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Performance restricted stock units and awards.</span><span style="font-family:Arial;font-size:10pt;"> In March 2017, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>146,964</span></span><span style="font-family:Arial;font-size:10pt;"> performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>150%</span></span><span style="font-family:Arial;font-size:10pt;"> of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In March 2018, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>227,760</span></span><span style="font-family:Arial;font-size:10pt;"> performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">based on the level of achievement of the performance goals. The PRSAs were issued at the </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In March 2019, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>129,963</span></span><span style="font-family:Arial;font-size:10pt;"> PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the RSU and RSA activity is as follows: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs and PRSUs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs and PRSAs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except weighted-average grant date fair value)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the aggregate intrinsic value of RSUs and RSAs released was </span><span style="font-family:Arial;font-size:10pt;"><span>$8.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. For the </span><span style="font-family:Arial;font-size:10pt;">six</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">July 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the aggregate intrinsic value of RSUs released was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total unrecorded stock-based compensation expense as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> associated with RSUs and PRSUs was </span><span style="font-family:Arial;font-size:10pt;"><span>$52.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>2.7 years</span></span><span style="font-family:Arial;font-size:10pt;">. Total unrecorded stock-based compensation expense as of </span><span style="font-family:Arial;font-size:10pt;">July 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> associated with RSAs and PRSAs was </span><span style="font-family:Arial;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>1.8 years</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sales and marketing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Technology and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,291</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1010000 807000 1869000 1220000 1158000 891000 2166000 1596000 1930000 1300000 3429000 2291000 3492000 2490000 6154000 4620000 7590000 5488000 13618000 9727000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows stock-based compensation by award type: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,044</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,488</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,618</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1727000 1983000 3510000 3747000 0 172000 0 325000 3694000 2045000 6619000 3587000 1393000 536000 2044000 1050000 164000 171000 327000 226000 612000 581000 1118000 792000 7590000 5488000 13618000 9727000 2600000 0.03 P10Y P90D <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended July 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Six months ended July 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">35.98% - 36.53%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.21% - 2.43%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.52% - 2.68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life of options</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.95 - 5.09 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.17 - 6.25 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">* </span><span style="font-family:Arial;font-size:7pt;"><span>No</span></span><span style="font-family:Arial;font-size:7pt;"> stock options were granted during the three months ended July 31, 2019 and 2018. </span></div> 0 0 0.3784 0 0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of stock option activity is as follows:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except for exercise prices and term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of<br/>options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Range of<br/>exercise<br/>prices</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$63.64 - 73.61</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 44.53</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$24.36 - 44.53</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of July 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested and expected to vest as of July 31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.45</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>116,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of July 31, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2444000 27.37 P6Y8M26D 85971000 108000 73.27 283000 23.49 31000 30.96 2238000 30.03 P6Y5M12D 116288000 2238000 30.03 P6Y5M12D 116288000 1429000 22.14 P5Y9M 85503000 P1Y7M6D 10500000 146964 0 1.50 227760 0 2 2 129963 0 2 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the RSU and RSA activity is as follows: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs and PRSUs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs and PRSAs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except weighted-average grant date fair value)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>54.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of July 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 647000 55.18 256000 61.93 527000 70.84 0 0 122000 54.49 11000 62.75 42000 55.77 10000 61.72 1010000 63.41 235000 61.91 8800000 800000 4600000 52100000 P2Y8M12D 5400000 P1Y9M18D <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Fair value</span><span style="font-family:Arial;font-size:12pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of marketable equity securities.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Note 10. </span><span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Fair value (continued)</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy reflecting the valuation techniques utilized to determine fair value:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other investments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>81,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company did not have any assets measured at fair value on a recurring basis as of January 31, 2019. The Company has classified cash and cash equivalents and marketable equity securities as Level 1 in the fair value hierarchy.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table summarizes the assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy reflecting the valuation techniques utilized to determine fair value:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">July 31, 2019</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other investments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>81,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 81130000 0 0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Subsequent events</span><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Merger with WageWorks</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 30, 2019, the Company closed the Merger with WageWorks for </span><span style="font-family:Arial;font-size:10pt;"><span>$51.35</span></span><span style="font-family:Arial;font-size:10pt;"> per share in cash, or approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> in the aggregate. As a result of the Merger, the Company's investment in the common stock of WageWorks was canceled. In addition, the Company assumed and converted into Company equity awards approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> outstanding equity awards to WageWorks employees. The Company financed the cash transaction through a combination of </span><span style="font-family:Arial;font-size:10pt;"><span>$805.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> cash on hand plus net borrowings of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1.22 billion</span></span><span style="font-family:Arial;font-size:10pt;">, after deducting lender fees of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, under the term loan facility described below. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">New Credit Agreement</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the closing of the Merger on August 30, 2019, the Company entered into a new </span><span style="font-family:Arial;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:Arial;font-size:10pt;"> Credit Agreement, which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:Arial;font-size:10pt;">, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$350 million</span></span><span style="font-family:Arial;font-size:10pt;">, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$300 million</span></span><span style="font-family:Arial;font-size:10pt;">, plus an additional amount so long as the Company's pro forma secured net leverage ratio would not exceed </span><span style="font-family:Arial;font-size:10pt;"><span>3.85</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 as of the date such loans or commitments are incurred.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Borrowings under the Credit Agreement will bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>1.25%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>2.25%</span></span><span style="font-family:Arial;font-size:10pt;"> or (ii) an alternate base rate plus a margin ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>0.25%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>1.25%</span></span><span style="font-family:Arial;font-size:10pt;">, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The loans made under the term loan facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the term loan facility: (i) </span><span style="font-family:Arial;font-size:10pt;"><span>2.5%</span></span><span style="font-family:Arial;font-size:10pt;"> for the year commencing August 30, 2019; (ii) </span><span style="font-family:Arial;font-size:10pt;"><span>5.0%</span></span><span style="font-family:Arial;font-size:10pt;"> for each of the years during the two-year period commencing August 30, 2020; (iii) </span><span style="font-family:Arial;font-size:10pt;"><span>7.5%</span></span><span style="font-family:Arial;font-size:10pt;"> for the year commencing August 30, 2022; and (iv) </span><span style="font-family:Arial;font-size:10pt;"><span>10.0%</span></span><span style="font-family:Arial;font-size:10pt;"> for the year commencing August 30, 2023.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Credit Agreement contains customary affirmative and negative covenants, including covenants related to the following subjects: mergers, and sales of assets; limitations on the incurrence of certain liens; limitations on certain indebtedness; limitations on the ability to pay dividends; and certain affiliate transactions, in each case, subject to customary exceptions and “baskets.”</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than </span><span style="font-family:Arial;font-size:10pt;"><span>5.25</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00, which steps down to (x) </span><span style="font-family:Arial;font-size:10pt;"><span>5.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) </span><span style="font-family:Arial;font-size:10pt;"><span>4.50</span></span><span style="font-family:Arial;font-size:10pt;"> to </span></div><div style="line-height:120%;padding-bottom:8px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Note 11. </span><span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Subsequent events (continued)</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to </span><span style="font-family:Arial;font-size:10pt;"><span>5.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition in excess of </span><span style="font-family:Arial;font-size:10pt;"><span>$100 million</span></span><span style="font-family:Arial;font-size:10pt;">), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than </span><span style="font-family:Arial;font-size:10pt;"><span>3.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00.</span></div>The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions. 51.35 2000000000.0 500000 805400000 1220000000 30000000.0 1600000000 1250000000 350000000 300000000 3.85 0.0125 0.0225 0.0025 0.0125 0.025 0.050 0.075 0.100 5.25 5.00 4.50 5.00 100000000 3.00 XML 27 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Restricted stock unity activity) (Details)
shares in Thousands
6 Months Ended
Jul. 31, 2019
$ / shares
shares
RSUs and PRSUs  
Shares  
Unvested, beginning balance (in shares) | shares 647
Granted (in shares) | shares 527
Released (in shares) | shares (122)
Forfeited (in shares) | shares (42)
Unvested, ending balance (in shares) | shares 1,010
Weighted-average grant date fair value  
Unvested, beginning balance (usd per share) | $ / shares $ 55.18
Granted (usd per share) | $ / shares 70.84
Released (usd per share) | $ / shares 54.49
Forfeited (usd per share) | $ / shares 55.77
Unvested, ending balance (usd per share) | $ / shares $ 63.41
RSAs and PRSAs  
Shares  
Unvested, beginning balance (in shares) | shares 256
Granted (in shares) | shares 0
Released (in shares) | shares (11)
Forfeited (in shares) | shares (10)
Unvested, ending balance (in shares) | shares 235
Weighted-average grant date fair value  
Unvested, beginning balance (usd per share) | $ / shares $ 61.93
Granted (usd per share) | $ / shares 0
Released (usd per share) | $ / shares 62.75
Forfeited (usd per share) | $ / shares 61.72
Unvested, ending balance (usd per share) | $ / shares $ 61.91
XML 28 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Stock-based compensation expense by award type) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 7,590 $ 5,488 $ 13,618 $ 9,727
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,727 1,983 3,510 3,747
Performance stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 0 172 0 325
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,694 2,045 6,619 3,587
Performance restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,393 536 2,044 1,050
Restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 164 171 327 226
Performance restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 612 $ 581 $ 1,118 $ 792
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Tables)
6 Months Ended
Jul. 31, 2019
Leases [Abstract]  
Lease cost
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Six months ended

(in thousands, except for term and percentages)
 
July 31, 2019

 
July 31, 2019

Operating lease expense
 
$
1,086

 
$
2,160

 
 
 
 
 
Weighted average remaining lease term
 
11.24 years

Weighted average discount rate
 
4.37
%

Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Six months ended

(in thousands)
 
July 31, 2019

 
July 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
852

 
$
1,829

ROU assets obtained in exchange for new operating lease obligations
 
$

 
$
199


Operating lease liability maturity schedule
Maturities of operating lease liabilities as of July 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
2,013

2021
 
4,105

2022
 
4,205

2023
 
4,233

2024
 
4,288

Thereafter
 
31,930

Total lease payments
 
50,774

Less imputed interest
 
(11,160
)
Present value of lease liabilities
 
$
39,614

 
 
 
Current
 
$
3,954

Non-current
 
35,660

Total lease liabilities
 
$
39,614


XML 30 R9999.htm IDEA: XBRL DOCUMENT v3.19.2
Label Element Value
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 13,007,000
Accounting Standards Update 2016-01 [Member] | AOCI Attributable to Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 269,000
Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (356,000)
XML 31 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of business and significant accounting policies (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Aug. 30, 2019
Jul. 12, 2019
Jul. 31, 2019
Feb. 01, 2019
Jan. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Equity securities investment ownership percentage     4.00%    
Marketable equity securities, at fair value     $ 81,130   $ 0
Equity method investment ownership percentage     22.00%    
Equity method investments     $ 209   209
Cost method investment ownership percentage     1.00%    
Non-marketable equity securities     $ 500   $ 500
Operating lease liabilities     39,614    
Operating lease right of use asset     $ 36,716    
Follow-on equity offering          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Common stock, shares (in shares)   7,762,500      
Offering price per share (in usd per share)   $ 61.00      
Net proceeds from follow on offering   $ 458,500      
Underwriting discounts and commissions   14,100      
Other offering expenses payable   $ 900      
Minimum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Remaining operating lease terms     3 years    
Lease renewal terms extension     3 years    
Maximum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Remaining operating lease terms     11 years    
Lease renewal terms extension     10 years    
Accounting Standards Update 2016-02          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating lease liabilities       $ 40,600  
Operating lease right of use asset       $ 38,000  
WageWorks, Inc | Subsequent Event          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Consideration paid for merger $ 2,000,000        
XML 32 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental financial statement information (Other income (expense), net) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Interest income, net $ 1,817 $ 234 $ 3,097 $ 425
Unrealized gain on marketable equity securities 3,774 0 27,285 0
Acquisition costs (6,596) (224) (7,780) (225)
Other (123) (85) (130) (276)
Total other income (expense), net $ (1,128) $ (75) $ 22,472 $ (76)
XML 33 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Jul. 31, 2019
Jan. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 105 $ 125
Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 900,000,000 900,000,000
Common stock, issued (in shares) 70,603,000 62,446,000
Common stock, outstanding (in shares) 70,603,000 62,446,000
XML 34 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of business and significant accounting policies
6 Months Ended
Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. The Company offers a full range of innovative solutions for managing health care accounts (Health Savings Accounts ("HSAs"), Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.
Merger with WageWorks, Inc.
On June 26, 2019, HealthEquity, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”) with WageWorks, Inc., a Delaware corporation (“WageWorks”), and a wholly owned subsidiary of HealthEquity, Inc. (“Merger Sub”), pursuant to which, on the terms and subject to the conditions therein, Merger Sub would merge with and into WageWorks (the “Merger”), with WageWorks surviving the Merger and becoming a wholly owned subsidiary of HealthEquity, Inc. On August 30, 2019, the Merger closed and HealthEquity, Inc. paid approximately $2.0 billion in cash to WageWorks stockholders.
The Merger is expected to give HealthEquity, Inc. access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and consumer-directed benefits ("CDBs"), including flexible spending accounts, health reimbursement arrangements, COBRA administration and commuter accounts.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, and HealthEquity Retirement Services, LLC (collectively referred to as the "Company").
As of July 31, 2019, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all unrealized gains on the investment were recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. The investment was valued at $81.1 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2019 and for the three and six months ended July 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report
on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
For the three and six months ended July 31, 2019, the Company added a new expense line item (Merger integration) on the condensed consolidated statements of operations and comprehensive income, which includes professional fees and all other internal and external costs directly related to the integration activities as a result of the Merger.
Follow-on equity offering
On July 12, 2019, the Company closed a follow-on public offering of 7,762,500 shares of common stock at a public offering price of $61.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $458.5 million after deducting underwriting discounts and commissions of approximately $14.1 million and other offering expenses payable by the Company of approximately $0.9 million.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases and investments in equity securities, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019.
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space and data storage facilities with remaining lease terms of approximately 3 to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.
Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in investments on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding charge through other income (expense), net in the condensed consolidated statements of operations and comprehensive income. See Note 3—Supplemental financial statement information for additional information.
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and six-month period ended July 31, 2019.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU allows the capitalization of implementation costs incurred in a hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
XML 35 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Indebtedness
6 Months Ended
Jul. 31, 2019
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
On September 30, 2015, the Company entered into a credit facility (the "Prior Credit Agreement") that provided for a secured revolving credit facility in the aggregate principal amount of $100.0 million for a term of five years. No amounts were drawn under the Prior Credit Agreement as of July 31, 2019.
Borrowings under the Prior Credit Agreement bore interest equal to, at the Company's option, a) an adjusted LIBOR rate or b) a customary base rate, in each case with an applicable spread determined based on the Company's leverage ratio as of the most recent fiscal quarter. The applicable spread for borrowing under the Prior Credit Agreement ranged from 1.50% to 2.00% with respect to adjusted LIBOR rate borrowings and 0.50% to 1.00% with respect to customary base rate borrowings. The Company paid a commitment fee of 0.20% on the daily amount of the unused commitments under the Prior Credit Agreement in arrears at the end of each fiscal quarter.
The Company's material subsidiaries were required to guarantee the obligations of the Company under the Prior Credit Agreement. The obligations of the Company and the guarantors under the Prior Credit Agreement and the guarantees were secured by substantially all assets of the Company and the guarantors, subject to customary exclusions and exceptions.

Note 7. Indebtedness (continued)
The Prior Credit Agreement required the Company to maintain a total leverage ratio of not more than 3.00 to 1.00 as of the end of each fiscal quarter and a minimum interest coverage ratio of at least 3.00 to 1.00 as of the end of each fiscal quarter. In addition, the Prior Credit Agreement included customary representations and warranties, affirmative and negative covenants, and events of default. The restrictive covenants included customary restrictions on the Company's ability to incur additional indebtedness; make investments, loans or advances; grant or incur liens on assets; engage in mergers, consolidations, liquidations or dissolutions; engage in transactions with affiliates; and make dividend payments. The Company was in compliance with these covenants as of July 31, 2019.
In connection with the closing of the Merger on August 30, 2019, the Company entered into a new $1.6 billion credit agreement (the "Credit Agreement"), which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million. For a description of the terms of the Credit Agreement, refer to Note 11—Subsequent events of the Notes to condensed consolidated financial statements.
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent events
6 Months Ended
Jul. 31, 2019
Subsequent Events [Abstract]  
Subsequent events Subsequent events
Merger with WageWorks
On August 30, 2019, the Company closed the Merger with WageWorks for $51.35 per share in cash, or approximately $2.0 billion in the aggregate. As a result of the Merger, the Company's investment in the common stock of WageWorks was canceled. In addition, the Company assumed and converted into Company equity awards approximately 0.5 million outstanding equity awards to WageWorks employees. The Company financed the cash transaction through a combination of $805.4 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.0 million, under the term loan facility described below.
New Credit Agreement
In connection with the closing of the Merger on August 30, 2019, the Company entered into a new $1.6 billion Credit Agreement, which replaced the Prior Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Merger and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company's pro forma secured net leverage ratio would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Borrowings under the Credit Agreement will bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the term loan facility will amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the term loan facility: (i) 2.5% for the year commencing August 30, 2019; (ii) 5.0% for each of the years during the two-year period commencing August 30, 2020; (iii) 7.5% for the year commencing August 30, 2022; and (iv) 10.0% for the year commencing August 30, 2023.
The Credit Agreement contains customary affirmative and negative covenants, including covenants related to the following subjects: mergers, and sales of assets; limitations on the incurrence of certain liens; limitations on certain indebtedness; limitations on the ability to pay dividends; and certain affiliate transactions, in each case, subject to customary exceptions and “baskets.”
In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to
Note 11. Subsequent events (continued)
1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
XML 37 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Income taxes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Jan. 31, 2019
Income Tax Disclosure [Abstract]          
Income tax provision (benefit) $ 4,370,000 $ (1,029,000) $ 13,826,000 $ (3,067,000)  
Effective tax rate - (benefit) expense 18.40% (4.80%) 18.40% (7.30%)  
Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense 4.80% 27.00% 4.60% 29.50%  
Gross unrecognized tax benefits $ 2,000,000.0   $ 2,000,000.0   $ 1,700,000
Unrecognized tax benefit 400,000   400,000   $ 0
Unrecognized tax benefits that would impact the effective tax rate $ 1,900,000   $ 1,900,000    
XML 38 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible assets and goodwill (Narrative) (Details) - USD ($)
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Finite-Lived Intangible Assets [Line Items]        
Capitalized software development costs $ 4,000,000.0 $ 2,100,000 $ 7,700,000 $ 4,200,000
Software development costs incurred and expensed 3,800,000 3,400,000 7,700,000 6,600,000
Amortization expense 4,000,000.0 3,500,000 7,900,000 7,200,000
Change in goodwill 0 $ 0 $ 0 $ 0
Intangible member assets        
Finite-Lived Intangible Assets [Line Items]        
Purchase price adjustment of acquired intangible members assets $ 6,500,000      
Useful life of intangible assets     15 years  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Narrative) (Details)
$ in Millions
6 Months Ended
Jul. 31, 2019
USD ($)
Lessee, Lease, Description [Line Items]  
Operating lease not yet commenced undiscounted amount $ 17.1
Operating lease not yet commenced term of contract 11 years
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining operating lease terms 3 years
Lease renewal terms extension 3 years
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining operating lease terms 11 years
Lease renewal terms extension 10 years
XML 40 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Subsequent events (Details) - Subsequent events
Aug. 30, 2019
USD ($)
$ / shares
Aug. 30, 2023
Aug. 30, 2022
Aug. 30, 2021
Aug. 30, 2020
Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Lender fees $ 30,000,000.0        
WageWorks, Inc          
Subsequent Event [Line Items]          
Merger related costs, price per share | $ / shares $ 51.35        
Consideration paid for merger $ 2,000,000,000.0        
Equity awards assumed 500,000        
Cash paid 805,400,000        
Borrowing pursuant to term loan facility 1,220,000,000        
Credit Agreement | Line of Credit | Revolving Credit Facility          
Subsequent Event [Line Items]          
Credit facility, amount $ 350,000,000        
Facility term 5 years        
Credit Agreement | Line of Credit | Line of Credit          
Subsequent Event [Line Items]          
Credit facility, amount $ 1,600,000,000        
Possible additional future loans to incur amount $ 300,000,000        
Pro forma maximum leverage ratio 3.85        
Minimum interest coverage ratio 3.00        
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning August 30, 2019          
Subsequent Event [Line Items]          
Maximum leverage ratio 5.25        
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning July 31, 2020          
Subsequent Event [Line Items]          
Maximum leverage ratio 5.00        
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning July 31, 2021          
Subsequent Event [Line Items]          
Maximum leverage ratio 4.50        
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, acquisition holiday provision          
Subsequent Event [Line Items]          
Maximum leverage ratio 5.00        
Acquisition threshold for maximum total net leverage ratio $ 100,000,000        
Credit Agreement | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Credit facility, amount $ 1,250,000,000        
Facility term 5 years        
Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum | Line of Credit | Line of Credit          
Subsequent Event [Line Items]          
Variable rate borrowing spread 1.25%        
Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum | Line of Credit | Line of Credit          
Subsequent Event [Line Items]          
Variable rate borrowing spread 2.25%        
Credit Agreement | Base Rate | Minimum | Line of Credit | Line of Credit          
Subsequent Event [Line Items]          
Variable rate borrowing spread 0.25%        
Credit Agreement | Base Rate | Maximum | Line of Credit | Line of Credit          
Subsequent Event [Line Items]          
Variable rate borrowing spread 1.25%        
Credit Agreement | Debt amortization commencing August 30, 2019 | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Amortization percentage of original principle amount 2.50%        
Credit Agreement | Debt amortization commencing August 30, 2020 | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Amortization percentage of original principle amount         5.00%
Credit Agreement | Debt amortization commencing August 30, 2021 | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Amortization percentage of original principle amount       5.00%  
Credit Agreement | Debt amortization commencing August 30, 2022 | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Amortization percentage of original principle amount     7.50%    
Credit Agreement | Debt amortization commencing August 30, 2023 | Term Loan | Line of Credit          
Subsequent Event [Line Items]          
Amortization percentage of original principle amount   10.00%      
XML 41 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Assumptions) (Details) - shares
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected dividend yield     0.00% 0.00%
Expected stock price volatility, minimum     35.98%  
Expected stock price volatility, maximum     36.53%  
Expected stock price volatility       37.84%
Risk-free interest rate, minimum     2.21% 2.52%
Risk-free interest rate, maximum     2.43% 2.68%
Granted (shares) 0 0 108,000  
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life of options     4 years 11 months 12 days 5 years 2 months 1 day
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life of options     5 years 1 month 2 days 6 years 3 months
XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Tables)
6 Months Ended
Jul. 31, 2019
Share-based Payment Arrangement [Abstract]  
Summary of share based compensation recognized
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,010


$
807

 
$
1,869

 
$
1,220

Sales and marketing

1,158


891

 
2,166

 
1,596

Technology and development

1,930


1,300

 
3,429

 
2,291

General and administrative

3,492


2,490

 
6,154

 
4,620

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727


Summary of stock-based compensation expense by award type
The following table shows stock-based compensation by award type:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,727


$
1,983

 
$
3,510

 
$
3,747

Performance stock options



172

 

 
325

Restricted stock units

3,694


2,045

 
6,619

 
3,587

Performance restricted stock units

1,393


536

 
2,044

 
1,050

Restricted stock awards

164


171

 
327

 
226

Performance restricted stock awards

612


581

 
1,118

 
792

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727


Summary of assumptions
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended July 31,
 
Six months ended July 31,
 
  

2019
 
2018
 
2019

 
2018

Expected dividend yield

*

*
 
%
 
%
Expected stock price volatility

*

*
 
35.98% - 36.53%

 
37.84
%
Risk-free interest rate

*

*
 
2.21% - 2.43%

 
2.52% - 2.68%

Expected life of options

*

*
 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended July 31, 2019 and 2018.
Summary of stock option activity
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(283
)

$0.10 - 44.53

$
23.49





Forfeited

(31
)

$24.36 - 44.53

$
30.96





Outstanding as of July 31, 2019

2,238


$0.10 - 82.39

$
30.03


6.45

$
116,288

Vested and expected to vest as of July 31, 2019

2,238




$
30.03


6.45

$
116,288

Exercisable as of July 31, 2019

1,429




$
22.14


5.75

$
85,503


Summary of restricted stock unit activity
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

527


70.84





Released

(122
)

54.49


(11
)

62.75

Forfeited

(42
)

55.77


(10
)

61.72

Outstanding as of July 31, 2019

1,010


$
63.41


235


$
61.91


XML 44 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental financial statement information (Property and equipment) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Jan. 31, 2019
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 20,768   $ 20,768   $ 17,301
Accumulated depreciation (10,895)   (10,895)   (9,078)
Property and equipment, net 9,873   9,873   8,223
Depreciation expense 1,000 $ 800 1,800 $ 1,700  
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 4,288   4,288   3,583
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 5,201   5,201   4,476
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 11,279   $ 11,279   $ 9,242
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and contingencies (Details)
$ in Billions
Aug. 30, 2019
USD ($)
Subsequent Event | WageWorks, Inc  
Business Acquisition [Line Items]  
Consideration paid for merger $ 2.0
JSON 46 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-2019x7x3110q.htm": { "axisCustom": 2, "axisStandard": 18, "contextCount": 180, "dts": { "calculationLink": { "local": [ "hqy-20190731_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20190731_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hqy-2019x7x3110q.htm" ] }, "labelLink": { "local": [ "hqy-20190731_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20190731_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20190731.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 428, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 41, "http://healthequity.com/20190731": 11, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 57 }, "keyCustom": 28, "keyStandard": 312, "memberCustom": 18, "memberStandard": 36, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20190731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Leases", "role": "http://healthequity.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Intangible assets and goodwill", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - Commitments and contingencies", "role": "http://healthequity.com/role/CommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Indebtedness", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134100 - Disclosure - Income taxes", "role": "http://healthequity.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137100 - Disclosure - Stock-based compensation", "role": "http://healthequity.com/role/StockBasedCompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138100 - Disclosure - Fair value", "role": "http://healthequity.com/role/FairValue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140100 - Disclosure - Subsequent events", "role": "http://healthequity.com/role/SubsequentEvents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of business and significant accounting policies (Policies)", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Net income per share (Tables)", "role": "http://healthequity.com/role/NetIncomePerShareTables", "shortName": "Net income per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed consolidated balance sheets", "role": "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Supplemental financial statement information (Tables)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Leases (Tables)", "role": "http://healthequity.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322301 - Disclosure - Intangible assets and goodwill (Tables)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337301 - Disclosure - Stock-based compensation (Tables)", "role": "http://healthequity.com/role/StockBasedCompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338301 - Disclosure - Fair value (Tables)", "role": "http://healthequity.com/role/FairValueTables", "shortName": "Fair value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "2", "first": true, "lang": null, "name": "hqy:EquitySecuritiesInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details)", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of business and significant accounting policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "2", "first": true, "lang": null, "name": "hqy:EquitySecuritiesInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Net income per share (Details)", "role": "http://healthequity.com/role/NetIncomePerShareDetails", "shortName": "Net income per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails", "shortName": "Supplemental financial statement information (Property and equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Supplemental financial statement information (Investments) (Details)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails", "shortName": "Supplemental financial statement information (Investments) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestIncomeExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails", "shortName": "Supplemental financial statement information (Other income (expense), net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestIncomeExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001001 - Statement - Condensed consolidated balance sheets (Parenthetical)", "role": "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Leases (Narrative) (Details)", "role": "http://healthequity.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Leases (Lease Cost) (Details)", "role": "http://healthequity.com/role/LeasesLeaseCostDetails", "shortName": "Leases (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)", "role": "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details)", "role": "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails", "shortName": "Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425401 - Disclosure - Commitments and contingencies (Details)", "role": "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and contingencies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "I2016Q3Sep30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_hqy_PriorCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428401 - Disclosure - Indebtedness (Details)", "role": "http://healthequity.com/role/IndebtednessDetails", "shortName": "Indebtedness (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "I2016Q3Sep30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_hqy_PriorCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434401 - Disclosure - Income taxes (Details)", "role": "http://healthequity.com/role/IncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails", "shortName": "Stock-based compensation (Summary of share based compensation recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "shortName": "Stock-based compensation (Stock-based compensation expense by award type) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437404 - Disclosure - Stock-based compensation (Narrative) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-based compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437405 - Disclosure - Stock-based compensation (Assumptions) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "shortName": "Stock-based compensation (Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2019Q2YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437406 - Disclosure - Stock-based compensation (Stock option activity) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-based compensation (Stock option activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "shortName": "Stock-based compensation (Restricted stock unity activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_EquitySecuritiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438402 - Disclosure - Fair value (Details)", "role": "http://healthequity.com/role/FairValueDetails", "shortName": "Fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_EquitySecuritiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "I2020Q3Aug30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440401 - Disclosure - Subsequent events (Details)", "role": "http://healthequity.com/role/SubsequentEventsDetails", "shortName": "Subsequent events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "I2020Q3Aug30_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Condensed consolidated statements of cash flows (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of business and significant accounting policies", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Net income per share", "role": "http://healthequity.com/role/NetIncomePerShare", "shortName": "Net income per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Supplemental financial statement information", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hqy-2019x7x3110q.htm", "contextRef": "I2019Q1Feb01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - hqy-2019x7x3110q.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - hqy-2019x7x3110q.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 55, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Intangible member assets" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationConsiderationTransferredShareBasedPaymentArrangementAssumed": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Share Based Payment Arrangement Assumed", "label": "Business Combination, Consideration Transferred, Share Based Payment Arrangement Assumed", "verboseLabel": "Equity awards assumed" } } }, "localname": "BusinessCombinationConsiderationTransferredShareBasedPaymentArrangementAssumed", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_CostMethodInvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost Method Investment, Ownership Percentage", "label": "Cost Method Investment, Ownership Percentage", "terseLabel": "Cost method investment ownership percentage" } } }, "localname": "CostMethodInvestmentOwnershipPercentage", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Four", "label": "Debt Covenant Period Four [Member]", "terseLabel": "Debt covenant, acquisition holiday provision" } } }, "localname": "DebtCovenantPeriodFourMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period One", "label": "Debt Covenant Period One [Member]", "terseLabel": "Debt covenant, beginning August 30, 2019" } } }, "localname": "DebtCovenantPeriodOneMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Three", "label": "Debt Covenant Period Three [Member]", "terseLabel": "Debt covenant, beginning July 31, 2021" } } }, "localname": "DebtCovenantPeriodThreeMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Two", "label": "Debt Covenant Period Two [Member]", "terseLabel": "Debt covenant, beginning July 31, 2020" } } }, "localname": "DebtCovenantPeriodTwoMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Axis]", "terseLabel": "Debt Instrument, Amortization Period [Axis]" } } }, "localname": "DebtInstrumentAmortizationPeriodAxis", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtInstrumentAmortizationPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Domain]", "terseLabel": "Debt Instrument, Amortization Period [Domain]" } } }, "localname": "DebtInstrumentAmortizationPeriodDomain", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period Five [Member]", "label": "Debt Instrument, Amortization Period Five [Member]", "terseLabel": "Debt amortization commencing August 30, 2023" } } }, "localname": "DebtInstrumentAmortizationPeriodFiveMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period Four [Member]", "label": "Debt Instrument, Amortization Period Four [Member]", "terseLabel": "Debt amortization commencing August 30, 2022" } } }, "localname": "DebtInstrumentAmortizationPeriodFourMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period One", "label": "Debt Instrument, Amortization Period One [Member]", "terseLabel": "Debt amortization commencing August 30, 2019" } } }, "localname": "DebtInstrumentAmortizationPeriodOneMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period Three [Member]", "label": "Debt Instrument, Amortization Period Three [Member]", "terseLabel": "Debt amortization commencing August 30, 2021" } } }, "localname": "DebtInstrumentAmortizationPeriodThreeMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period Two [Member]", "terseLabel": "Debt amortization commencing August 30, 2020" } } }, "localname": "DebtInstrumentAmortizationPeriodTwoMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "label": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "terseLabel": "Acquisition threshold for maximum total net leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_DebtInstrumentCovenantDescriptionAmortizationPercentageOfOriginalPrincipalAmount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Amortization, Percentage Of Original Principal Amount", "label": "Debt Instrument, Covenant Description, Amortization, Percentage Of Original Principal Amount", "terseLabel": "Amortization percentage of original principle amount" } } }, "localname": "DebtInstrumentCovenantDescriptionAmortizationPercentageOfOriginalPrincipalAmount", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentCovenantDescriptionIncreaseInMaximumBorrowingCapacityProFormaSecuredLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Increase In Maximum Borrowing Capacity, Pro Forma Secured Leverage Ratio", "label": "Debt Instrument, Covenant Description, Increase In Maximum Borrowing Capacity, Pro Forma Secured Leverage Ratio", "terseLabel": "Pro forma maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionIncreaseInMaximumBorrowingCapacityProFormaSecuredLeverageRatio", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantDescriptionInterestCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "label": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionInterestCoverageRatio", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantDescriptionLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Leverage Ratio", "label": "Debt Instrument, Covenant Description, Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionLeverageRatio", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "pureItemType" }, "hqy_EquitySecuritiesInvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Securities Investment, Ownership Percentage", "label": "Equity Securities Investment, Ownership Percentage", "terseLabel": "Equity securities investment ownership percentage" } } }, "localname": "EquitySecuritiesInvestmentOwnershipPercentage", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_ExerciseofStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exercise of Stock Options Receivable", "label": "Exercise of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseofStockOptionsReceivable", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_FollowOnEquityOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follow On Equity Offering [Member]", "label": "Follow On Equity Offering [Member]", "terseLabel": "Follow-on equity offering" } } }, "localname": "FollowOnEquityOfferingMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Remaining Lease Term", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining operating lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_LineOfCreditFacilityPotentialIncreaseInMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Potential Increase In Maximum Borrowing Capacity", "label": "Line Of Credit Facility, Potential Increase In Maximum Borrowing Capacity", "terseLabel": "Possible additional future loans to incur amount" } } }, "localname": "LineOfCreditFacilityPotentialIncreaseInMaximumBorrowingCapacity", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Awards [Member]", "label": "Performance Restricted Stock Awards [Member]", "terseLabel": "Performance restricted stock awards" } } }, "localname": "PerformanceRestrictedStockAwardsMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_PriorCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prior Credit Agreement [Member]", "label": "Prior Credit Agreement [Member]", "terseLabel": "Prior Credit Agreement" } } }, "localname": "PriorCreditAgreementMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/IndebtednessDetails" ], "xbrltype": "domainItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeiturePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period", "terseLabel": "Forfeiture period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeiturePeriod", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "terseLabel": "Forfeited, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted", "terseLabel": "Granted, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitGranted", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (usd per share)", "periodStartLabel": "Beginning balance, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "terseLabel": "Forfeited, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted", "terseLabel": "Granted, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitGranted", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (usd per share)", "periodStartLabel": "Beginning balance, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_StockIssuanceCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issuance Costs Incurred But Not Yet Paid", "label": "Stock Issuance Costs Incurred But Not Yet Paid", "terseLabel": "Follow-on equity offering costs accrued during the period" } } }, "localname": "StockIssuanceCostsIncurredButNotYetPaid", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_StockIssuanceCostsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issuance Costs Payable", "label": "Stock Issuance Costs Payable", "terseLabel": "Other offering expenses payable" } } }, "localname": "StockIssuanceCostsPayable", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_UnrecognizedTaxBenefitNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefit, Net", "label": "Unrecognized Tax Benefit, Net", "terseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefitNet", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_WageWorksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Wage Works [Member]", "label": "Wage Works [Member]", "terseLabel": "WageWorks, Inc" } } }, "localname": "WageWorksMember", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20190731", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r96", "r142", "r144", "r279", "r280" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Cumulative effect from adoption of ASC 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Cumulative effect from adoption of ASU 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r15", "r97", "r98", "r143" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts as of July 31, 2019 and January 31, 2019 of $105 and $125, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r127" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r39", "r40", "r214" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r149", "r151", "r186", "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r151", "r180", "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r21", "r99", "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r64", "r115", "r122" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r94", "r258", "r271" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r37" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r153", "r182" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate", "verboseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r203", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "verboseLabel": "Merger related costs, price per share" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r202" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r208", "r209", "r210" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Consideration paid for merger" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r207", "r208", "r209", "r212" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Borrowing pursuant to term loan facility" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r68", "r69", "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities at period end" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software development costs" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r22", "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r60", "r66", "r71" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r228" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r131", "r263", "r275" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r130", "r132" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r135" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 70,603 and 62,446 shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r42", "r44", "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r116", "r120", "r206" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r72", "r213", "r215", "r216" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r51" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Total cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange revenue" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect from adoption of accounting standard updates" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Acquired intangible member assets" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r11", "r12", "r259", "r260", "r269" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r32", "r74", "r136", "r137", "r138", "r139", "r229", "r230", "r232", "r268" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r68", "r69", "r70" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Debt issuance costs accrued during the period" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Lender fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r197" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r64", "r73", "r198", "r199" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r192", "r197" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r64", "r125" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r64", "r92" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r78", "r82", "r84", "r85", "r86", "r89", "r266", "r277" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per share:", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r48", "r78", "r82", "r84", "r85", "r86", "r89", "r266", "r277" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r75", "r193", "r194" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate - (benefit) expense" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r188", "r193" ], "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "negatedTerseLabel": "Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average vesting period of non-vested awards expected to vest" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r23", "r95", "r105" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails", "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r226" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Marketable equity securities, at fair value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails", "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r103" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain on marketable equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails", "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r6", "r10", "r101", "r262", "r270", "r285" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r102" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Non-marketable equity securities", "verboseLabel": "Non-marketable equity securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails", "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r218", "r219", "r220", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r218", "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Assets measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r146", "r147", "r148", "r219", "r252" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r218", "r219", "r221", "r222", "r225" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r146", "r147", "r148", "r219", "r253" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r146", "r147", "r148", "r219", "r254" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r146", "r147", "r148", "r219", "r255" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r223", "r225" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial revenue" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r121" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r116", "r118", "r121", "r123", "r256" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r121", "r256" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r116", "r120" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r121" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Purchase price adjustment of acquired intangible members assets" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r64" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedTerseLabel": "Unrealized (gains) losses on marketable equity securities and other" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r111", "r112" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Change in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r50" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r46", "r78", "r257", "r264", "r278" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r73", "r93", "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash, net of refunds received" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r83", "r88" ], "calculation": { "http://healthequity.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r114", "r119" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r267" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r61", "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r101", "r104", "r108", "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Investment [Table Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r281", "r282", "r283", "r284" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r281", "r282", "r283", "r284" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investment [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating lease liability maturity schedule" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remaining 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r247" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal terms extension" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r261", "r273" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r12", "r260", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r23" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments", "totalLabel": "Total equity investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/SupplementalFinancialStatementInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r32", "r133" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r62", "r65" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r43", "r47", "r65", "r88", "r265", "r276" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income and comprehensive income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r77", "r79" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent adopted and issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r68", "r69", "r70" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of intangible assets" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r235" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r235" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liabilities, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r235" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, Non-current", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r237", "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r234" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r245", "r248" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r244", "r248" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r76", "r91", "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "verboseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r53" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r54", "r211" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible member assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r56" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of marketable equity securities and other" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2019 and January 31, 2019, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from follow-on equity offering, net of payments for offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r57", "r183" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r128" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r24", "r126" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r128", "r274" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7", "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r7", "r126" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r190", "r287" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Software development costs incurred and expensed" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards", "verboseLabel": "RSAs and PRSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "verboseLabel": "RSUs and PRSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r140", "r272" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r141", "r142" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Secured Revolving Credit Facility", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r243", "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Net proceeds from follow on offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock, shares (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Offering price per share (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r203", "r204" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense by award type" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r151", "r179", "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of share based compensation recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r116", "r120" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r116", "r120" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r25", "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r153", "r182" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r158", "r169", "r171" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Term Loan" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending balance (in shares)", "periodStartLabel": "Unvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance (usd per share)", "periodStartLabel": "Unvested, beginning balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable as of year end, weighted-average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r160", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Opening balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (usd per share)", "periodStartLabel": "Opening balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest as of year end, aggregate intrinsic value (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest as of year end, weighted average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r150", "r157" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r175", "r184" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable as of year end, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable as of year end, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest as of year end, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Capitalized software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r35", "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r135", "r140", "r162" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r135", "r140" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r140", "r152", "r170" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r100" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "verboseLabel": "Subsequent events" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r191", "r195" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessDetails", "http://healthequity.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r81", "r86" ], "calculation": { "http://healthequity.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r80", "r86" ], "calculation": { "http://healthequity.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeUnaudited", "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r288": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r289": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r291": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r292": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r293": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" } }, "version": "2.1" } XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Maturities of Operating Lease Liabilities) (Details)
$ in Thousands
Jul. 31, 2019
USD ($)
Leases [Abstract]  
Remaining 2020 $ 2,013
2021 4,105
2022 4,205
2023 4,233
2024 4,288
Thereafter 31,930
Total lease payments 50,774
Less imputed interest (11,160)
Total lease liabilities 39,614
Operating lease liabilities, Current 3,954
Operating lease liabilities, Non-current $ 35,660
XML 48 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Cover Page - shares
6 Months Ended
Jul. 31, 2019
Aug. 30, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jul. 31, 2019  
Document Transition Report false  
Entity File Number 001-36568  
Entity Registrant Name HEALTHEQUITY, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-2383166  
Entity Address, Address Line One 15 West Scenic Pointe Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Draper,  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84020  
City Area Code 801  
Local Phone Number 727-1000  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol HQY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   70,621,252
Entity Central Index Key 0001428336  
Current Fiscal Year End Date --01-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 49 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Net income per share (Tables)
6 Months Ended
Jul. 31, 2019
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted
The following table sets forth the computation of basic and diluted net income per share:
(in thousands, except per share data)
 
Three months ended July 31,
 
 
Six months ended July 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income
 
$
19,366

 
$
22,517

 
$
61,188

 
$
45,094

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Weighted-average dilutive effect of stock options and restricted stock units
 
1,363

 
1,517

 
1,496

 
1,529

Diluted weighted-average common shares outstanding
 
65,583

 
63,397

 
64,785

 
63,060

Net income per share:
 
 
 
 
 
 
 
 
Basic
 
$
0.30

 
$
0.36

 
$
0.97

 
$
0.73

Diluted
 
$
0.30

 
$
0.36

 
$
0.94

 
$
0.72


XML 50 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated comprehensive loss
Accumulated earnings
Beginning balance at Jan. 31, 2018 $ 346,274 $ 6 $ 261,237 $ (269) $ 85,300
Issuance of common stock upon exercise of stock options, and for restricted stock   0 18,604    
Issuance of common stock   0      
Other issuance of common stock     0    
Stock-based compensation     9,727    
Net income 45,094       45,094
Ending balance at Jul. 31, 2018 432,619 6 289,568 0 143,045
Beginning balance at Apr. 30, 2018 396,974 6 276,440 0 120,528
Issuance of common stock upon exercise of stock options, and for restricted stock   0 7,640    
Issuance of common stock   0      
Other issuance of common stock     0    
Stock-based compensation     5,488    
Net income 22,517       22,517
Ending balance at Jul. 31, 2018 432,619 6 289,568 0 143,045
Beginning balance at Jan. 31, 2019 477,079 6 305,223 0 171,850
Issuance of common stock upon exercise of stock options, and for restricted stock   0 6,651    
Issuance of common stock   1      
Other issuance of common stock     458,494    
Stock-based compensation     13,618    
Net income 61,188       61,188
Ending balance at Jul. 31, 2019 1,017,031 7 783,986 0 233,038
Beginning balance at Apr. 30, 2019 529,299 6 315,621 0 213,672
Issuance of common stock upon exercise of stock options, and for restricted stock   0 2,281    
Issuance of common stock   1      
Other issuance of common stock     458,494    
Stock-based compensation     7,590    
Net income 19,366       19,366
Ending balance at Jul. 31, 2019 $ 1,017,031 $ 7 $ 783,986 $ 0 $ 233,038
XML 51 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible assets and goodwill
6 Months Ended
Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
During the three months ended July 31, 2019, the Company acquired the right to act as custodian of a portfolio of HSA Members for $6.5 million, which is expected to be paid in October 2019 upon conversion of the accounts to the Company's proprietary platform. The cost was recorded in accrued liabilities on the condensed consolidated balance sheet and allocated to acquired intangible member assets as of July 31, 2019. The Company has determined the acquired intangible member assets to have a useful life of 15 years. The assets will be amortized using the straight-line amortization method, which has been determined appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.
During the three months ended July 31, 2019 and 2018, the Company capitalized software development costs of $4.0 million and $2.1 million, respectively, and $7.7 million and $4.2 million for the six months ended July 31, 2019 and 2018, respectively, related to significant enhancements and upgrades to its proprietary system.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2019 and January 31, 2019:
(in thousands)

July 31, 2019


January 31, 2019

Amortized intangible assets:

 
 
 
Capitalized software development costs

$
48,410

 
$
40,583

Software

6,430

 
4,252

Other intangible assets

2,882

 
2,882

Acquired intangible member assets

92,084

 
85,110

Intangible assets, gross

149,806

 
132,827

Accumulated amortization

(61,038
)
 
(53,161
)
Intangible assets, net

$
88,768

 
$
79,666


During the three months ended July 31, 2019 and 2018, the Company expensed a total of $3.8 million and $3.4 million, respectively, and $7.7 million and $6.6 million for the six months ended July 31, 2019 and 2018, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
Amortization expense for the three months ended July 31, 2019 and 2018 was $4.0 million and $3.5 million, respectively, and $7.9 million and $7.2 million for the six months ended July 31, 2019 and 2018, respectively.
Goodwill
There were no changes to the goodwill carrying value during the three and six months ended July 31, 2019 and 2018.
XML 52 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental financial statement information
6 Months Ended
Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:
Property and equipment
Property and equipment consisted of the following as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
4,288

 
$
3,583

Furniture and fixtures
 
5,201

 
4,476

Computer equipment
 
11,279

 
9,242

Property and equipment, gross
 
20,768

 
17,301

Accumulated depreciation
 
(10,895
)
 
(9,078
)
Property and equipment, net
 
$
9,873

 
$
8,223


Depreciation expense for the three months ended July 31, 2019 and 2018 was $1.0 million and $0.8 million, respectively, and $1.8 million and $1.7 million for the six months ended July 31, 2019 and 2018, respectively.
Investments
Investments consisted of the following equity investments as of July 31, 2019 and January 31, 2019:
(in thousands)
 
July 31, 2019

 
January 31, 2019

Marketable equity securities, at fair value
 
$
81,130

 
$

Non-marketable equity securities
 
500

 
500

Equity method investments
 
209

 
209

Total equity investments
 
$
81,839

 
$
709


Unrealized gain recognized during the six months ended July 31, 2019 for equity investments held as of July 31, 2019 was $27.3 million, which was attributable to an increase in fair value of WageWorks common stock. In connection with the closing of the Merger on August 30, 2019, the Company's investment in WageWorks common stock was canceled.
Other income (expense), net
Other income (expense), net, consisted of the following:
 
 
Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income, net
 
$
1,817

 
$
234

 
$
3,097

 
$
425

Unrealized gain on marketable equity securities
 
3,774

 

 
27,285

 

Acquisition costs
 
(6,596
)
 
(224
)
 
(7,780
)
 
(225
)
Other
 
(123
)
 
(85
)
 
(130
)
 
(276
)
Total other income (expense), net
 
$
(1,128
)
 
$
(75
)
 
$
22,472

 
$
(76
)

XML 53 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation
6 Months Ended
Jul. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,010


$
807

 
$
1,869

 
$
1,220

Sales and marketing

1,158


891

 
2,166

 
1,596

Technology and development

1,930


1,300

 
3,429

 
2,291

General and administrative

3,492


2,490

 
6,154

 
4,620

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727


The following table shows stock-based compensation by award type:


Three months ended July 31,
 
 
Six months ended July 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,727


$
1,983

 
$
3,510

 
$
3,747

Performance stock options



172

 

 
325

Restricted stock units

3,694


2,045

 
6,619

 
3,587

Performance restricted stock units

1,393


536

 
2,044

 
1,050

Restricted stock awards

164


171

 
327

 
226

Performance restricted stock awards

612


581

 
1,118

 
792

Total stock-based compensation expense

$
7,590


$
5,488

 
$
13,618

 
$
9,727


Stock options
The Company currently grants stock options under the 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock options to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors.
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended July 31,
 
Six months ended July 31,
 
  

2019
 
2018
 
2019

 
2018

Expected dividend yield

*

*
 
%
 
%
Expected stock price volatility

*

*
 
35.98% - 36.53%

 
37.84
%
Risk-free interest rate

*

*
 
2.21% - 2.43%

 
2.52% - 2.68%

Expected life of options

*

*
 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended July 31, 2019 and 2018.
The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(283
)

$0.10 - 44.53

$
23.49





Forfeited

(31
)

$24.36 - 44.53

$
30.96





Outstanding as of July 31, 2019

2,238


$0.10 - 82.39

$
30.03


6.45

$
116,288

Vested and expected to vest as of July 31, 2019

2,238




$
30.03


6.45

$
116,288

Exercisable as of July 31, 2019

1,429




$
22.14


5.75

$
85,503


The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
As of July 31, 2019, the weighted-average vesting period of non-vested awards expected to vest is approximately 1.6 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $10.5 million.
Restricted stock units and restricted stock awards
The Company grants restricted stock units ("RSUs") and restricted stock awards ("RSAs") to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 150% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals.
In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from 0% to 200%
based on the level of achievement of the performance goals. The PRSAs were issued at the 200% level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.
In March 2019, the Company awarded 129,963 PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 200% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals.
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

527


70.84





Released

(122
)

54.49


(11
)

62.75

Forfeited

(42
)

55.77


(10
)

61.72

Outstanding as of July 31, 2019

1,010


$
63.41


235


$
61.91


For the six months ended July 31, 2019, the aggregate intrinsic value of RSUs and RSAs released was $8.8 million and $0.8 million, respectively. For the six months ended July 31, 2018, the aggregate intrinsic value of RSUs released was $4.6 million.
Total unrecorded stock-based compensation expense as of July 31, 2019 associated with RSUs and PRSUs was $52.1 million, which is expected to be recognized over a weighted-average period of 2.7 years. Total unrecorded stock-based compensation expense as of July 31, 2019 associated with RSAs and PRSAs was $5.4 million, which is expected to be recognized over a weighted-average period of 1.8 years.
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Indebtedness (Details)
Aug. 30, 2019
USD ($)
Sep. 30, 2015
USD ($)
Jul. 31, 2019
USD ($)
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility      
Debt Instrument [Line Items]      
Credit facility, amount   $ 100,000,000.0  
Facility term   5 years  
Long-term Line of Credit     $ 0
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Minimum      
Debt Instrument [Line Items]      
Commitment fee percentage   0.20%  
Minimum interest coverage ratio   3.00  
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Maximum      
Debt Instrument [Line Items]      
Maximum leverage ratio   3.00  
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   1.50%  
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   2.00%  
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Customary Base Rate | Minimum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   0.50%  
Prior Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Customary Base Rate | Maximum      
Debt Instrument [Line Items]      
Variable rate borrowing spread   1.00%  
Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Subsequent Event      
Debt Instrument [Line Items]      
Credit facility, amount $ 350,000,000    
Facility term 5 years    
Credit Agreement | Line of Credit | Line of Credit | Subsequent Event      
Debt Instrument [Line Items]      
Credit facility, amount $ 1,600,000,000    
Minimum interest coverage ratio 3.00    
Credit Agreement | Line of Credit | Line of Credit | London Interbank Offered Rate (LIBOR) | Minimum | Subsequent Event      
Debt Instrument [Line Items]      
Variable rate borrowing spread 1.25%    
Credit Agreement | Line of Credit | Line of Credit | London Interbank Offered Rate (LIBOR) | Maximum | Subsequent Event      
Debt Instrument [Line Items]      
Variable rate borrowing spread 2.25%    
Credit Agreement | Line of Credit | Line of Credit | Customary Base Rate | Minimum | Subsequent Event      
Debt Instrument [Line Items]      
Variable rate borrowing spread 0.25%    
Credit Agreement | Line of Credit | Line of Credit | Customary Base Rate | Maximum | Subsequent Event      
Debt Instrument [Line Items]      
Variable rate borrowing spread 1.25%    
Credit Agreement | Term Loan | Line of Credit | Subsequent Event      
Debt Instrument [Line Items]      
Credit facility, amount $ 1,250,000,000    
Facility term 5 years    
XML 55 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Supplemental Cash Flow Information) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 852 $ 1,829
ROU assets obtained in exchange for new operating lease obligations $ 0 $ 199
XML 57 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Leases
6 Months Ended
Jul. 31, 2019
Leases [Abstract]  
Leases Leases
The Company has entered into various non-cancelable operating lease agreements for office space and data storage facilities with remaining lease terms of approximately 3 to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Six months ended

(in thousands, except for term and percentages)
 
July 31, 2019

 
July 31, 2019

Operating lease expense
 
$
1,086

 
$
2,160

 
 
 
 
 
Weighted average remaining lease term
 
11.24 years

Weighted average discount rate
 
4.37
%

Maturities of operating lease liabilities as of July 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
2,013

2021
 
4,105

2022
 
4,205

2023
 
4,233

2024
 
4,288

Thereafter
 
31,930

Total lease payments
 
50,774

Less imputed interest
 
(11,160
)
Present value of lease liabilities
 
$
39,614

 
 
 
Current
 
$
3,954

Non-current
 
35,660

Total lease liabilities
 
$
39,614


As of July 31, 2019, the Company had an additional operating lease for office space that has not yet commenced with undiscounted lease payments of $17.1 million. This operating lease will commence in fiscal year 2021 with a lease term of approximately 11 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Six months ended

(in thousands)
 
July 31, 2019

 
July 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
852

 
$
1,829

ROU assets obtained in exchange for new operating lease obligations
 
$

 
$
199


XML 58 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Net income per share
6 Months Ended
Jul. 31, 2019
Earnings Per Share [Abstract]  
Net income per share Net income per share
The following table sets forth the computation of basic and diluted net income per share:
(in thousands, except per share data)
 
Three months ended July 31,
 
 
Six months ended July 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income
 
$
19,366

 
$
22,517

 
$
61,188

 
$
45,094

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
64,220

 
61,880

 
63,289

 
61,531

Weighted-average dilutive effect of stock options and restricted stock units
 
1,363

 
1,517

 
1,496

 
1,529

Diluted weighted-average common shares outstanding
 
65,583

 
63,397

 
64,785

 
63,060

Net income per share:
 
 
 
 
 
 
 
 
Basic
 
$
0.30

 
$
0.36

 
$
0.97

 
$
0.73

Diluted
 
$
0.30

 
$
0.36

 
$
0.94

 
$
0.72


For the three months ended July 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options, restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
XML 59 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Income taxes
6 Months Ended
Jul. 31, 2019
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and six months ended July 31, 2019, the Company recorded income tax expense of $4.4 million and $13.8 million, respectively. This resulted in an effective income tax expense rate of 18.4% for each of the three and six months ended July 31, 2019, compared with an effective income tax benefit rate of 4.8% and 7.3% for the three and six months ended July 31, 2018, respectively. For the three and six months ended July 31, 2019 and 2018, the net impact of discrete tax items caused a 4.8 and 4.6 percentage point decrease and a 27.0 and 29.5 percentage point decrease, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income. The increase in the effective income tax rate from the same period last year is primarily due to a decrease in excess tax benefits on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income.
As of July 31, 2019 and January 31, 2019, the Company’s total gross unrecognized tax benefit was $2.0 million and $1.7 million, respectively. Certain unrecognized tax benefits have been netted against their related deferred tax assets. As of July 31, 2019, an unrecognized tax benefit of $0.4 million was recorded. As of January 31, 2019, no unrecognized tax benefit had been recorded. If recognized, $1.9 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2019.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.
XML 60 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Summary of business and significant accounting policies (Policies)
6 Months Ended
Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, and HealthEquity Retirement Services, LLC (collectively referred to as the "Company").
As of July 31, 2019, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all unrealized gains on the investment were recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income. The investment was valued at $81.1 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of July 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2019 and for the three and six months ended July 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report
on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Leases
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space and data storage facilities with remaining lease terms of approximately 3 to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments
Investments. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net in the condensed consolidated statements of operations and comprehensive income.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.
Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in investments on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive income.
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding charge through other income (expense), net in the condensed consolidated statements of operations and comprehensive income. See Note 3—Supplemental financial statement information for additional information.
Recent adopted and issued accounting pronouncements
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and six-month period ended July 31, 2019.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU allows the capitalization of implementation costs incurred in a hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. As a result of the Merger, the Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
XML 61 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed consolidated statements of operations and comprehensive income (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Revenue:        
Total revenue $ 86,623 $ 71,067 $ 173,675 $ 140,971
Cost of revenue:        
Total cost of revenue 28,183 24,492 57,482 50,040
Gross profit 58,440 46,575 116,193 90,931
Operating expenses:        
Sales and marketing 8,391 7,243 17,361 14,103
Technology and development 11,645 8,398 22,550 16,377
General and administrative 9,262 7,893 17,971 15,400
Amortization of acquired intangible assets 1,494 1,478 2,985 2,948
Merger integration 2,784 0 2,784 0
Total operating expenses 33,576 25,012 63,651 48,828
Income from operations 24,864 21,563 52,542 42,103
Other income (expense), net (1,128) (75) 22,472 (76)
Income before income taxes 23,736 21,488 75,014 42,027
Income tax provision (benefit) 4,370 (1,029) 13,826 (3,067)
Net income and comprehensive income 19,366 22,517 61,188 45,094
Comprehensive income $ 19,366 $ 22,517 $ 61,188 $ 45,094
Net income per share:        
Basic (in usd per share) $ 0.30 $ 0.36 $ 0.97 $ 0.73
Diluted (in usd per share) $ 0.30 $ 0.36 $ 0.94 $ 0.72
Weighted-average number of shares used in computing net income per share:        
Basic (in shares) 64,220 61,880 63,289 61,531
Diluted (in shares) 65,583 63,397 64,785 63,060
Service revenue        
Revenue:        
Total revenue $ 26,282 $ 24,935 $ 53,090 $ 49,756
Cost of revenue:        
Total cost of revenue 19,745 17,199 40,394 35,246
Custodial revenue        
Revenue:        
Total revenue 43,614 30,715 85,566 59,149
Cost of revenue:        
Total cost of revenue 4,209 3,502 8,332 6,941
Interchange revenue        
Revenue:        
Total revenue 16,727 15,417 35,019 32,066
Cost of revenue:        
Total cost of revenue $ 4,229 $ 3,791 $ 8,756 $ 7,853
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Stock-based compensation (Stock option activity) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jan. 31, 2019
Number of options (shares)        
Opening balance (shares)     2,444,000  
Granted (shares) 0 0 108,000  
Exercised (shares)     (283,000)  
Forfeited (shares)     (31,000)  
Ending balance (shares) 2,238,000   2,238,000 2,444,000
Range of exercise prices (usd per share)        
Beginning balance, minimum (usd per share)     $ 0.10  
Beginning balance, maximum (usd per share)     82.39  
Granted, minimum (usd per share)     63.64  
Granted, maximum (usd per share)     73.61  
Exercised, minimum (usd per share)     0.10  
Exercised, maximum (usd per share)     44.53  
Forfeited, minimum (usd per share)     24.36  
Forfeited, maximum (usd per share)     44.53  
Ending balance, minimum (usd per share) $ 0.10   0.10 $ 0.10
Ending balance, maximum (usd per share) 82.39   82.39 82.39
Weighted- average exercise price (usd per share)        
Opening balance (usd per share)     27.37  
Granted (usd per share)     73.27  
Exercised (usd per share)     23.49  
Forfeited (usd per share)     30.96  
Ending balance (usd per share) $ 30.03   $ 30.03 $ 27.37
Weighted- average contractual term (in years)     6 years 5 months 12 days 6 years 8 months 26 days
Aggregate intrinsic value $ 116,288   $ 116,288 $ 85,971
Vested and expected to vest as of year end (in shares) 2,238,000   2,238,000  
Vested and expected to vest as of year end, weighted average exercise price (usd per share) $ 30.03   $ 30.03  
Vested and expected to vest as of year end, weighted average contractual term (in years)     6 years 5 months 12 days  
Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) $ 116,288   $ 116,288  
Exercisable as of year end (in shares) 1,429,000   1,429,000  
Exercisable as of year end, weighted-average exercise price (usd per share) $ 22.14   $ 22.14  
Exercisable as of year end, weighted-average contractual term (in years)     5 years 9 months  
Exercisable as of year end, aggregate intrinsic value $ 85,503   $ 85,503  
XML 63 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible assets and goodwill (Tables)
6 Months Ended
Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of finite-lived intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2019 and January 31, 2019:
(in thousands)

July 31, 2019


January 31, 2019

Amortized intangible assets:

 
 
 
Capitalized software development costs

$
48,410

 
$
40,583

Software

6,430

 
4,252

Other intangible assets

2,882

 
2,882

Acquired intangible member assets

92,084

 
85,110

Intangible assets, gross

149,806

 
132,827

Accumulated amortization

(61,038
)
 
(53,161
)
Intangible assets, net

$
88,768

 
$
79,666


XML 64 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Net income per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Numerator (basic and diluted):        
Net income $ 19,366 $ 22,517 $ 61,188 $ 45,094
Denominator (basic):        
Weighted-average common shares outstanding (in shares) 64,220 61,880 63,289 61,531
Denominator (diluted):        
Weighted-average common shares outstanding (in shares) 64,220 61,880 63,289 61,531
Weighted-average dilutive effect of stock options and restricted stock units (in shares) 1,363 1,517 1,496 1,529
Diluted weighted-average common shares outstanding (in shares) 65,583 63,397 64,785 63,060
Net income per share:        
Basic (in usd per share) $ 0.30 $ 0.36 $ 0.97 $ 0.73
Diluted (in usd per share) $ 0.30 $ 0.36 $ 0.94 $ 0.72
Antidilutive securities excluded from computation of earnings per share (in shares) 300 100 300 100
ZIP 65 0001428336-19-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-19-000021-xbrl.zip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

.(XM:-RM26, MLM%%]FM2KQ!Z\GB>UI^%MLW;OAU2@5(V;V\>24Q$*+!"+ RTH)%;EL@,/)?P M1A6V;6U/4R/9#.L^%5I/S(5*T6 M G0%A$(N<>7_X9Y:27$YA?_GN#SH2=QQX%GXS(< M/QJ2:9^+M/7J>Z/S;P&.U;R F"'/C0*.J!">\B7R1=F!.Q ^%HWAV*ZV]9Q^ M@7R#.?4V"&>2=N$F'5=?#%<37*O*ROU0N,P-M&GD2ESB^V'E,<-*K52^/Y6U M?@*NIIO;='=GVQ:6Q=LT1)[W0#P+EAX%+A:\I#80U/%SLA5'$5]H8G,G"2,H6/MCK5/Q]I\SMH$,1$2S"BCE"K,PX@QZU.@IH93^"8G\B=A M;7)%&G6VMX^U+^GT_2_):%;)+^X_I*,TGV2VOGE+O)XMM#7.%)QJ49,HTB%Q M.5%@3R"$,*@@50"XX-1=Z<=QRG24DB+5J*\6Z+%\29,JB"27X +MN/*0[25*PEP99,V_[OBRK:J^>?)FK3F@PN1 M*R*.5224T!R[81!I:ZA3YON8KW8,Z%BS8\W3LR:=LZ:+F,\8 M1]BGDJ(@((+:#"#%I1^$C+UEZ/NI6)-=B4;#X=MO6F\JSK&=9PFW4QW^9ELQ M;&I;=H22)A=ZBGC0FKSGY*E#R>5\DZNHJ(5+AXP*[0OL>8%"1$M$:6F7*=<+ M>D@;D@7O%&[6B]B:$=J9/=3#9P60'DXW I#=OILY91#!6 9<*<=_S"29E M]Y@0"6)P!+,F^GRUW- M ^730"@IE><1' D+EDP)++W&[._2P]L 6,HKES1:?]D.\)5WS?R M[)7^H=4^2Y% ME 'G>Z[/(HU$(%Q?2$TYV@%QJD:/MOO@^,[1AN='DWRV#+NVC-VOT>0::MWR M?6S']YGK[+A9!#^-DTGSU?.YU'OIN@G/+W-TWX:9VF2O^7P3 ?= MW#0:?J&!YETZBD>]U)Z*S%II?IR.XFD_A=]_V&OL^W3_/60KC]EM^+"'[M-* MU_DX:_6ZW_(W*56J]RZ@>P,-;65A\M>$P +#V(]^72C D7$U\T+C**3*/U+M'8Q7Z MC$6(4"T1HSYA)"HNU0$-HM6&PZ_1R?[:R,ZM?E\\9[U]=N*G..L[D^?'Y).S M/9$OJ=M=U]VNZV[WLJ[K;M=U]Y5 M4OO4]IUW>VZ[EX.-7===X_KP-[DP&]Z M/[LNN\TD(5U&M[RNV6-'N>=)N1?5Y[&-E-O6/);+(-\.>#OR/6/RO2CT;6=E MT0,U!7N8XXP?C7\[WV>WWF'D>Z,!2.V+,3KKKI:"S1-!J? 94\)C(>$^XX*Q M"%?QYYR'C<94ULLG*'-&].WY,5E(_0P?'H?CYR2Q'/>S9;@&"R,V'%[4NA)+ M'0YU7=P: JF6!SH*,:]#+[0(A1+*]W3 E2=#XI8GZ &E0;.!CF^-8-*C[[=_ M6ZO@[=P/B#J,:SW&>7.,0TI%&DF% Z&1CP,O\+ -YC8AWE[8:(WZ?[XIQM$K MCM]QC\JN56\'@!T %@#HUE/_W"@44OB:48*Q9D*AL$C](T0B[1^K7M%; *#+ M3F*FMA, W[1,\(%$_0L@HMG842]Q\@-]AN=MDE]X)36WEF'C"3Y*^"4PWT4&Q'Q)\DF6]DR.>6'GFMWN(F/>?2LOK^:Q M$U*JB((%K,WA+)*21V4.=" CQ-5I[>(YQ5J?W3\,O7[Y^H\&O79"-EGFOPLN MZ5CY;5F9S&L4J(@@H5PWHI@&C"NJ9A4;3%WGIFN4OC$KDRO$FE0].E8^2TOA MTOBYYCLCF$KA"ZV)'[E">ISBXC"-LP!)K['>V-N9[\?F9W$E<-]&(O*"**RR29@?-78J][K1;SIVU^AP'2 U&)-- M99,QV:U5(CH>;#$/2C0/2 D##TN71A%S>1!XA#!$RH 4C8G?F';_NK5^2A[D M5'0<>%G:^IFR8HT?YG+ROEIV1#XSCK M6MUVC-@&1F1S1O1"&6$419BJ4&(_4,"312,$UT4X1*>QCD^KDR+^SAK;GO/A MN2V7W)V>OWN7GJQU3XU\+)5V0QP*%R'BNY252GS@^RHXD2']@DNO.: 2W9EY MQ\"7P\"UOIZ^JT'/=T.DM4\Q#KCV@Y*!F?3$B:L2'(V!7=PQ<'>R=DE<3%#- ME^9KXG-?4N)%KA=H&C%>G)1+RHG?7&V1O4[*&PRUO>SSM(Z+WR$7UU(TO0C[ M,HQ<&;K$1RK R%6%!\!S70_3-ST?;\[]1IKT@K>/BR_V5'QO^_^]6 EG5N9U M2X"J%6$,9:"CP'49\+#T="1]7L7*>P'%C:H9^Q[9V6N;\U$*W&1>:VOKX78L M?,DL7*M"Z$:'RS-J=W$H1;1;:-"YJUB%C KM"^QY@4(FNYG2THQ3 MKA]U:M:[#LP[/WA6>L7EJ*&<1P5@%7"K$?<\GF*@J M(4M(WG3IAB:\2E?,.Z4UVN'9.=FW':B]5U 3W)7FVX^-!!*2N5Y!$?E MR8,26#;;QZP95)--=U0\.U"SGL@_3>+;85)]W\BSBR7]:?H M_06)C=,1\GU MH.@AC GZXP*=>T#4V\]VF6SM]?;C8H_B5]K?GG!@'_[\;9 XAL+CT;/3FV99 M,IH,GYW[+!Y-AWP:0-A"2,X$;@-Z9$_XV32?/SN=1#^Y)OR?.+T-X\\F>;YU$9V MC>^6AC$9VPOZ:9;T)N,LMZ^9)/&#\V!=_KFY95*;%MSP.,UZ V!F9_IH/L(X MX_O[++F'D<'5BU)DQP7;Y/J>][)/2JNG\J$FP9D=8# MDKSDS6J\I /+-X0_EC!LQW4N-JD8F]GAWOCA83PJ:./F M#1GH,] 2/-+,]*K&(HN$7E#_R.Z(I>BUTS#,DF3?2RZ8<#8=];($B >.W*BY#:;QMFS@\U+DAA8[#F)LROG-KE/1R-8 2?.9Z1?75U\ MPE>&P7GQP3"7H9=T-#4W308@*NX'EN?@A<.I6%.I!DLT(=@]^>"]:Z?86U;I_GE]192Y4;'@]+YOH>IT,C MKV#?_F*A\Y:7;.3(@G!>XLAK\GHB MP@I#_K$)3BQ!=F(/S-91=@V";=U_]\?FAO&<^() M4 L\'1X4;T<$E>KQ,,TG]FEF:N;)H[$E+K@-]M7<>Q>GF?,]'DZ3);K^]WP1 MOV$05C4IU K[MUT0F,'"8E6K]"*RWR>C)+.HGOS^" -VFD#/4O-= <]:&X30 MCR(W$JXD+@'8]$):5AK3H9;A2KSE1@#U7P#0T,S*7@PHF(Z7=9(FFJ;6$/$Z M3WJ?^M/,H,>'/\\[H5:F@(65O E0O,O&#PLD4 GQ K1@(V%8=TD*F]^<5'QA M7\D\:B>*(L0EPR[A(9$JXEQ&U8&%8HRL",5]],VHF-DT2TZYI_WX&6SFU2V% M[QO9T?AN8I'*H$D1 V+T*3M$,W/@[/6JG&7MX;.174OFRP!08H$2'&ORP+VZ#8_[[ MMB0,XSXLIUD=JR2 Z9C;M85-^#9^!%9PL5?!>P:XGIH=,M<^@((,!&IVKK1. M>^/[45KMZT*LC]'! 8(7@H&*K"(0=GTK@Q:L3O.\FG I;C Q0_D$%#$SVKD< MR=_28BD4D-I"U56-:5XNE3^,8=I?>X/QT)"WW40K8@U)/XS[R=")JT4%T]+* MUN^SC3>+MZ2!F#VLY/*,DU;%ZYKE'H\6,+54?6#%[^X2F_)5ROA5.5V*Y=QY M2H9VO#6"=(S]GUGM,JZID88&ALGO=COSZ>W_P!L,VWV/83%!T2@G,OM86D$ M\+?3@J]'XXDS3!_20@VZF:[^,A+)'5]=8N MTBLZB/&RS[3+ZEJ[D#5*A 6+X;KXOK#IZ@\;I/"TQ@),:U^'CET!^<+,U_O;[+D@0>!F.#P3B@ L#"F95F M/\PG#\R0]I-1?YE)%J7=B^=*2RI*#T8Y'2:E'V1%:M6D3#[#+36GDF]FE[_! MB_PA7/C!"EGS\6LR3*PU9:*;,.611"%UL0Q0) *W%*X!D2&[GE?-DI*00/M@ MBA*)?5]1A:O :P%U1]@B\!$,N[6;)I\> -7X*^)V>M'0\HU3K'2Z0GVS)F: MO?[?Q!C_EF[F'+_ <K7*0&]LN3\R/GZI=KDUVX?@%P>2L^SD% MX!H5G^NK,3):P7!A/3 J3B*L$]GI ?.7O_[?#^B#_0RO[%6?URS1M_0!Z/FG MY,GY,GZ(5\ZJGM+^9 !_PC:4_O7>>#B,'_/D4_7'C\L>\P^S\-I9/#G&'UZ. MOBW>0<4??_RPXNHOW__*3_RDM['];COXB2=.7ZYU]R:G[6)?**-['W>>^_2W M29>D1RBZV-0:-'#VN4;/_C8PTA1$_V20.\61RW],A\:!=G4.-/)663SL"(32 M)K+XFO[>&%&T=#L;2U8Y@VCD Z'_ E:@3?'8.TS].-QM8DW.9"TN/>"K#;3@ MGRYT"RQP"K%B=,P]H?.\*ZII_OOS1[*67ALKO6>4Z3 M87^7';[H]6EIWM*MW^4V M*29GU!>.W!!LM%]RP_92?MM77ZBCRDN@2DX*JA3>95#EEOK?^4?SALN)D&N+ M8&VA!Y[_4IQ3-%PK](4+F'>WY^V?=ZN$\IE%?G[X,[N1'$0SOT%RJ;+*!41] M=N1Z:>3*;[ +Y"IN"+\\W'2HN_S\[E[^JO6:# MLYW7VA1&A$0Z)!@)Y'&I-56"!=J7\%\4:1]=W6V%DL^&"+1*RI^C!Y.579%)N4 MM@B(R1!8+LVW7+77?"[K4<;%Z.UE!8DNTV:-T4SYI"1;8L05VFV $Z_WK'.$ M^:8;-[^R7#+[[R"KGO$8WR?7MUD2_WIMJUE]BH=/\7,.D_O3("O7;[=%B;>? MEP,;#S3[ASSBG"K?I8@RS0//]5FDD0B$ZPNI*4<[H$)5K\06]P #4AN6 4Z: M+4.\#4YMO]5CN)1+[7E0.$+@XZY\W$ZBJ=] M4SSIA[W&3G8<.SEP*_=YWPMK5>A<\F;W8H]K'VK!#V3$N"BT^*FH2 =3^;&L M/KZNP>''$EOW7?XF]9?JO0OHO@3_:^HQ2:4#1D/&B<^5=EU/,U;58Y+,UZ82 M_VR6:K+S[:PQ&;)%2?9Y-:ZAKH7F\\-4MS[_C3X3"!OYR?QC<.Q@BDN:UY5Y4V*Y]5 MUF!-RI$^VR)K17VPGB4MF,6-F0ZPMRT=-Z],74C^Q?)SM\E]/"N95RD/KTQE MFIN+4@".\=.H7KML>7A%D?AY[3F H/C&"=<47$L75\>^H. K4Y'.5DU+UA1H M6UM!;:$R6Q%AN74EM6(-33G>+#;ZDBVG5JQH6I6A>Z&FVM(<;I_+:JU;.K MBOTM) :>HLX^E^B2#IN> :?N+#RR=X90V_/:OJ[5DZ M[Y1U^F3C0R1O,\2NDF!+J\2]025!O*F4X%&ZQ[6H@ERM2\FB?^\8_<>Z"G-O M&X:P9O\_VNJ^XVD.-)!?@6;72QXGA3U0V5-%LXV96?5#2XZ*WG$ QXDQHF@O M5O4"L@MQ/)#HCGO?!PV?-B!E#55_,=:^4])S!7;V0P%XY[=.IU*:R!OH3")NG?FHZ-QXZXUFX9)5;76M>N1 L6DHSSMV4^V@\TE86,+TS8/I.*Z\6][Q%:-.0L&KR)V MNK3-(_9>;QN7;W?\YLIYXGH@-&.NYQ$F0A2$C*!(5"T'B::HZ5BZ&M7^5!ZB M+3?5Q?(_V:MA="8RH#QJHZ]WN;YBK,D,];WII+TJX3FGLK[+2?\;NL&H@/AK MQR,W=*_ZXN>\ J>LHG(P1^^WQ\?8TE:+)*_6!5>&)!21AUR$/<6TTEP$56OX M(.+ZB"*ILJA484N%I;O@%^,IV"BHIGG_ER2SKZI+*_)"7,B*L')OJ'N*XGZ= M,&H3*IWWI.NLO;Z_M4?%C+.%J[DR':X]3_L!"5DTZUL>:2)%8WW+-W+VE^0A M3D?PO9Y[2KXEV0-96S6)V>BF%SN5BQN7K29 -,ZW9T$0G6R^/-G,YR%U* )S MT9>8TTAZOO"Y"F5E+@8>;:[@[BH'?ZX<5#:(*+EL-[E,;% M[73X_*7(8#NH!FY+IW9*)&T!Q@@Y3^\,B1_ZFH9(\RC$OA=RM]+_,8VB-TOO M_.>&],ZM,08CKT& ::T^WRDL;^PJ$O1&,.?:<>'_\85.LA4X^5:*Y7E@NYQ; M@(I$$4*N!@1TD3!U+ID/], M@.."=",I]ED&$-+#9\*E/O+%48:"EUHZ;1;X3\^A;+P\75M M0;+:21"31+L1$Y'G+2U[9J.2LU[11:^1\?W64]Z(1:!L1M.W]L*=.<=EW?>(=WY>8=0 M FM/N)QX/$"AYWIZYHL,F=B]U-PF>[623&TQ60F]8?*B3T,Z?&K1I"]&DV[/ MG+/(5C!M,ISB,FS=2]8=SF%N_T;8#16'FJ[G,--6 M(&MW/OJ:,&!L)@PX#3151 9>Z!,1\,A7,WN3L9 ?41BH43_\_3$M*P"VQ/RD MZ$:*[L3T_4')!>N?[9E:=V)Z(8G?]18-7<+WB5T]M/EQ7:=8!EL%I2_JU2O9>DU.%6+3I) M8% GC-J$2N<]Z3IKKTWUIICB&6?[?J1HH -3R<&5E&//KS@[9,A??ZKQUJG> M,_?5*ZG>C'>IWIULOE39S.:5P3@*M50<1TA$6/L\I.&L>PHCP?IB#:=)]5Z5 MQONE86)Q1;R3F(QO)HCW"(!HAY?KOY+<-O(:]6LMK,:.;5C4@-?K@IU;%^C# MPF)^1.;YW*7"CWCDAUX0:,3$[(@LTI[7-"X5A%BCF#_XW<^.L^\39 M.GM:[M,Y:5.#(SN#:G332,A3FY:F);;,^^J!00FMG4+S('"%JS#!KB381R%5 M%3AR$/^G!\?C>Y3P%2.-YO5>7FN,#B2Z->G6I#7M]L[H#/A0BFBWY!1T7JJ7 M<^P)*D+*0TZUASP5AY8=4*)*02KT>. ]R#)_(#\ANWR?BPBR:83K?H=(ME MA)#S"%*IJ2LDP 1&B J?,X%Q%1LN-0^/B!"++LEE(&C.)^GQ*]YL(/C9*1+6 ME_FGB5GUZOM&GKT$P;7)#=-1L,'VLUTF]/+Z;X/$B2OW MMC-KK.S8ILKPV9G !9/"F7D[_IXX6?*8);FI#F=_ZJ=W=TF6C'J)Q&=^X]ZN-E[,7E_JP8[O3/MI/"IF:U$S M_S:>Q,/Z[WJ<3WX:3_Z9 "CVQO7"V M#I8*1L!ZYA*S0/'HN:2,W!!&5JV.&?4B\\V(#$#B;FK*,1(2OA-D>CI7H!YYU%,I^)9+&A-<\-7Q'( M#BSH$/XXC&;>#EGMQP+00%,8]N$!7V#U@1D,5A44:%8NM^(C6_ZI ++)KD5\#1 M=T"ZYB_SG'X*+#L99SF\!-0KR]>?03J/)BD([U^&\>C&,:^U%YM'%]@_?312 MN>"":ZMU.CW07X"?8WLE<+8EQ-'*SS?.7Y(12)WA\/EJZ0EKW@,:1.;$^^+! MW7B:[7GKM0'22A["&B:_@>D,@QN9_P.5!WAZ:&O>6A4%]!F#;'95S K>I9D) MY1^-8!&S/,Z>#8Z:'^P..WU N>5E!20IU)Z^4ZQ&^:C>- -U:3)7B6K(^^_P M]N$X-Z\NB*!4B(H[S5O,#<4[ATE>:&"E.C9_8 G&,_D.Y)_VDQ$04S_->T8* M&"5@8F_.TOS7Z[LLL:I?8HC0R>QDWI;_[<6?4MB4M+<.$7Z9D^-+W&4VHN"A MFSU)QH'_/H^1) MZG(VZR\0BN92G,+?INGD^3.P1#:U'/$SS#K[-HA':]L4+4HWTX/6^T\,:X;P M-?Q+\0MZTN"WYW_5=G$.\59R_L-L8:4OO7*$_/FG:$LW.&;B2HJ-CO!=2605 M%RT*?/SP2X'M-\Y_E5I2R>GV>Z,@]1/8E+YAW!G*Q+U!FGRWFV/UM!+N[](1 M/!_>OPC)O2&87B6JCIS_B ')LBK,A* ;IRZ(C!IGI(EED K ZVI@E@SCTA8H M1O@T $LNM48![&\. )+!SZ#3W5I;<#(H :2V .;"?EKHAD^@A(!!"%)J3XG'?UVV%O6DZG%2JJN4/YRX;/QR7L^?Q;J[0)/1- &J N((_ MN4(SYY'TU\>([^,\LO^4]/C%P&D.'&A4 S 9-[)QGDW^]<6\P;*O^?3W=)0^ M3!\*-FV0S4=E0,EZ-K\FK_(Y6N'P/Q[(XL 2QR0$/F\A@WTP4@3V71QI[:DP MP+Q*%@B8]OW6$D+\>_L( ?/F2:$$CF)C^&R;ZA"O;ASW6UQSN]VL/G#7:YQP@A(8D$#;B.D*OIK.H*0ZBY!)HF MU)Z]:+_P*C2J[!#B7KEBE?Z/H.RH4ME1+R@[Z@3*#CY(V5%OHNQD]69:3RTI)U\.22M\%II=5=]50L?7EE$XB[(ZBZKS Y>]+ MUQ'SF K?A&*),,)8$U=*$C+B514[0B]<\?J_[?8?K. <8_L):IX 5D\FS0JE M +>% +%?%T>8RUI)[2#6+&^2+1W4KF@M#9S47N\Y3RPVW;CYE>42V7\'6?6, M1R"KZ]LLB7^]CN]@$3[%PZ?X.8?)_6F0E>NWVZ+$V\_+&62&JOZ01YQ3!9B* M*-,\\%R?11J)0+B^D)IRM(=;VXH>D"$F\LBH1[-EB+?14 _62->9$ MKV]5&1-141S#S_2J? )?%*[NC]-1/.V;1CT_[#5VLN/8R8%;N<_[7EBKXO1= MWNPN[]8^U()?WRB>%B@_%5H?3 5>]_4E/?1CB:W[+G^3\2W5>Q?0?0G^K3C_ M!C/]F@P3*V^NI0(SC(:,$Y\K[;J>9J57.@PD\_4UVR $&C==#[&XO\WU8[ M0.DVW7DK-?V8BI'+.\6HW8K1.DJZ<53^@HVW1#]S$\\Z4Y[MZ2"(CO\!-K*@ M/8R?3+S;W%]4Q/;.;,$:L;YET%/=+R1/[Q?RYKY2%Y@A *-1\0C14$4$?JVB MAD*/M<Z#R5B=>I#OQ:O>)ES=O(T@P MBIA/B!)^P"+A"L51%:;EB:"Y@KL[R;A%3NW.NXY#!K7B6$% I8B$$#0(=("D M)U%)!H%&5.N6DD$;3[N.H?*\Y6G78O#PB[E-2_31&R3]Z3#Y^6Z]M%^W#05] MP()]!REOG1S&P/&'\/N'-?:.&X6(B%!)&OC4=Y4F'%?V#D=<7\^IFPND@\CC M5)%(R("Y@9SU2G69J?V9P-X^&L]9-DU.;28I4#\?'FJ1;&87R^ UHWS:];"! MO#G0W7 X?LH_[7$B669WF"&O^@<7LI]0=4EJ=03[>766M7=NO+L^J)&AMN'" M,F)4I!$5R0V]9#@L?[7:D_D,D^U5G]>L[+?T ;CAI^3)^3(&4EX>+2SN?3HJ MAA=/)^/JBR)GS7[SE/8G@T]2WGB((^$1(F#Q//['*C>F!PL?/^;)I^J/'Y>S M73[,BNO,^J-A_N'EVCO%&QGL4'71\F_XE9_H?K?M]Q-I_(DM'/[F\DB-EEFK MU=(E[ZV6[GYS7TXG/,;D9ZS+C]#:L)EI[Y%%N2Z0OXJ0MH;(8;6@-TW&1)K? M@=CZ-$C[(!*:V,+"9WQF!'P"YGU']*MF]*LNB'ZWED+'R&<_:9F@-9OZT2:Y MCJM ^4.E%M4'/PMFD\> MM*\?_ESKM5+5_UXXJ=ZM!/@;=]]\W)VG?3+-7!5B1;ED4OBAISV_ M//VD2(3L=!$LLP(G+Y7RQO(_V89Z-^O.UKY\_<<682M;5R 3S+WH]I<=!G1- M>,^M""*7\Z@>Y7H::XHXT-\?J"BXJ(;K\E&6AVWG\_T M6L#AM9.C0/N4*A&2R(V4#*2OJ:PXG.(&>\"^C: ^2$#_;Y*-^W$^,-&N'L'D MQXYCSX%C+UT^RWGE D0]X6F%F>@R^)*5*PE_O@O?J#S^XLZ./K4.CB>AT(EVE)N*:(:2]0OJG_4"HR@JD3 MFBI%F_LS\#A@0D[A+%UED$.HJPGHV"O5IAV8T73+T>V#8L\-.S9 !YU[.5" M)?<#Q0AQD0H$8D%UCLRYA\E;0<>Y>SDXNV'RHH]CS@0TSGO>;5 T:BU61*0Q M12122* (= [AHLIC0J*(\S-7-!I5,'"G7YP95'3Z14/Z1:T]@2>1]B6F/HU0 M*%08HE!7B$'<:'U'[PO2+QH/\R W[FJSTDO2*RXJS",:9W=)V@5ZG)$'>I,Z MY,TC/2(WPC24/F6!T&%(?)?.8MCZ)9?@Y2T/;^$G[C=C%@9\'J9\G>&Z2Z MA^>I-3ZA@F&MM!]H7RL>\3":F2P@_\]?JC?JY]C8'K&3YF?'XIF\'WSH M$E](4-U%Q)E1XI5 LR P$JWO$W,ITOP(22AND]I]^YT0FVK"G'G%E>GPL'(K M;5J=%FE))UV76K'4'6H6G0Z,^?Q\"7'L*C?$'/[S% E"+=SJ-#KPR E/HS=F M-1N\?7M?"KY"C2I@>Q/F?D3VKOCP@O#IPI.K#Z6*=BN_KJ@YL#674:AL,:/???EQ+/%EDZQ.TT0L^;.^,D-?%& MTF,\H)%P.0-CO=((/8E.F*-U!(VPT3HWM-&P@$X/[%"ITP,O60^4J&9W$]<3 MB'*I",&AD%KK634Q$HFWJ*%Z$CWP&$5XWK?^9QVG?[*] *OO&WGV0B/+0WHF M[K@ +[1]C,;9(]HH:Z\:%/.M59IL^967BHO,4YX>UQ_VW#>A6RW%AQ&>> M]#WANS)$D2"$^K,VR;S!@JH+D:9JU ]_?TP,UGP;FZ]J[G55K=CG:L%.8MHN M*)9\AFGB54SS;E:+ISJP/T/XX\#.N)8NCDL%\X,^E\+F:X^Y;A0R$>A 5GUD M=2A#O[E.]VV@@L9V'QUM]Z\ #'*S,NGW9/A\XUP8I'I'AM33(6FMM!G%DF") M0B]DOD:8*RVJF@L1L%9S_L+F>0C+-T=2=K-:BK897EIN^[V#>H3%8P-ML+^- M)_$05BA+>D9E-6HMK.!UTA'M(HB$)/C/SRG) ;K>M_KL>YY.?QI-_)D#IO?']"";0GS^IN&G99&NE MUL+)S:HAUI3@>AJDO8%IZIZ4L.1,QLYMXF2S-7-,VU$G7FU_^6CC^ XE_07[ MOC2*EDE)S$OE**$0 WH"+5BBP-.2ZPJV ZZE?S)2*J(80=*77YGK\)$BDVO$ M<9TGO4_]:?:=,PO^:$8?)$@6._4>R(0=&M%&+EBVN<$!YH' M+@MYA*OF/A%WT>DH]Q0@V!SXW:P66'Q7V.?R>FW&-8MZJE\[,)QU-X\+S:;^.[?;DVHM"'2 & LCC/J,^4T$4 M19@H%OE((MC:/\7;:+"U89 =M55SO?VXV#(0]BIQ,)JKT8O4]<(>+9/.S#4= MI'EO.,Y-).\WN,\?PA9]L(M@/GX%R\WRY+7'0XU<%+F!$L+72E%:)D>' 0:= M[WH.A"32E+J2R\"E420\)=V2C'5 -2L)"18>:'*R\WO@]@20Y='XBC.PG@Y= M4>MO[1LQ:.G@TQ1,Z\SLHW&=KK1@/'3WYL;/DI>X(*4EHMQG'PY<7O)A9X]U M_0C):\)"FR^[\Y#$AC;M^8L#\.8\Q'W012: V<8AD]X!R3^.T]'$,2W=TX?D MRBET&%@\XW;X;MII/L39KXFYHL <6(<;I_8.$!#]Y XFVC=*CG%I/,*6)/ 7 MO.=I/!WV2Z&1I-\+&9(GPR&H&G!Y#L\=9\YCG-H?)ED\RN^L2!FF\6TZ3"?/ M=F3%0T>]]!'4+KCA 5#7B?MF>"!NQM.\&N1=Z5J:/7KA.?!.>\PR?"Y>52HE MM\GD*4E&U3,>8W- Z^RBS:QSZLMI&TO>N.H7F\\-81R[U@/A9$.Y:(^P_@' M*4C"K#=X-FXDEN13_<7'_J\I/,8(T M8$(@V6RH>?FD 2@+3B]+K IJ'G45/*/ M/; SG^&J7O5Y#=-\ RK/G9^2)^?+^"$>_>BL\MMB-L!3VI\,/KGE46YYF+=U M\@!P]09(6'K_PD$[\XJW[JSA>X2('Y=$]JO'D##.'W<;Z.[#^EOR/1DZN*Q! M^MMT;';>@D5NN=,ZB$LJRBTKIX8LS2@+AL[K')TF^;H9+AQ+=E1RKE1"2BHI MP.+*&9<0&1?28 /Q7!729PDHD]0^I)^",)J ## $-JH^_6B,WXZ>+I6>:$E/ MZV3:3!*O$VKCI]&"1-M$(MMH?XVI>G9NA8V-83:S6!M+^5: ]N>S>YS>#M,> MT'W\/4Z'=@'Z\,>S,RJ$-OQK;P&I72+UPB-!+;9A:=;W8_J6AL8=8$EG3O?]OWO^ R*"Y<'F$MC*<'U)=DS<'$B\%( MUWNZ1K"[Z<;-KRR7R/X[R*IG/()Q/@4/^=&( RRH9-P1^U^MN/[V'H_QE^3>#@9%"&25\[G4>_&NM[SZ6V>]E- UR1_ MR^$9)YDU0H%?^^;XHF_1WP0D6FL-K/T8C'%0R\'TG93NA8_343SMFQH6RY44 MJADL,'L#OIH]G"TG<"B>PI_F?)PYJ986^S!WIK)6UM\+9T?_Y]$7(\PS6$,_ M!MG_JH=32JHIH]P+?>SI**#"=:O=$HJ+FH=3(QKZ/N'"_?_9>]/FMI&D0?BO M(#SVCCL"8N/@:4=W!$5*TWYVNNUM>[;C_;0!@D418Q#@X)"L^?5O9E85#AX2 M"8(B2-5$C%LD@3JR\LZL3-,PQNVQ/1B)LBOP'G"8)UUPS\ZS[N%\43) MX*H1:(^H,OV7Q;ES*I8^I2GZF H>#Z %!]UE'/"HOGD\,(>VBNLD8A"?5#0, MW0D'V2:GB737T%+F6]Q):0+F]'^Y:V[*0,PL $B%X3[LKT=L3L@5DGP=Q(4A M2X:((=_WR#]%GXMS!NB0]$MG:!K<=JG-4EM9+9SCG1?PY3EI$LHO^!4/^H:; M;H-!JVUV+*/=[?7MKM7IO9,YWBY@A[.,V0?YQUK2>D9QRA-%*U+==P M96B#"K,]LV3_"RR[; BS!F8@(#_,O2GP]3ILMW*>P3'*^S2^0/F&@WU/JD&8 MQJ ^Q)7*M9\[4':C\&>KMA\!#"],X\*C=P0<>%576A7RG@YY+86\"GG/%7GM M2T+>FEMO-A-]*>]7\RC]DSR<'ZH^E$W>HR*3J=7-XK73];NQ[6M3I^99J$7 MS>"VW;XV>CN'[,_OQ- M!A7)H"G=4^40)=?2 R6\J;1KR]SR9_C8"8F:!^[AYO,*3<1:+7ADXW^C: MW2F>8/$UXQ//7KO;M01?W]1-^R6K,3=7EU1\5/'1QO/10L\?LW]KV$;;NK9- MO]E43AUXCG/%C>MCXJ'*AZJ>.@Y M\% [+U@S&%O#_G!DCW*P5$3TU#[45#SUW'MJ\:J/U ME-/:(0]ZAXS77]=O5WS+[S)I4SC!($SXE5O\HDH&*F\3Y<#X4=XIBB[X9O/, MX2'7A\&]F8N#N%L^1VDK>FM>Q6EZ)C.K-UN MSV:V:;0GW>[$9GW'G5C&I.T.W-X$@;C3]8,73"LW#ZQ3\36=Q,34DIM[!/R3 M&=RCMFG?]KMV_W8PMCL]X/C7_>M![]8<7P_-?GMX52S68]W:M^W.T!@.[9%U MT[-NX=&^;?0,:S"XL9_,X'YVGI>L49%#2&/WI:LH%2M,[+*[0X!SV*6'*DQJ M W;^SJ([%O'"47\Y=^RO,/J^QXV5^M?XYM?/@39,[](XT6R#\R:]>)]30V5# M%!K8N'H4L4>L>-7M#RR#]:U"OPMS9%O](5YEN3%&G79OT.U<#P9#L$Z[M\9P MK<+F=1H#'.-XZ *WC*FH$)4L^H)WH,LZ%%>A;("';60*R(;W24&9_^?Q_V50 M6-%G5OC'FE*S\GOMK:+-UO.]+O8\)JQ-I5'W#90L*)ETO CN+)=1^ .F39C_ M>)PJJP(%;#LOLMJ_!K6ZU\%B2<:M8=[TS?%HW!U?WUJ#:_/F9AL* $Y/O$#4 MGPIB#]@9??@FZJ> 2%^I-S5N$$:4M-Q^A@J#IYN>M-;=K=JDEMK40L'("O&V M.!O $%H"3,'A$ZDT-ER>I$WV>PMU^7M M=2974]WUL-#HM8PQ@$HY6C)1"B\NZ_/\GJ>0FJ3$%\LF)?,H3.] PT=\EZ=: M3\V_9UAH.P^+C;K7=KLW'-P,++,[Z(][U_W!:'QM=09MVQJWUVJ]"YR*OX6$ M&8!I E%8_(\HC.,+0ZV^<;P*D?R<"2W@A.;(JY9^&E,YB4D8170#DJS&EQ.N M[;P,.;'K U![R3MYK0&-"BC@+D! M]T-PXYC$/MC-2*0E%1@9_I/6-MWTEBJK R+AX:B$W,T)>0QJZ>V?],9CL:#47=HP\,W:X1C;:3;O%5: M)A7XLQE^[,,0GIBL9H[PZ8_;G87*AJX8]=APJZ0DJU=';.D[4H/]$GE@Z:\_ M*BI;"2Q_[_T$&#OS[MD5UDW68A;@:S'GL 5>,\RYS:H)6:A6ZBRP3"@.?%0" M*'8_ZEH#K)C>N;UMV^/K]M! ACV+6,X'E^OE<&^4 )X,8FX#_Y;&PR]FI0J MQ#_4O$%W !.+&6HO-S\EABTL":A8579.VHQT?,YV59UB=O]ZQA=W1S/1ZV MA[T;()2QU;[MW?2,X>D(Y4\)Q)7)+E-H/*-'=HZF1@KZ6#B/6*&:* 2+SCZ M'48(["P];/.!:'_' C #?3C5:(EA)$#?%/Z*L5@RH+&?3F6)'5$;B\L2)S?U M>- S7+U45J%(8IU*'QS;OZF<5QOT02'F5B4H,(4,!+RX M-/XE/9L$M<7"X_OE1:?#@/$RWA$CW1#^9C^$".;68/Q36:'$0Y*1X#1)R7L/ M'*-F,+XV+!#F@X%Y M>W/3*3I4-S&C+R$6TX.E? JPKG;,/@47(,@;R92,XS$E\J$Y01&S!3[&(> X M4E:\$H$ F<]7FXEAU 2P0AAU8R'_E2C%CVD@[ =J",>,$O3R,.=U>V#8P\%@ M<',S,MKM7L<<# S+'@RLWJT)=EH1J<3^$H6W" FA M_OU3P.!/!(%">MPWH#)]L7\XUF[U:X_& GYT_L)L?, ; +T#0?5 '228">+A @^"%(@=M(NX #ASR34 M90.*<"FB*T72UV5)<[!9N4_LGY^N/_^IO7>F_T[C1.@S, 6+0.'X2; 6C9>L MTS"JA@*7)/(1F4&_FZOW'2N>W:O=]L>C^SQC3D<69V!T>Z,UKVL M1<*B(I1?E\ !II^#_^O BB8^4C9[*M@=1\G_^Q/CAT0D^.EWT$^ =:R0U:52 M?O9K$6#E&4'50]8*2YHXP??/LQFZ[O QPJ8=&$A1<%Y9^]O [PYG(D?$WT$A M[VUX?=/KW-Z ^ )\O>GUC?Y(X.]X/#;78DK'P5\N^A3^G@)_K6/@;QB17T4T M9@1)X,-> I0#6+R?2X33\.Y!P:_8'7;ZMFT/AV-[,+;,F\ZX/[ZQ1EW#;-O7 M-VL7IQ3O?@')#?.D$D7_'K7X][-J&?9?>NV!P9UO].Q$5$[MX.V M81H;0KF*29\IHAY#F]#SV*>S7/J>2U<4!-_-ZF.3,SW") !&_G.,3QEG ]F W" W7^"?**%N M>]A'QO%];L&M^MV$W2.<'-+R66D)MV01E@]'=X:P@<+(@Q.!9S?Y[38O] ,% M]X['A09&P9EGFYW;,?8_[8ZNP>(!:Z=S.\(PM'%[VQWT]O)[##EL*0_I2P:) MS[// @9?) B&!($G'!W(.%;X27EL+YQF'.:Y!S\'K*$,[GC1OW5^9>^N.]8O M567#2XK%H9^$\>##2G;&1QZX.R;JYRZ_;G=T>].^&=\80\!XX^9V8/00]:_; MH][@-K>27@;US:.@_K>'4*'^[JC?V9 ,5@?J,\>=2WY/7:ZU:1K)4%SR$/(8 MM6A'OHT\+(/(X[CT8>;7/H9#ZZ;3O^U>CSM&WS*NQV.KC_0Q,D>C7O>F_;+T M81^%/F[#-%($LCN!]$XE&RSKHTCLN#\N_N<71\Q1OV];UWVSUQG?#(:WG6OK M%O%_;(S:XW[??%G\;Q\'_[U[I1OM@?_FIG3AER$ NV%AI&^;HD:(M0Z849H+ M*P\7> ??F7+7JHT5\V20^(.VH%0PD?(5 MP_GQQ'RJ&O!1\[V%ES@\.41T3141.32%X4&71;A8>) %Z\_+7[&ITP06@GTF@FX@#$(GEDL$9W-Y,2"GS$/:CVG0"]4D,CBM[X38Z-Y:@]+!S#SD 5( M;X".WP>A=D>=WT5+YR/*'2N7.[WVS__BIACN.3Z.MG5]Q[%_?#+JV"8+*''7L6ZL[ZEB MMW.V!R.#*LA:-M< M@[BQ:+LAB:RF;)H) ]V7LC S7W:9"VN,WPG&UE^BF(]E<#O@\060.W>3 C<> M]8:WQMBZZ0\-8V#T>V-$[OYUIV/U1_OYBHZ'W'/ .X7>^Z!WN[4A<;N^$.*E M]Q3O7W9/\?'MH#,PQN9X-!AU;L?&8&"-[7ZG>].S\ YNOX+5I'J*JY[BAU?G ML@ZKSF4?5)WK6+7C#AMPK_)IVSN3O[3E7%T1,K7W!7>!4W 8" ]!X5J/-B<, M?A3. DS%OX>?R(.!:;WH6^'I^L\9TSB7)_+;CYLL,VCGR3)]LW,S&HT&XUYG MV!VWA[=MVT;]Z]J\'5Q;AMT,_:O!T82&JE_'M"ZD6W4&I[)*3B+4)J@*,]:C M@H; M7.;1;G+]E%^8SORI/'LUO_B!SMEZW*D^$LRQ?:F=PDV.TK]U[HX/$:ANJU5HPRPCR<#=JF\_*+:7AVZO\UC;^'$ M]^YD)*ITW^JI:UUX+TV$5BBTAC?*@^P6->B!C]H=D"P@/N/)HWGU/603Q426 M_&)GG&$'O.ZX8G00J6%TYP2P_:DV#1= .9Y;,O1H2%R1O \ZR:IK/V;Q<$I/8JB!G][T+5NVEW@NIV;3ML<#CO&L',[[K;;X]ONR+A9 MK<'_$J[(VT[''E[W;,-NCSKC?N^Z?3LRNN-N[[H[&-D=XRBNR&=1:RNV8Y.8 M%52OR4/W*6$+S6IIOSN!P\OM4G^1WL=8FX+.F<;DUB#) O+L$9M"P!YSOUTF M[$0)(:R<3(^$2U%"LYH#\J7]L94K_-'#'[!FC.>*/)[<]'T"A-R,W@.,&MB4 M6,QA@BJ',Z5"YF'P;] W\MI]..@^KM9BV:> ?+7.YHR73$_F ML.K_DUWM^),MPRA!2Q_K+FBF!'AY[>>9ZZ$$18EOO+#D"KO%)9%7C0O MP'I(L%DO%NH2;)7K&%B#54=SZ8&1[L)+9XND'GP9U!329!ZU "UN#T+MPDH&VS?8TKZN;!;5-JS2L03%#:8 :(.VA9UZZ)TL/RX< MG<*ZS48W;S:,?O/#G>.MN,(T[:W3%!^6D[00J;;M%\$1@L!!71^^X#UG1(DS M.KT9EG*:QOP('$"329H0:"G7C-1T/7/IP@"8)IHP7;IR93H8@Z.\7_O:=8*U MKX3G>_U[0*G5+U%I7VR8#O (\7#E6]39@[4Q%L[CZE=+?WU=@./_WC!FS-CW MM>_FF]::.-$=6WL?;WVM?8>OR^\H_ 2@]IU(D@HI'7'@6C@@81R!]D?FI(S,-V,S++9^-74)TT;8( MF#&R/333'W7.P'E5JIRW4KDOSK)A-L%&]&*W &*&!<]GG.!-[SL8D*=&%R.> \&-6+)!6K)NF2V(.P(;_QW#XI0!CX2^+]0*D<24!%68K MGBYR^ 73$N<'7:>'7V5Y-WH>)"X?A\J9SRAH@\OQ/5@(_/A(,@W6L<)_^$U/ MD:]:A'Y1# D1GQ];_IH7;MMJ50?*$@B#\B? $9#\=5@0O(.#()+\*(4P9K1NM@V_B94&$(D@D0L M!%_B)3[+4H?_!,!+H$HN*&:G-Q$-AORZZ[K>]+_+^>J<*:XV7"/QF2ZY(D?" M[CEM3!W%8JH6:B5LF>!3F;\. M .D[<. /XJ)SXGQ'+"FX HD2">S40.\IC37$>^'H=)3$@1CJ16ZZ0$\;(B0O M@%]<(.V./[[';80:W G;'!["8!_>V,9P8%N6/;[M]+'.ASFX[7;@:[L_,'KV M(4WSBA9M^RB)$)]!X;_WV,/^/B5I9==^N>,O1AP(BP4X4U%MUT$Y$(3W3H(\ MD?.7.:SIZBX*'Q+TKX+<#R,* >4R^XH%*"*PM !L$M$*E( $Q8E@D@S8_ ,C M[HA=%0L5Y2U98B:HL!!-+46MIGX!ER6)[;,"51@OI! M_!BCQX ;AODD+E[N=UT>CV)>A#+WRIG>.W0Q:[H^.4I=]#+CG02\%$ 2,BS< MRQ"%%$#)P/Z/G 2G="6D,!:648:1P(AC> <&U &N?/PW5^WXM1$X<[*F"J(7 M1G:B@$Q(O(R"+!M%P3T3-V (:-BN0J@2F0;GSD."?(+W&<*'73=B9M#]XQ*5EY1 M+0:4%@5@4)O1%5A1K]&6-N3-1O.<'!1\P)RIE#6_;P0D$=%QP/IR%,4IS+:I M\60X[8OO<)_#<(JQ5U*AX8DO("X#7"KI1.@5:'=TPS!D'Z0(L82K'4@ >PQV M(P?(OD6X@)* N@F"]P^68'WA[/MR9M$I#<0N56815\"INC"%Q!UD:5C%I.1%T[/ZZ)JP\1'ED?'Z MCYG^F'B"YD4.%UICU%*@I?UOEB^E]#RJJ4+KDV6BKR:IYR?%31!00GPISNY" MS80'CVPFVA+H$3\\>0T.M\(+FXA14*V7A=VYOV^Q!&.11^?R[=N$VZ!J.!G= MT+ED?L(5I"R8"IE1+'A_I''F(!@CG.#,NTLC>5,O/W,:.U^"J?=@"6#^_2=% MIQ:8#GX8L<( LM1T1.)H,Z4 DM WU,K3?]RZ?N+'@ET+ 4*++PN%.S#LZ(8< MEJ&)LOK=13< L!;!(S+5&8;"MD4'UNU^"36#1%J$.F5*M:T!=[W<91DQD$:P M+9!>'Z0&(9_6>>!VZI$%R ?@-@0@J7#2B>_I4&BFE3$0)3G8.2D&R9Q"V%QT M9"I+R,V2G*+SA4KQ0L8=F%3;\54B8[9H1T;EQ3M>0'='4_(8H'$2Y^M>WRI! M*/^:=['F0?$IF! QF8W96F8,&X2!N7OE!3QW)W]5/(ZJV[(H);*7Z15Q39/' MV<5SNF!H()FGWQDCWDK]L1[$LK$&((O1YX*(NDC)7 ?^,:6H/F=LY'3@^Q5* M"VW;\>-0#K)VH'SWQ1]H6N)6 MBVB=XFT ;33=0$F7$&ZUC,N^P'%F4=.CYMLWLQOV_Z0!XYX6JRM4:/X1R;C< MGDMLH%BCNNST1N(5#WU-)SIJ-7&*#D1XG7B-+GV@>0>)N-Q:HM!0 @4I\\#J MRH<4U>FI[@"?70B<8I?28K2(OYH'HU::>0-;O??NI4PO=+:9 $LE'Z8#"P_1 M2QD^H,Z894^1E5V\2P,VP)9F9V)8T5F<&#M(6L>;UM/"\*W5,E:[ ^V;KB=: M7)>[O5)?8LQ*)M%9:/+*!>Z1^G>^Q9Z2A^Z')^"A8,&V(1M*$9(_I9;E4NO4 MU53@?=<;5GIQXKC?[^ P@NF5"WI^].%O,_H?C#C3B@U7Z]5":_$E"*+P8A$2 MXB;B'?IDL("Q< R%W#80;MJ9$R?D[$+"1'M>!-DFF#BX%.V+\="G'@;IT1O/ M_?W",2O-]EB0N-#@G>F]%Z,QAA%G#5427RJ]J&BRA<<5>F[8%/5]U,9\8H5D MA@H[]8I/7XP5OG\S&E_';WXJ5EKA-AM.)1UJ0NT%8N/6+RA;WF("/%2FCF8- MKN&1T>?K/X>P]LS'(/,FT.9.$XJ.\>%:.4W_79N%H'ZN/F5&5G\HQO&I,(7#:W-P%4ORD&.'AT7CE#-$=(=- M(V"2 3(]IX!V8J-%!H/C%?,&X*ER,OGF>&9+N\F3S&.6@1 #LF3+P2'.BY10 M"-K+ '+Q5YZ-!>RCD/Y0V&9+^\I8*5:*RZDO6KI_)'3%E?-$Z/%DR+.>1[@! M_[\F4>H"N)%[D_NT>DE^&SF7C@A,7Q=NV @>*ED>!ZZ51#U MI]SWD#N(KV0^XJ8@U>2Q(&Z$>_9? ?EF**,N<^_"^)Q9+T'TT%)=Q)'(JFL",00:/11Y*. O@G(B#8'1RY"\PGZPH#%'Q+H M>0FF,DS(RRIA"F3&$J&$!,+=*M6_TXI6EX(ETQ)P08.=,EXU'MV/64!1&AAT M@A3:?@Q@?#=+$'F2:PHSA [MJZM4=D:*63IB1Q\Q<[Z62@@\I;WR/4GM8\J63'B.?4SUI).6:RU4 M89SQA)P,.7BL,.O&JK+D*&S&@F6," !'GE4 M\A2KD))V;3)[SB,P&B!>$%CDW@KDCP_(2E;*\ M7]=9\D5+!=T+9I$3"P614?X\K-1!=P9):I+ 6:*I3';C#M&B&B)RW03G* ;E MU];@1.X<]"Z:,(NI4T<0O B7 P@H^FF!>TUK]/*VY7'L>BW7-Z+5 ^R('MY M9$JO@]UU?.^>'/7%!!^YYR<\=.B$.Y$+CL=4 M5ADL]WPM)E[@2!-=2N ,F\LAB[^O;RG;N?!@"HU_]7X"ZLR8CG\'W_)E) G-0UK(@C:D+0I&R1/-I(3(LLJ$+.-.IR4+8:-%KI7K>Z0B MKOF+WQ0 ]$:")D]8G%*J(PZ$ZC*/%+@P-*JCP. 3>$[X6(2"A:_ZK)"2%3%D MVH1L@D?J:-V6M4#NF-'6U6/)G;F:5BCVD>D"(?)DO.JC!2!H_=(5,(]EWIC( M67I3_S&WT(L6!H@@F4FQ) M%P2>,&%SQY]E5P"EZ2J=P)A.5R8YQ(>"QEB*&1:2\[)SX(H=UYG26-Q_+KA5 MN,\Z P//S^$1VT(J*#IW4*WC/;1P=92.+=K+S[P?_,+>O6CON;(&GK"/VN** M\9U[HZC&D=2]"OF98$5[$3=-R3(@@Q=)F')_D/.NY'_N>81Z(2L)+X03 R7? M;R$F0(^ \GRU!$ ['NG&I1W"FNZ]* QXHTX$Z!29>TR')H]+S(ZWVS'X74(B M!!QW'A2/H5Q\*4))PF*AIL)8TL:= TJ(&Q0^FKZ9XT;;MEYQ=QBXRAU]HBA< M/DSN, ?< ^@YE#:?G56(/ OOR;"GYQ .PK4,6D"'PK [#;5P'K/^-9O]Y[S? M*D!(AFQBJN PRZZ#Y(?UZ#%_2I$-\=?*?5IAK*8<+N6FH>OIP,A$''1!4=YX M"_4RX>;7-X/OR8TB#N/E:/0719C!&W+[M/CV@_ 8XPTG 6/!./Z>(YGK!(43 M2\5>^6V6Q%O@(02E4?-G>*Y=Z>4-"=\QK]!9[+I:Y$44!LI;TSAQ80(Y=*R7 M(EUHCE.]$GE="@R_![Q-4CK"-7Y67M\V-EU& R8.1;R>\5TZ]=P?(2WD&4@] MKMRTM-]DE.F!$5I.RG7=2O[UYR;DGL'(H[EV8RZC/-CT!'67T@46CAN%V85] M<4>?E%'$!AJ7!ZI0[R($R?1(XO(!UWFBT&^X!O*YX"Z6"K>,X35('_F<9ZJ5 MG-L17:;+%928:BT]%@*7D2@P0%5SI:!#W3CB^;JHX!1O\N=)/YZX94:2 6_! MK=UM*JBJ/(15TK2%ET3>CG?XG< \>#D2]_V%6K)A>X1*+F:>\)R\'UY2N#,% M=!N#ZLP*P>HI6""DLD=B^W(5*&'Q)A;&U'FP+U.8,N_1:G2<;9GWCAR[Q4]T$5:Y^4;:!\Q' 8K<(D8RTILA\K[W"F)IM_5]P";"!7N M:PB5$F<4=6JT6P^-Q^3Q)ZZH( N1OC%=EGZBBD8 [3"F3#(T,M &HDP^8!3\ M9H_,O2Y5]L#:(B)!F_O..?IY^=TF_FOF.,/[6Y)5".MTZH'@@H%6A$" 9G%( M''8=%$7_;,%'7/*QKE0DD=F*F:LX2T'DNN J.92IB]MR.+](*4_WN\^)S)_N MRG PDP>12ESL1$D< *0DQ!Q)BDD4')K3,&";(['KL5>1D2 L;E3?0":YW_U' M<BBEIGR/$D"&FE> /9$\'E-S&5:Y1..6'^.G/K^41\7'A!&?P> *X M15+]$Z]J\U66=AT*!!DSI!/N89AI_W0F850>D#Q#Z<3/:.J\ MJ4&>PYO9Q#IB-.8L+KU[KB"&9" "+J.QX052SUJOG-32OF#JA2OJ#^$%55FE M-LO] @CGG)'NH_/Y/V4V^1FFIG_)GAQ@,0ZZ2E4)K M&[0L0I'"C_RP_P6<[,OPVY^?/G_C7Z*5> 5V)<-*)12VQ=7A8O,M2:0<VHRJR#&!7TQ@DXZK&3XK*%V-=J@& MQJ8 M(BEJ0HE F9!(#1<4GU=2H67ZU6ES;40I P'"6>J+*HZDZO,RWA2"+$4JA<>, MXK<"7^3%VT)XMWQ;NIP3+O),MZ6&D]-;.MERW1E5;9%I(Z''_9ZD22*^83HU MOTY""4*B"@NO["ER8U8C;AN;R14ZKNDL7_-]UBN("X MJ*7BH@V*B]9&_,7"A9QVN5DLM=N0< MJR;S%D[RU%VAL3&T;V^N;;MC8>_DSO7U;:\]&)BFV>MW;FRKKKM"Q[F;37>% MMM3D7#!,;C]E.O/G*#V;E?*26DOI MUE:N'OV555K,"DQFSK'OI9,4&RZ*P"Q)E&X[K19J7+U\A(B!9 0J=9#$!2BL ME]N6G>#+^B_6"DP\7D>:C&YB/2$ MA$P&43.EF$;.*ST6O(BB_QCW0%&YM@]R-X5]R&6C+^"#(?T#'A9+YY^+&PWP M/IM?VJJ)S\#F^/HP[T+\2AUY\#-,ZO&DR M_S 8M/I&N]OO==Y]! -^BO=Q #3.,F8?Y!]KG@U<%8CY!+5]7$7PRQN3JC0F M4_PGRGX6J^)3V?UW'^5#J[^93_S4J?;:2XXX.-$2-\ :#,T$:^&(\^)R4!ZM MD(KF\H=&E?JUOQGTOX\E9+56A&;QLQBA^%5$&(S?B%G$.RM3E/7D'!G[^]%P M?[,(?D^<.$QC="3HHA50(;08K_9V+4/V3*"VW<58 8H;4T)/!I=J4" H'@:& M#FMT.]HQW7IG>Z]SS,6GYS:]MW>S:=6ZQ MN<))(6*3$='6.[VV0D2%B*=&1+-[C/WEYW/(!NLX0GX!_=VI#W$/Q*WE6!N! MN04M=EW%/39_'0QJY:_5]M(8C?P,F.U07"$H1B"OM/^/.0CU*ZR74^$\SV#? M54FU>;*DK1N]*MIU8W47A3TOJA*W^U6\[ I[%/: 'ML[8!N7H*Y>LE;:/'2S M]:YQ5LRJF;[;HZB,HDKY 5JC\EDTVF?1ULUJ41?E/%.(6+,7UU;A!(6()T?$ M2MJO\N(JQ#TUXMIZW[P,#GI25^R!I_#'2O\ Y78])UO4,COG9(DJW&D4[E0Q MI!3N*-QY\^M[ZR)+=W5DSJ(EVMZRJBN&UF6K7FAC56 M:5!HV' T-!4:*C0\-1K6FDW8/"U8>5@O%&_M]F6PSW/VKPYY5[?#KI9=,#DU MD&ITVS#.R>A4V-,@[+'T0:6\ (4]"GO X*F".I>D42IL>U%)9U72$)NO"#Y; M9.&,W*]%URMUV\@+Y56(/U*^6!5 =!8M46A^66C>;M2 MZIA"+YFIX57% M=\WNN\JS$F0KOHU5<#D+7BV%N^= V#ZCKC4,*H-B&0$&1/!( 1=G:40])@"E MF&R621W2LY[J?[#D(8R^Y^TK95,+&%.0UB$674YC7FZ;4 M\#9\P%;*U) ,&RP4VFM*4J..\T4Z J $HN>5["K->,-$^!%[N!6:;^J\>RKU M' \U/PSN +(3[,, M1#3@Y2TY/2+UEO9)MC I+GC*ECYV)N7/Y?VM!0O)VD_+9G1\ZGR]L,"UH!UO MH,)FV.5ET^_4U#LH?D';>^_]1-PQCD/7HSY%Y,!Q=FN4BM"%WT5[RNQKG5J% M.>Z"S&?5=9JWW5;G0#1K:7^$ 7W.[+-(P#^WQUWVP/0![6Y^N)G]JUC_B2 MD]7?'>S@U:O&8<7&84+TJKYAASM=,T9AO7EYJ/8;J(79FE''LVGZ*-%1# M,44:S0!,D\CA';8SO:9[#@LTK=S1U$KA//]SG(%]]I0U)4 M*A'O41MW5-K^VV-<+&UFNY6NWNY6N2YW9NU6FGH5^NR*LQ^<8W46!'G<\^KH M';O6LJ^*K)I$5N>4AWGAU8<;6!7CA+*^$7)":74OH]59E=R4YZ75[69R-MJR MK'@;]%C[>B51M^-2GZ4;G4H%^)[9:6/5O#/7YBX8%4V]7:V;JD+%R]##CKL3 MNXJ2<1EFPIDCVD7SO&ZODDNSJ3SO\B(KWR@1>C6/5458E,^VJ3[;OMXQ55'M MK;+BE]+<#6DN>?[#BY=QRI^(+)R?_KMXVJGBJ&ZOP*1FI4/ZY M/+!VKXK$4RA_[BA_NN2MRS!,%*(IWOILCFV_BK^VP4;#KK>#SB@.](S!44.C MTB8!JR'VRE%NX)V/ ^10C#BIA52EG:!K1M>'S^EZI5!=>YA[[IP*U*YT M7/B[+":*)43Y4UAC.*)*['E%89T77H\36:L\+UOJAHME&.!-I@]8.IV7"%JQ MZ:=L&<9>>2'R.UY='9N\-/J6J<05 MJZQ\O1,$J9<\\LKTCIODT])D5$@=MT*5U&7-=JRM"I-@0?C\PA8.N$B3%&:< M ?IA%7S PSL^F+OABA<])@=M >2=F)>9#C><%9:>]Q94[!_>+';ER)\L]N?P M(N8F6'QX-H,_1..,+?X5V8_C=!5Z.7XF&_. R\T_JA:H-EL=;7)0@>I#>GY8 MINKY<:2>'XB(6!5\$^9DC6BR_A^E:MM ?=CJ8_MK^&OAC0TEZ"777R68@GS! M.JPL6I$_:P15@P"ZJHJ<]G,O/C]E4:[-(SG&$KC-U02(]_N5,P,@?'#\!^2/XI719UUD3\=LPY/@L]9,4%_ZCOET(U+BYLQ?KO7FFJ2>/P7MD)K@($_ER$6: M8\024$00SU3[CE?4OF-=I%YR!X_-#1B:L9?5-AYK:[W(7A[#Z;]3LO%NKC]] M&P]/R'GR3F,K:Y(F+_5;#,+@ZA_#X1<-G@1+#(^'MU_4J1>9?!.;*\+J@.4R M.!3L!@SS>.,[0N(%< OOO_2%7OI$S$3R'!C(">X\ M5&JD9P#0Q/U^-2&- .U?%L3\/42F(&8ZK##"#FNXB+NH]!N\3D.+3G-N&..( M:0 *A@^PF6IW#AC7M$ _A/F 7,!T=J+OC/<.8?\ADSQF+O#MQ*/QX%D7D-1! MRJ,>?PBS<,EP9F#M7L(6,2'[A/D>V,&\9]L*T!&W[[TI3 C&\RQ%/0BQFR\> MT)]+KE#8!@[8%(\Q-^S!4@<>"U!"]*!?V;WCITXF)O.EP(FD/G\+*2YV%MBB M+@AX8SE\%CZ!8LRU+VSS!E]-0B>BAF_<<,!)(^'6S[P$WE&"H>&[3A9=,^(A3D:G+['Y0IY0"(O1K2BPTO$ M*7#7"/;\$RS1"Z8 \>BQ H<0/KW^BI/V:"UU@%9BJ,+FUX#-7[T?EX[+#>LD5V-&]8;S?$]6 M29C&H.LWN#-<,XC[THIA;<"'(_4D.=NL0H6^YX:^Q^B_IM!7H:_BO@I]%?J^ M*N[;B,J:>]36/^@\W_SZ1^;BUJJ<8F/ <.Z.#]479S.X8 MBIX5/;\&>K8LO5-O(RM%SXJ>%3V?K'F5J9O]5]"]2M&SHN?70,_MCFY4:T)T M7O1RKV82@X9M?/XFT4N$<:$A!MJ;Z\9KFIWOSZWM3[_>K4%CSJB14B5 K MY#LI\MF&K5!/H=Y)4$^WK,NH@JJ0[^R0K].MTC+D/%"OSL!8TY1<1;Y M>5#B&94W*W7-57BI\/+(>'D9C5?/ MV3],.6.)\X/?IX_QRO3["0O8S$N4Y7INEFM;MRLU2&\L1U?H=.+H@V%546G/ MPQ6BD*_)R&?:>M\ZJT8_"I^:C$_O;=VHY#8Z#V9V@7[=\5,EL)1Y>/'FH:VW M.YV+,! 59EX69EKZH-IU.869"C./W$JN5ZT7A\),A9E'[A(SZ%X&SSQ?=^]P MYZJQRKP],_/6U-N54O$;R]\5.IT8G7I5N+5")X5.FPVF?A537J&30J?-Z-0^ M*^YT@=[9K\]T%5 FW<6;=#V],U"990HSFX>9V'O],IP-"C,O"S--6^^JV(%" MS0:BYD#O5;ISV3S,/%\/[>_;.W$I*_7LK-1>I=H-C67H"IU.B4[_ZV]]R[2J M5%92"*402O$GA4Z*/UV^6W:XVJU5&6X7;[AU]<[@,FY2*LR\+,RTK%K+0RJ\ M5'A94^2JUU>1*X69S<-,R[J,*R_GZX+]5Q Q6.%_V52[<[Q T5ZX43?&6^_ MSD"]3AZUF+DIP,-3;MFSLU/?VWJOIVKJ*N133A+E=3M[A'IO]72K4FZM8F<* M^UXA.[M G^_G!&"@O3%UVU;X;7" MZ\O#:U,WJE7G59BM,+O1F#WH'*.C?//P>D>#XIE]'0/)#TTEF?X[C1,VU6ZN M/WT;#X]PF!= V2^^_S/K;+DC!!K:X-+0N^TJ/=">Y6*-['.IR%F1\R63LVWJ M?:-*:R]%SHJ<%3DWC9Q[ [W3K93WJLA9D;,BYX:1<]?4V]917 :-)&=R&_Q, M2679]_0OSS-SF>^+\_GEC?&&/L,8KOPLEE \TC:<7W%)W[P%B[4_V(/V9[AP M@H_:^MK*;HL';YK,/UA=3N8"]OMX.Z?^[!? MQ!/=,,^LL&8BO@TC+9DS^'_$F+: 7^>QQH(IFVIRX?L-^#^I_\@9).BRFF68 M@VKC4#G]:J_"I/UJ;^H:#U2[81![Y%@*9UH0!E<>=:$2M:02YP=@+?Q2;9*W MIE%Q>023MZ;9U;60!]3YNG[ZF>Y1';*DSB$K>F];/^EK_0]P.;"^B"U8D#@^ MO^NE):$63A+,6G40S$GDN,D!"V]WNH>LW.YT="UB\9*YB7?/_,>6)BFBVK"Q M]Z-$1147IVCO6+1GF8?@BV49DO8.);E#SN9MIWLB>AL8QB'K[O:M%7I[3N]X M2A8658N^5"UVTH56URB>_P9T/PM],!=@6(VK.;,THO/&FM/P(WS0PC325D(/ M'^0^"NLMJ0\&K(]DMP=L(>"?BQL*PF@!2RINR32XRK&7NO64>K6R7ZY,F09 M4BB@+NS=6<;L@_QC3=W(-;(\8&B_V:Z!"86M_ZZ@KY5_,[?_5.VMEQRP6^FM M7N/W=5: >E[QKS43MV"L696-M=Y^_*GWG-\EH\;.$3)TJ^UXU>2NL&7Z], 9 MY"3TI\2BUPP55'LTT'BJ&^:[[.Q4^1CV$0[TW)#Z&&GGYP:#2R?LKRN6DR+K MET7IIN:;730@=E9=3A$ZJ97);:#X]V"4)O,PC<$TC'6-_7#9,M&6+'+1@+UC M\1;?:6VIBD?-2*P'1D4G3HT!AU.&"%_9\1TC7J2.[V6.[RUGW*.Y$]Q5:A?1 MX'.\]+-[=\%G]YIH4$G ?I&I MDOOOT)MJE?9:*6_PN;,\$=4=<@&G<=<$%8HU$\6J7PI1**90;*?=]/5^VWH5 M&'::Z^F5#J5:JOES^SM*,;5*^WMW:@912]K]67"/>BY-5-IJ]3M01SVV\Q9M M"G-? '.K7_=1F*LP]Y28:_9UTU:86Z^R=\+SK%9_JU9-\'1TNTE-K"UO9@U( MC?0.QII3R(O!ZQL1NV=!NL6K>[$!BC>_MBNU_]UQFXTWC2[Y8"LU%;FX@WTN M+?05E% X*9(K6+P8P1^C+LKY$?P%'FREAGH7=["*DRM._FPEE1>]W?QY_=HR MOS!.-^LGCWO?"1?CONVW^AH\X'MA4'$(70NCJM-;_7>59YU%X:+RMFWSX'WC MA?*ZZJ^((=>*0.Q=CT&N+0DK@Z9MM+IG )J]:S"(@5H:5@J0M -_K-'5@Q-K MT\@#(QT)"[>!_,;Q?>TN"A^PAL",R@A,TACH/HYU',U/D>#!UJ]*"5952BCM M)0FQ?(3P,*P4:+@,AF7V6^8).99MG(AC=(T)L_S*GSG %_?6W@)%2&*-?@(0SN!XS^2I@^;"'U>KIOY4"\)$FS!>ZPDT?Q@-=NN!TB\J&44TC!:GDSCQDC1AA.\T:.S%\L@B M%J=^0E-&;!E&N*H4L#G2_C$ M8]C=CCV\[MF&W1YUQOW>=?MV9'3'W=YU M=S"R.\;^S.<;U;\"FA_!+W"\>4-K9\V:WH8A=6,H?2Q?M_C?[!$8VF(9!KC& M51Z%'Y<@=XA)GHR3\X_X\ =@V+[G;MK(GYMBBR\J;OYBVAT+$%I,2C^N^'); M//KU_).6A69#->MUO\%P#(G"E8!)H$+?S 6:P\@F>=.A)%FP. _6/(01M^U M+TZ4P)E@I8;%T@\?L0:B[Q&N<]@"Z+QI"C!?L,4$'LQT5&>Z\ (O3CCVR\EI MGF44PDND[( R$&!90'CBP0.]#-_\[>N0C_[GD!X/9S,6M;2_\'=11I J'&Y< M)GY+^W$BB4^^_ZCQ0I(A%D2<>3^PIJ1'&@BL+W63-&+9NJ=IE%56Q,&<.\ ^ MK*Z8+S!B/KMWX)N5Z7EU1AAKZ7A37&(:\RE)Z>:K\&+8"0[AAGL+0,LN$*=X;/FKXO$0^-E2H"XA3_8RO>($+J/U.D'VG*[=2$*46+=Q19SW(9I% MT^^,+7'KDLX)4$!\DI@ $(LT02*> 6;%^-/#W'/Y2B1=>\$]BY.61GDI6*)U MX@3?L[D#'0<6VZ+W5E:5[>P>0!NF\480+-,H3I&P@'9DW=(82,Y)M/?>3_R@ MY\X]TX"C+V(M7>*#,S#SM$?8$^SYO2^#' LDK+1\ZX2!?TV\+Y07]' M[#^IAU@B@2AG)'ZQ&;=QO1M@30 #_I$QO62^LN&8,U4FN10WDF.VZ51:VB=@ M3< AD"L"@T6D= 1:4*/MWL>8"*0()UBAX\Z1;VDNBZ@4+8IQL 3]J4[KX0/@ M,@GRL Z.8=H<;;U(P_*K.*H@,!B@A*,P6IC>S5>VSX<@;BV6GT//6:<&T!D< MWTW! 5(..L)5YL&;AAC_;1!NSD2:]V@2&EXRB!+%XB*3')4R3+2&!$M_QZH MC([&=:(I%2E>.-\1E_X#Q^K-/#@#8 P0K5%'Q@L(Y#FXY-['J8O* ')ZKO4'"0R5+I<^823N@1K45Y 76T,KJOA=-9W?S.19$%T-)PL- DLF$P9H" MM&+T\27!8&DDG(ZK5D?A+#FG -4K=EP.2-0@BDMO$%7FIB/ML;6-@U<4"*7! M*XVQ:L2&Y!1YDC%#Q>(W8V\"4KQ": S:*E"7T']6Z^65)604B>6 ^-BS0OGOX /%R1.;5L9#KDWJ$;0[@ M[;)$1,3-.@R "?*=$4DMX'T$B="$N0$]35V6H>:J&=PL',UMOZ-@Z3V,@^RE8=A[VTCU!+ ,Z%HIFC18#N/ >YU,,<9#L\@G$1>&3._"4@ MHXL.A-STKFP#HJJ]8:W%=:(JE.NLY#00K@SA7/BVKNMO&\L%. L>6?2/A-$" MAD<=/%V2?B,,DR $&7#"B-1SZN]1L&MM@G7\XE]G'.5I^2(IOB1BP!Q,.)<0 MF)F)R7%*>$8\#^-B@(1<1Y#'0H/!QS^'5P#_[ZA#EW3>PC1Z^:=\-W,X,N!A MR$W^'*Z_5S( N<6-UO02Y3<^BV1#'!7'0G,M1L X&0, S,-F1B=S1%\"]09D\0$G@ E@R&S&#< )VG!!2G(7!I\!GH11*81?YG]Z$<'*;NZ2\TT0G:[-PP\R4TYX6DN.A-QLB#<,#'Q\-BLB+'\(K3G0 M$$M6QQ1XO)N(!^!+EV'1;$!O9*Q 7D'R\R0*OW-;2KR=+4+?L)FJIB973K>9 MF^M<^B+"]L]VR%-A^Q<(V[\ A_G&W'D0^N'=(R'Z%,24'RZ1K]?-:+;/E/.. M-6_1=A83A[/D 14O%H 498",P1UR%M3BN:*89!/JTG$%QF-2VJ.VRZK @VS MI6V:-Y.7N05!1IW,Z23NZ_&,&5"RFN M63C5ZN-FI\3-?_ H-H\N%Z+J][5[^K?/M#=NAK,,VV:,I!*&;A@K..*$K<-^ M@/V,<^A@6 3H'=$UG]TY/KDWE[['OZ+!6+CT*4@%>AL/QJ"]^UA&S2KR[:P0 M8KA"#HXK+'30>\%0]9 %\[!9W0BR^\Q9#M2&:#J]%7MY_\KL7>ERYHO'8$PV M X]/;GNV$'2Y0N1XS"/38AR^%S&K-9ZFN^ M-R.I9G9XI+FET9B(==D"N2=\#1"ZB*4CBVH;YOOO/^41AE)40=_D.<"LVC*T MG"QI>?=]_?V)'1ER1QCFNW?\%./AV2EM/EL4/-YBZ7@1<5LG 8(%[LU#5ENP$AID)Q _7 M&"MGD;E,78UMQL*6 $HLA&=D:H!<'#I=[CT,6G)#GI.Q],OPW33>FA642![Y M]V+[%-1*3NF1V;BJ G\45B:I3&D M@%7<#!E L_^SO$";DCZ8P0JO MN)E7S%) &1K'N2 N93>,EB&EV6!XK@KRB!N^_95+P"^%3Y_XC@ &/'61;.R#=E&]7-;VY%D4 M,'$Z^;=(CQ2A!SJS.$'H>]DVB/<00?\KH%2FKPD%"@I1 -?Q63!U(MHULG0A MQJ8>)@[%N3"?>3%>^,!'KA@&4<)(Z'$\40F3(\CQG0(6Q"*=B<(G4CQQG/:< MB>=["09VDWE(O$DXS[BX*2Q>%PF0?$6D3:)''18J1_$DLG)YQ9,G15;'-$OU MS(4BATF6!8:2&=.,BCEA.'S$P#H)\AQ7.74!!BUMS ! $1\T6T!AAQ[;NJ!9 M2JFH^"(R _:?E%'.F9. &)VDBGKCQ[I7A,Y M0(F[L!_ 9^B[+5&C;3:M"!(F)D1:,.F1'?!K8QP-&,H4HPFUPUE+Z M=7<0+4"KH*A92FY5%CCD ,;-I10XHT,AU$7^Y@J9YBR7/D7PX&>1[$?((W"> M])T\R1&P#;&1+9!)P9A%X)*!6QAY0HEMG"^'U!X\\=F4DB(KM%>O^UXF8ID50YT2&Z73HZ_]W&GGQU!-Q*-&-[U^),QS>$=T'Y!;N$Y +AA7 QS M;YXGENJ+\.QO.:=2#(TBKF3.8G*H",07&$@16X#W@+$IQ"1LFX'TPN%YP$, M$D6E=K^^.[J!F$5.G4:@!YW=0D1XR+>\#M.6]EOX@$KF*BYMVB,,\];(+U4W M99N(N=K_.$&*6"0'X\=8N#Y0T+"$.TGJ53F*8]@GI'N+'+GPO>R.BD07^3;7 MSSR\R(C"":=(/%^89JMS"%;$&?X&E0C]N=[TES=QNS>TAL-AYV8T:G=N>C=# MVS8&YO6P?].Q!X;5?5-TK=:G2]5T/6J$R>O 8;CIFA=VP"/:^WBWS+%ZJSGK M(5P-B;;,4NN2*UU!W[:P9BFB&-<-6&8%3)FLW%"1FLUVY4O5!US6-P>'UTR8 MIN3U:&@UD\-J2EA6JW,>\*E:ZD&']9':4+D1GD5E>LBM>PZ-RLVRJW,[ KM M'L[#8S.VO"1-U7HPW5,PMJ[9LFHBW%=>A.0P!MKN'%R,J,A +^0LJC/KW(N: ML>V2D"ISTH(G5C!#H>\[\::1*DO)WN%,L6"FH($A;_RA94EF?';?#7[[R[EC M?X71=^%_J;YPTZA7=&WFYG6+(+/;&KR$P+W07*?NU9"F)+P"D*#/ MQ:T%F(WDEQP.IL&KL_(5NT&>8TI6?-^SWF[=@L?8'>]#^#!?. M6BW7!V^:S.%/@*FH-(M72)UES#[(/]: _2;K+Y%7]$7$V-9^0LQAO_LH'UK[ MK=)/@[H';,A="OQKK9?O5O&2;K3/9=\9"N\\4 M C^P+],>.SY.R_5OZ]XKZ8*N@!%[[.R%*[N_>D1^KKK_!Y[YVX&KP$& ME\[(OVZ+)"HV?C0T/E5WDL;QQ1<]& J*V?9N.Z9V[@[>\IXR9,8R? M_$21Z99?4X]_JL[D7Q0P#=1]SJU=V0;T* 8":T2 78^N,G%7;I)\XOB?\HS4]I?N>- MODKS4^A[KNBKM+_+Q>-+Q]V+U0"?=PS#(7R<..[WNRA,@REFUH71A[^Y+F.S MV3EX/5 XQFD35E2+ VR"Y!PQJ1H^WQT"(W8+@>^RT%@O> MZNI6WZISO[40+)M?6!W%,DJDE4D>R8D:^IVNZURIUU@_P:)NO@UV]4YSZ%7#JCJT; T.Q:N7?4/1\"?3<'NB]3E?1 MLZ)G1<^70,^V;MMM1V+;MZSZK5 M-]U8OG\JK&Q.98DS0LM.1:U#H:5"RZ/F_)JU)I(IK'QAK+P43*Q4(*#6<'*C M_7QG=))V1Z]8KD0QE0:9Y!>)FI9N5/)-*]14J'EDMZ0^Z-@*,\\<,R\%&VL5 MW^>AC>WH^#RW,M-O?OT6)M5R^4ZUWX9T##G&UL\L_7Y'"#0S0;G?U;M6)9'Z MS+;/-!M?E7)5I'RFI-PSP6ZKY#U7I*Q(69%R@TC9[.B=:G==%2DK4CZUDZ92 M$;H=M]EL\UCQY0OGRSU;[_8JUQJSGLWF);Q MKK21/JQZ=VQ;71@]SS_BPQ^\!+;K\F]6FHL_U7)@E\4**/=7#J*&];_Y]=N< M:7)%>[[ZUFS9&CS@>V%0<0A="Z.JTW?>59[4"]R(.3&#/[2X?#K:+ H76@)0 M2>818^6N\!4GQ&;RG"?9IJX5^S;M.9"6A%N6]MR 6WEE;7L:5-W3@Q-KR\A; M.!$\I4WA"&"7,$3QD'#30;J8L$@+9UJ81MIO7X?:[PR_B75MZ0";%#\G\603=C.+B90(IOL!^>'$"2AC@_E0+V(/V!TL>PNB[]@6P M.T DW5_%JTV?6U$V-=B0@\3DLB!!6A*;3HKI:YH+HWCPQQ2W.V6"G-< @;"; MP]H!=@(F$9 6#NFN5K=K:0V"P19>DNVT/F9A&E5)EI"IXKN#RI.N*+L'K 'D M7-5%-$W%?G$1W:0#.%_]I*5]3G,]8@;03#P6 4H!'W.17<=)E+I)&J&B@NS0 MNX>W8V*'JQR<-)OIM,0M)LQU4F"+#\ OYTX$O,01N@MQP1D(>L$<[T,_7>#( ML[+J,HS7)\)9%F'$RGH28H3CNF$:)+23;1SL :R.C'L7F?<)^>]./I%GRJ&> MM5?$:@U.: ZVK7KLP361?J:>D9/SI9WMID>/^5,M##)*SX_ =>(YJ')@,<7\ M&*R6:;XCGM/@ [%:G?8[DFDKNY4;G#H(D$T:/FW(%6M( 9T$Y*YM(Z\[!R'8L3,MN >)U'#"&72!.Q M9^+X#IB)L1P1EP&OLQ2H(M(Y,OIQF)'\LY@H?&9[G,T1 +_-D*S?;VY5MD,. M\8)8;>4+.Y)1=4$ J2SM-[K$MXMZ@%C&1H#%[2"MFNZW>;;LYXLZ^L\W>:5? MCWWBK1^')IEJ\A%UO#7*?*4G9+>.$)%4Y M"K8'25V(M:N,?L4J#F<5&W2!%PRU5S:.#U%D*V?D*.M"61?/RZ%UGI)GXZ W M^GEV<,JTFPVW3AHPO_QZ=3V%&PKHA6+1QS=U>6.VYDA<5?5J])Y[\?DIBS= MCCV\[MF&W1YUQOW>=?MV9'3'W=YU=S"R.T8%-9;[]&;:"'Y!%V &!F?MLL@V M#&F$P?U$G;F7M0M*KMF=W(A5$VZ58&^&'%."O3;!OL5;N!Y>WD)8FS/G<3BI M'\3%.QP(\TUV;(U:0R%>]!)LB#088YA'3=4..AVC!* MYA2V__O+&>$.?84I7?MZP[V\>YBK^P1ZT/\.%LW8!]\&; M)G/X$V I[HVZ UG&;,/\H^/J[<]WV0U7[.BTC8*\6TE8<4H;]HM1W74 1AD]&T M'EY"94X#/:X"1NRQLR85LW@-B&P? 9'/! :O==]';9)\;C"X=$;^=25BJ-CX M\='X5&V'&L?+%18TL/G410/B^6XYS2APW101?V[UVC9(.*MB5\=G=JY*#)X! M+[L,]*W48U:A;R,["[PFU'W+:7A$(3*%PQ>#PY>.M^\N&&]?$_]1FI_2_,X; M?97FI]#W7-%7:7^7B\>7CKL7JP'NV"W\)5O='VBGR%*DF"(8[W-4+[[1,XY< M;X7347=8J5O. %/J=,QL:X_K9P-B#8Q[Y97'*T6^SCO ==3+ M+$&/)9QP#8: M[X8_8ZKNZ[:M!$2S4B?/&)VZ^J!M*G12Z%23+T*W!PJ=FH5.9X9"%ZQY7%ZF M=K&;AM$%BI]&]"-L_$ M0#.3D*V^;O8K"=MGMGVF&?>J6J@BY7,EY;;>'E3R&RE25J2L2+E!I&SKW6K! M,47)BI)/;2]7NM:VXS:;;38KMGS9;+G3T]M]I6&IXKJ*G"^"G W=:%?)6E7D MK,A9D7/3R!F$U0OG%B;IDPN<0XHRR+M/O33!<. MN..Z81H @"<,\%<"?5IIN@WDU*JZ[M/B?P$1,_#)KV($VUNS9ZCMH##3",6M\Y4V'9: MYN4*VXICQ]Z/$OY5Q9JF4%1U,%2=N%G4^QJ5B,/I^FDE8D>);!9E^JH*DOVD M1B?4$0%"M>B(;OEXE"UTN#8%+Q8A M+&7,U('WB_!VXKGFQ#%+0/(^S#UWGKTVY<=07Y$ #7I_]< M"$#.3]?:R1_R3 W/LU$-C9.JAF9E#ROW7%??]>"4NS;K48B]51Q#B;@7S'\$HNX5TG M C&_9!@RVQR8:6G-9NRCIZJ1[+/8ZNG(6TYL&&L/2.A!X@7BW*8KD3_X'<-T M;@)X[O"0X4IU%>W!6SGE:>C[#AS5 L/$.&HQX+@QV+B0)SG:-'9Q@1,@M=D, MUL/#<(X6I/@JOC/UX(<(@YPSQTU"$;?TTRD%1V%J!S1W+WFD%;F.S^A+OE/M M9IJZ/"HY8L@$]=6%YC'4/(8K(N':P@D )RF^.DL#%W_?$'V1N=^KYUXX5I?F M_OCF:;S8_=RWYF%?5?6\/,LVGY^RF! \C^082X#@U01PZ/N5,P,@?'#\!^NV[@Y@E_@>'.USEG+C=Z&(8U@8Y^!_0+J RV)N/VI%=09L)GP M 1=$F>8:F8:@KR1S(NQP;;V9,@._>.$4DQ.FGHN9%!_D5@J;*-TH,"3[A5?@ M$.ES<9=!&"U@G<5]F@9/O>>+6.\H<\PI2L_;]CZ-V\!:_Z#/6A_ MAL!A5H'PX$V3.?P)X!6W!ESDN\N8?9!_K$F,-UD9L*S,H(TXO:U*&)_#,M]] M?+-V@4',7^FG?MT#-F2N;MT#]LX9&J\ \D6:B<('3E+/5NY\D;MIC$H2:"%L1\N6R;(=5&_ 3D?_[2B"[Q<"Z ]H'*" M-B7=(W2:JK;C&J[ ;4",;^L16#0_-; \*V#$'CMKTE7&%T?D4U4PMH^ S><$ MB%>]^:-VSSM+0%PZ<_^Z<@]$L?;+Q67%VE_QYA5KWZVH>C/J'3:FQ>*95?#8 M(.&*P;$:BWJHHC-GP,LN WTKM<-3Z*O0MP'H^Y8#8D3I*0J/+PJ/+QUWWUTP M[KXF'J0TP(MC/:\,?94&J-#W7-%7:8"7B\>7CKL7JP'NV%SR)5NC'NCM_.KX M3.0E.]%WACF$^QS8BV^W(;TC*\4O#^WQ^W+%U)\[T1-VI+>K=9=2_95WI*J3 MMHQ29'4:LNKI5ENU+5=DI ME"N>6;>D UCF"=LDF3W=[M:J_I]I@Z3C M%3TK>CY=[W>K4ZN]H\CY$VSV%2HU!I7-#GRIYUV?CE#]CNK8LO=,Q%&$W*IORC/') M[.IV3PD*A4\UX5-7-WM5W!,*G<[(QWUDW:.*"70>NL?E96__@P58>)P7:)XN MO,"+$RP$>[]7UOT%)W'O?F/H?')Y!KK5M516V1F;HY>(E3V]/U IQ HKFX65 MIFYW*UUB5UC9$*R\&$RL8N:??P;N13*5GC[HJ5MHYVZ87R1J=O2V4<5!K5!3 MH>:18R=Z1S'-L\?,2\'&UZB.G6VBWN\LNL.N=$'"[B)J2?^95I59)1"*(50BC^=!3J=&0H%/SMGAD"*7A6]*O:O] F% M4(H_O0)T.C,4.C-]XO*RZX:+$-;_7W(X85=[Q_U/ZD5LBHXH)[CSL->Y$V,K M=I5M5V]][G-R).OM015&7QD$C940EYJ!\DJQNG>,[@D*JQ56GUL51(729X+2 M%Q.;?GVAZ5?*D"Q]T*]2O43QI'/R.[Q2S*Y6^EIAML+L1F.V72ES3*'U&:&U M4B3/5I'S'D@4QV]\7?8)^>PWIXO6B MK?9.5DMXQTV>3J#:>J=W#,],K=3R:6A&.B9NMH4 MW36 [MI]O6\=(Y:CZ$[1G:*[[=[[-M!=I9)ZBNX4W;V0T5"IUM!%& T4:?HY M<28^R[ZG?PO+\+V 7EC?1AU;MCV^K"Z'G^$1_^X"6P79=_\\!G MG(3^%(;\ZO@LIA+!"R?ZSC!85-[."R[XS:_?YDR3T^_YZENS96KP@%\H ++G M$+H61E6G-[OO*L_J!6[$G)C!'UJ\?AXR>*?-HG"A)0"B9!XQIBU@I'FLL6#* MIE67_3^I_\@YDFWJFF68_8H#:4EX[*4-JB[MP8FU:2+\75N^VSI3TK'S+9R ="S[ M!4FGXDRQ]Z,J]C623"\$#$=D"59.$_J>_*";OXC8*">($4G#! >2Z1CBA?;I M&QI=L/1:E.AR#3RQ9%(=!P/RKB/E. M\4Z=]J M&3G]EVA_&84S%L?P@^-K,R;(WVSUUI^?;N:FW5/LKE\_N[-S'MIPO6[73E%GPZ;-')5.X0OJU<.F[[8>B]+K7IZ=&;GH M7V%/S_ ?8U]ST#H]VSB,_*Q0)P,?XD@N3>T&:GT( N*=9;?S-[DJX MP'H>6#8&T_YR[MA?8?0];CA1?I964[A@VGNQ[Y]TV.2I?;_NW GN6,[U-JY1 M5YKR 12TC+R%$\%3DI:HV&'L$0VX89R0B*GN4SM<6]QDJ,,0:0 RD5OG=XX7 M'+)*NQ;F[:(BX!+<'KQDKH4IB&F 98)^A7L6)^0]@ \(B^%4@MT!I M GZT#(F1N$X\/V1_YL'[:VEGQ@DN1#@JI?T8'*Y6YF'U#LZPJ,8]=*YP^#[^ M]P6XB%U#$M9&7EZGP.D=SNK6.)U,:UWE? 4#Q&4(_Y5E4U M$>=9$GI^RF*NXSR28RP!'Z\F0$[?KYP9 .&#XS\XCS%L[N=Y)."W'U"E M@58U^^7-W^+;3L<>7O=LPVZ/.N-^[[I].S*ZXV[ONCL8V1VC@M3!!$]$Q1'\ M L>;U]=PUM(^MV'(\67CIW7.@7S?]<-89+OD!@^R@V%ZEP*7L W.5_5=M!1@ M*,#5N<^".*KK!"[SV;2*5B R=_LKR;TO9>M\XGI#XOS 2-6]AX$J[?V$!6SF M)3]5W@XLX @.B8V+58Z 34*^JKQH'QQ-.N0(WIHUF!X.42A(5N[@@)>]'&\$ M9A]F/1BG!-'A:L?EDDQ5\Z"EH4U52AN9*S[SW&J*5':1D*EL;1["@3LGYL#= M/'.MLED#EA>ZD;U[YC]RVA+^BFD:H1JF3/'+-L7AE70)"C%_WM&F+.>L[(?+ MXK@HC&/NIMH6 SQ0JZY="_V,VY_-.'X7=0OR*B@QL0G1G8(@K8[09K_5KI[O M4%(*:U $VZW**:J'X 70=.5I+Q8Y#U/\A'!:,Q8*RA\RJ,V6Q,7"5.F%M>N% MWB:1_ZQT+$3KM^;)1,P-[P+2&H3U4K9<Y;@5GF4:D M)T?LGF&:Q2*<,A@%L 0TC%B.>@]XQ$=$-9%>C%.?QPM$.>0PB%O:4(MA3][, MH&69>V#B!@?&QA1,\ M:FRQ],-'&(UZSO8^9AQUZ0.4<1!8^S4#[&681R*T8@U?E7"1X &'6@,%/KP (C=>E=ES0BH,D%K>N";2(@0F_&T W,BDMSD\1+?-SGC-_2<3/ETEK M7- 2LJ]XO$4N*$O5H6/"5R-GL=32I;2_<(0$EC#59E[LPA3_@0.$ ?*C6CC_ M#B.D,#Q4.9S'CW0J\6T&_\#SY3$VQ8LU MW/BN3)-JJK\$UQQAM),O'/Y \^W>\3&,HV'AEWN//9PPHV%X2(RS-L6%!W] M0 >NMT2*I(/%E?G9T:,Q@T])WN9N!>O$\3$L%*/AX?O 7\FH)0 MGWHB^9KBUD(?E5PNS^#CZ:_.O>/YSL0C"9B"9A/)A8.@!R$Q1:W4<>GWEG9P M1 P8*7$7WN\5%1;D@ROS\('_8KX?:[=.=!=JUT[P7=?^: U;\IH19VU8MZ"Z M\[MC'.Y]![B&_CUN?FT3?)T@[T(0C1L10*K[(U1R@T=*F@1V_TBY!8@#I'>A MMCEY+#0E*&1A @@7C'$V'L^!>U\!%*2)&[7510L42=KG:F,L6TO*<1WD) M*\]L@"^CT/<+5\#RA9"PTDLLC/@[S)P"+SOE-8QF<(%##!6A"=7$C;;S%KJP M5Y6&^F;GX)N]AT6PNH6,_II\S-O%F],,K!+,#[CW$CC$#Z#F!+E&Y3AMIW\P M#+D-D"#'U"I-#0Z+>-C#'"?T=_F1T[H$=A,L3#5^3=@ MF26,2]E NPU!5G^]LO'OF0<8GVE47V]&:(!YL7@+1]:>&&V#6H2.'21'XFPI MBFFDO1@M<" M+M"^EJ0--NV_ A\]4*0W/'BP'GS%FWE\&*-;VP]P MF(+B2('_K+$2W%]A0[1*O&661G&*O@RN!.T(;U+=Y$7'@K*4PE\Q MZM:9Z:UKDS0!'3 !I6SA<:\!K#V,OI,&Q5%6]@57AWZ)%) V)8@]X$YD%'#]/+T@R\.] MFC GXEX->9QDFD@'2#86V"K3U$V*_B-8)-=B9X#G8)L!FA;)80^5]?#8GY!\ MIB6MHX(M0#85"IF"S%RF$^"4N>@,9^6BJ"\L)"6I2$E92F5$F*XM& P/,H$. M6O9;T/@.7/,2O5VX;ETC_H1P)]OW ; )2.GOVM2+R<'&8SKR3#*%IH29R%N* MJL!ANZM#&1,<%#.&@7$C"9#K5>X0/\@-"K8!1^=189&ZMV.V#T\Q*YB>$I,R M-R*8IY1+# 9RD7KJW81Q&1FT/(I:0;$ MJ(<>0)$$XZ/2<<] @C7&*-V X9=PM\-^5M*HNQWE9;R2NQU%:;/!I5T](;RK M30X3EZL<3=J&$5OZCLNF3S _C"\$L8C@ @S>>S^A!@HZSQ4%8F,6X&ND=^- MY&L.87G#W.\M[$/G#@:](Z,H"X(X"U0Y#LN7MSH'PD=?MRU@087B9>3<6=$G MX%RYP<"*>(&*218+CIP@=GADAEM<[[VGH;<]=("V]Q!BX;Q3#XK*Q9,47] M7WQC+Y1XH*+P@\QCG>R?S?0Z8P!-?.%L$%1/= MR3*Q")EG0:5>-;8.X>[6P=Q]U>SU&6G\LEQF/2NU#P\=ZP53Q)F$]ZP@3@^) MB-454.!7V@-M#HO9@XG53O6C#2[-S&MY(4F@!\67,8GTL"BN:9_V&F*OAK*C MY1!N7GV*Q\4VH%"AUER&3A%;.!Y/@N$2G_0VX:O>$)"W#%&8*BMB!:-.0:^C MDA!;)EU@5@?7(QT0(UZ"\8R()S4#EW5Y#I_(E^/)."$(.):@U(L?8U L6J"8 M8I[@4\-M?5D&B>RSW_NW53KCLJ.>,C2S M91MA&J 79T$__"W 74*AI*8[]93K$JX/_6S]_)N,0>#TH]$(?'%L1):255 M=.4FM>RZ,+2J]8V=;_ MO8FS425J0E$GH' T0DC1G=,+U [EDIH<\EGE!TVQ M:$H X!M5(,A,96*"RV4K<10'2,CEO%.,(!I9KOA4=-['T7P\T<$&2EZ[0B-# MZLHBU 8&:69;$ W27*]XJABL,!ZK;1 _42-RL]%$*6X*.3GTH'P*YXZ<*[!N MZ K8$Q^USS/8WS@"PXY,_F\H11/(4)YE)>:]RECFNK:_1U%GJ5'CMN^D$_H1]D09[F(#I MS!+OO?IC2>/!X<34L \NP1G_?-0],OO;R:\R&GY%N_WC!W71XF_V9C\U=_[$ MK5]6,/WB;H:[:4HI6R;W;-BPL_NP0R>7;]BL\X#GK0]#^VCW:[#9C!>[=6XP MY0+_R:5_D[<2*,H/"N,&]/" >3UES]5[G^/G:#Z[Z_W\B3S:T3P!>9>\W7P3 MGW01=DOE]SO8]3L.]K-VXMT-+9BV>MD\^B":1[\R\NT<$OG>+8=@[3\,G.'W M,1B)H8O:>Q2__V$X]+S1:/^DS]$OOWOI_4I_-MG&IUR')Q1 N]_9**]3.3EI M'"SAO1*;K2@P5NJ6N_>Z['2!'GJ71:+\D6CH\2^-40Z7NDD&7NMCAZ&*-MEUIGI0V1DG7AT77=K<+=%U_%71] M3[GUT'F]""/DG&MM=BK>#CO];G]REIXM6'O/23X;\^K8K8K=WBAHNZ^95^6A M*P_=?A^Z.FC"G=KAI3N^HUHG_?U+097H9W5F=Z4V5BW\9\-*X'LG4);] TT4 M>VSV@J5Z&AI>8S8CV(-T_-D"N*=M;XT37K$<]Q_S)!6@F317UAA&X3%MNY]Z MT^2]Y7JSV!M*2QLJ7YUB5Y;_U=BVFTZD6SW9>AXK.R]M@XS4R+!--E]@U+BI M800!KKH(DD- 3]3J:8O1G>R@$6AVB*D*] MW"YV$TVPYID!<:CZ5LJM#8QE$[ASF\:C.^ +3U^BHT6IC!FWIV&+?# -M2.]M,)=H*,'=SO8A? M:RI'6PUD9]T6%9S_8ZM)S=;6<,F[59/>=*I=V10>U7KMQ52/[J%.P"%IKKP< M4ZC#-(JY5]6R5*T(UR@4H_PT0V(%$<'2YT56H:Q*(S1B8+'>U#(D[K6"\0YF M!MI/S9CEO401K$R&/O<>-/PQQ=E[*_&U-TW1M* M*#,93;Z'/:-Q(=DC86F\16[XN4;EW$9W, ?-U:?_P)3)$@B#0CF'B@LMGW7 MC24L=GX8+P,6V_6NO"":*=&R D NDY4:ZRWTL-V:1]MNVN;J,];VV8'AI-;6KO M5*W/>/3-O40^X,72L1@%[TPZ0[%.*%W^-O;R[&SK2LNU8%S;0,5OWQOR>7=F MO[AUQ5!R'>S3EVFYZBB1]9M2=Y<^IF1* M]PNJ%S1"OI:.9:N[#&[N5.YL'Z!Z :V923-E#&LO'OKUUQ]P5>#E_%P$CG3F!%@\ ?4RA@SUI>G]\, MO5FJZ0>4TOB6NYX9+6\6.C;JUC(5D1X4QRCL.KS0@F??&N508Q^CJR0.#._0 M02M#^*436(3]$D@5:M( TELUMXABV MTV0V!DS*W5,#\%8ICB?NN@"R5.(C@ M-FPERUV.Y)Y>&.+E7SUV DJ?<[MV_%]ZWU5?#41'YK8:EIK=CK#R=W0L/X]& MQP,GH,YOR01[+SAQC+L]7:Y&>%)/[=E>T]HV[6"VX.C4I<'U7>K2,'&N/(O; M-@=,M1-_EC!3FH>YQFU1/'9"B7I3(_.LDQMVI@V]F.ZM<+]R![MDQ7-JL^+J MOH#8'06[V^,]W-T.^:,$HZG'!'>KIV$-/"^TO 2C6#Z051:J5[?"691V@(XT M8UQ'A_LER3 4-\36?^SPQ^'/8*F'*LR>^./0'\$E("*F3NCP)' YB-<_YZE" MKV/(A(18WI["ZM$)Q@MO$)W4RHQ1L"NCK1 K6_EE/Y50;ZF*(S4_( M6SJ?1[EVTA+<$_YNZ8K^46*V#I#%.)[*)H\%SI9\F-V.9-EE1(+C$*V!C;4P6P M2MQO=,"GC3N(*J4*[Z:>L7C_9B<+UR9[+I .4J7QH#MN1Y7-@57;F3[VF=.B M0,GE&;J1[K3:N_P3+VH?U^JYCF%&[I$#HW*9:6WAU%OVAQW]\HF*Y,BX^-@5YC$2(=]PEP*K M!05]O?;AMT>4_/1$^X.UM79$8X4'[>AP@^1S(Q(!TC 1-69S#(KJY(BLEZKY M@):.^8EG(.\/V'/G^E=OZ"U(@S@*X>_AIK:?*BAL/X9KYM+SA#M5K9YO]GJ=4XZ_7:C7CLY:Y^?GYV=M\Z/S!2I#8FD^< E;19; M-A\Q^:E1M?Z8.VR87;$J^,\Y-D>4+X2Q4!=*5LND:73L)]_WF^1_>RD#[4*%8):[V94U/U."4AX]P< M.^X5W _L#HQ^SPG2R9!2H20-3GIL@U:=.Y=N=!VF\SC49TNF!N?*D/]T&)'V MWN%Y\^!!,,K N4XP8<#AQM5: _'KY<]%)O: M8^%D>@C,RT-_H<<&G=BQA6*O:NVWGZJ"^E848J=3L/.F:,7Q0HA+YC"3=^MW MW5@F[[[$Y-TQGFUEJ=FU'Q6[HH(6Q;1(XX,SZ*=D6A!O8:UU/ ?;+<)P@/ 9 M_BH...6/'#Q<6B1.'58(M8;AC[(LX#W7[3Z&(W8);Y46H9^"NM8(N&X4LU-$ M&"0NG+#(7+]FX93 ^0/L*SB>D-D<8(8O#4'Y[]A,@/$@IP2.@;\ID>KG):P;P>6X+L,HQ@[O$<%#!;=9!1/9 M%'KD>TYW2WH+3 (LQP=J7%LSB@M-+'Z(D8R<2WD6I:POP"J##O0/W&9V\0[- MT2<+PZ^0L\-/4B/=!:]8!>3%?$@1B^Y$7=@)'2X8..%WH^[ ]8C,D5LIS46- M?Q2SXPG>CX3KW6#^C-*1B'(2BML$_M3'87Q>^VIGFYR1/4GQ[]BM'930:W_T M&UVA2C5;0^S7*!EAHH@:NT.KC=YMVF_B(LK7P+YTEQP.FJM)F2:JN*2(*K44 M-T?Q1N"6RFT-SR$?#E#GDM\BHTUF$L@_* 1K2\8ZV6U-[M@=QY.)Q9X P]32V5)5*IB&945% LXYG-^9=1CN?ZZ9SMH_V65Q_1DO& IY.* M\ +\ FC%N62C4LRKNA%I%\4:MM$3>WO!+BA BCKD4"\2LT!=I[Z;?*MVM;5E MOE7&6,B2)C\CZJR&S%. )= MB$+5'%]-_:E'?ZP8#M[EW0 ;@'L6?3LPE?E0*=@ST'$=GX &Q Q;& !J+V1T M 4?"(*H_1+[XROEMO;>?Y( M?\6(-:B)9!C!(0A\>+XKA?N\PZK4Q&72PSR$V!\# 0:HQ2#WO^78A^'L@CT+ MT$3F- !$I0"UVZ=M*-8^EB\IUDXQ=.@% BY@4+X8<']6+ZL23B:/?487F"6" MH_-NM1- _))L>2;Y(3@T=IRP&SO7F N(5 C"=,]XVSW7;8LT\%THT^@5]2S) MFDTF49PR?DGHD+VM$W/RUIFWI!V)ST GNFDMFM0E?!2RB<&Z)3 MZ-<9/V8X+X?-8K*J/==BSADE(CO$&VHRCQB_>T!XIACX8BOFQUEOZX#<@)24 M+P!-+[-PAF%+8D_E])&=!293%+LD#!>\ MOJLW;.VZ@$0D9Z>DE1>ER!@QYH6\2<8V IUI K=A@(ZQMJ@D%AX1>JQ7D4BF M\04@YRAOUBQ-@"MZ\S',Q6K4F!(XYZ[/:3Q_2TPFL7*YV.V!GH =;S5H>U& MNU;K]YMVJ];KM\X;]FG_HGM:KY^RM'^&;7&ZDTQJ]S MT)\MN^$FBV,1_T0M:D*"D&Z%4S\!-APYY;X5&#Z>IB&0(F^/C_2[XV5Z=35\P,'C)4>:L2KDP8^2IE MQ[,NS_O [6):5GP$3@RC]7>3A$K^X9=A?@MYTAT&)5AU5^&*4*_@&D+(AGME #'Z5#I1]G_DE(CZ; M"%H8XZXD*-7@OSA[RAV!-0PKCR"4N&& >4)O/7:"X)L%^DL MD7A&0@!9J"K#X="3EJ<3W3'I.^8"&3AJ0V!95Y(/ G9(1"HEK%LBCE0]4A5) MEIST !4(7'.5\HYD("Q.I9<@?-#Q #C<"%VX1LT/H==$24*($"NF6[5.R::/ M)/#@:2%3N9,7K^##;)=AT(R3Y7#%*\)1Z1T#=$3U2&E';DX[ M@D^BM>6D(''_:$AN8=IM.Q.O=NTV\UFO7G>:M8:G?/F>;/?.;WHMVO=T];) MHNUZ;]:Q>]OU"]"F]?$C55C4/W"UTL=,KUQMGU]T3NW.2;_9O6B@GNGXRQ$T.# "#7$:B M"7_$'D1T!>KB%QJ*@#FDF)'FQ)S#AFHQ%DDRV $C\PP8DQCL'87Q3CI<=ED% M<]=<#TUP>4M,Y$\.$5"4CDD M9$G")LJJ=3G:4;SUC.=DYG"<6F6PF3/EZ*Q.X2EJLKZ)U^E"K/FH:>=DD5B35A6 M[:31/SEK-)M=9,OMTTZ[V:N?7K3[H"V>]D[/[LVRGHI%]:K65TRGD?S8G8:; M=^Z?0Q\5!S!R59]2'FC.H[+3,CP)E9CJ4.@6IQ%G""T/JC_,5?$B#V)OQ\ # MCE!8A%I4=4HFRF0T>AJC(AV'1@ M?DIQI(1">7*N5'T&$^3\SN]A=!TR>[5HD?DMDNP0W&8A??8H^5,]*TD0,Q=H M 5Q3!V@+0PF5+#OMVI1C:3$%93PHX4A4(;WP3SFB&?D)%EL:M'/F#0G4,@^! MQ9\HU)_**Q;94++TFHP9%93F_.;$PTD^;$;DE>-4Y,\@UY!#%')^,_$'?FIU M$59:UIA.0@?GY ?$Z6!$G56,;H_8P;UBLG]YDF6LL2%TJHZ?A:F,@@_ MAWA%.4YY]85Q +B%B;I=RT+Q="5YNMSK%64&"UQD*%$((S1W[9-_<>;QI%$7 M*Z@ND'8NK#*%$C+!Q5!K%A'R_#R4WAJH?;*:<-?RDXF=KVL\YK"&WN(H5%YZ86HIYF]A@QK%>LU!L^\9+Q-U2W1!S('&P7WW@+"F MLR"Z]10XB.LG\5QK-IX#_#CS5&L\%)D!W>3<*%QUU#75;(;B\)RVS]]) M;6'H.K&;9-[\2LY/GWK#21@%T5@U!$@JN9@1.BZEI+A"NK1.'1=.7R37BDI( M"H";5)T>/%DO#1D@AS]L=2'P2B=,8,04[+GGM%+M[#"%);3K!GC!MD3&"Q)=G '(=Y:E1E M#7=A /WW%LAXG.^ 5+@R!4V(S%7*CW0%^E'H%FHMO,(#[RX%R'-WQ][:SR0P MB -F:YZFH"-(BG@>1A%W^HHJRW"YF>T[FR:-/R6/%Y$XD6T?%NBLCM9R-VJ<4$-WKTD$L$AFIF\R&(J!?(I=^+SYYR@+F-#5E7H#.8. MI0Q@T; 5M;Y8]"58D.6-_>&J%=4+R8^5NL>_%M()&=G'+8#BI'7 D00.B8%:-(["&,H0UYM5J/>]/+";. M&V@"0-4,3Y2D]SAP>#1\_6[EBEDG-&&V8>)PQ (Y ->S6KH%GY:#:,P%087! MC6[S2I(IK5#]DM%I\#%]A"N9'H)X-!7C(/ *R"J9"B'YZ$0'^5VNW#6*69!6(^!M0/.FK&!FS& M-=6*/:9\?C:#3O,]7?:\$C2/_ ^D^PXXR*K RD>GW+H#)6^O5X6*E!:Y?+- MEF/@#9TIBW%,Z?5='[DG>QQ81@#/==Y7/13%-9]SLK"_)"#7L>">#,U?XH0$MP,R>3:1_"!Q M4B)2SY57428W7F^XC2_G,R7\8%)?XNCF-O,!BUM#\DKK&EB+(\):M05M'"PR M KV4:$;$?4F2Q,#()!\9/0]^I=!$IL5CD@@%0M%L4SXVA2.I R!&3A'ZL%Q8 MCS'Y)7(+E[4I&J#EYN)*5\R'@ MPT&1P&+NGT/0 .4%*Z(Y7IAC@^MC@94' 3"9^1%BW(@I%GA.G!UPJI+,O#F, M49;Q>3[D"Y(]H0BFPH::AR+Y#*86J5:/8P+]6'!'^$DR)T290!RA$6OA?@92 M3%E^0UH\9/I[+C+_6LI]5>8[S!]!$'09(+;?ANV,2&4UW+U)4?B;$G(K"HR' M([<$ZY4Y9SB&*;:!&!T>[N>08R9CE!&A%%$HQ]AL/@A0,9[#J%7!T&\H3T*L M2 75+W;F;H7;@Z_?%Q,LB,>G7T*]RF9DX>A^0-0=^S8?ADW$THLH'58GQN;\ M>##"7K%%*LZ MX2^83" .J(6J?ZG3.^AI95=&40NO/%M MQ7"QD?,3*Z6T(:,30D>$6G*)1W&J=U!FI\H\I= O4"6 N*6W"I% ;QT^C<(U MY#1&-2J^S=$>+F\0#0:W8C:H).5L?[6+>&6*%A+GE1]'1)$*I(ZA5&^5NW&! MP@BX2 _B,%Q^['.X,;B"&30@ZQJM9S&ZDB0:7#H:(NU;NC+P$RFLCDLD/&:/HD M5Z^D4(3=.ER+37%MJ\B1NYQV9%1S+V^\D2\ TQ.?&$@\BG!QG6P>8?G^YY$V M8V"6!5#;)&"LG,;+LGFY5T)QM K+8F+&_A **=0J&3I J(2CH/2>A8>17BAY MQ@632M9P&;/0X;X^JA59;\IM*2YGPISC\"D9N=%(>__,T-..W5H&J\(Z6C#; MGTSL("EGO?(8W4CZRMPJ'5(U\,"F,HHN,Y??8LSNBOK2)@8\DD)<4!I#'NPP M?S\[U^GU6T*/[+XVLZ V^'H!@L8A9O?&KK85Q(W5YT753<^R.!6%U6GQ?_+? MPJTC(.=C2N0!.>RC.H6UT>B717X31##:7K8Y2WFA6549-TW9KF=M?5N0'MI8 MF-GZJ8'R&@44V%@D/LZN6#^]^6R;3HF-UK8-<5ED+>XPF6XR/ZI,#'POY(H) MJN3+X1V(!Y0DL $[M/1,:=J12((#N5;!,B)1)F6%(2Z43R5E<@AS&H0^F0J) M0202MQJ5D:'MD[R'LXXR2?@C-O0T^L1\,&S:1*7:4LH!^5-)&Q$N@1-?OE[] MZH>N-X"!(.,N?*BADLRHE0PJ"J$+%ZM'X!($7/V8Q9;@]SQ3,?(PLF50,L[U M1@[ZM;-RT.432[(?L][B1,M4[77UA@$!9 ?Y!GC^= J/87&)CE;BA\ZM1K*C M.)&6X$P!H!FX8T+3X59')M0F,V,)I)*2IK&G"D=-BTC)6(^,K+WD+1PKS#E"_&Z//!/N^JPPE%'(_XOK7Z8\H%FD% M(PI(&4VEZ1>-;,V#:NI!]$0#M<%P7,A]1OW'X#8+0C%H#M;EQA0"(!L=)!YU MSQ['/C!ACZ#=",NX<&FI, ,=L)55>,]K"7048+]"Q;ON!G#2!0_1Z&W37>W)UC6P=M%*N!C_X6] MLY]5@W:*;Y%PNT3AMD>+G)DN+;)DZ()U% +&0N*@/=K35'4AQ9R4T)SAA'$6N2 M9_,XF3NA((SQ'>(PT[A0!QIQ;I<1YSV*.#_:.55E89?'MO73A1]@Y6%52FP: MC6.[VVXW6V^5!^&:()#(^C +#Z00%7-AX'EM)5H C!Y.@NI6S=I%=H,;B+9QTX@YR MW/6%./0W,!Y@*A@/I$L% 8IZD8QC+'&8Y=AM[@%LQ!#K@.<@I+!8\J &(1W# MPA"4+O5=E&%3R@M&Q#1@/+(Q/TE4ODL>W_B-7<@YGC8ZL21#C&J#:#%3$=4QFRLO3Q$6]:M:KVTQ#\CI9"2^8D]J]/5<*P M'F=3$?]BK$*&L?S*1O.$!-[2V\P7)%C0E5AGQPT,Q8(2[@A\$*C7*24(B'@0ZI8$=ZJ_!]B=@ZE$BA125':/4TU?G7\!P%4UUHR:HS M##(GBE2+N)C+8HE!KP+O*MM$?X(1D(^2(_6T$A*6QPMUM)Z++!&X24;RZ=R$.6IZG"B\L[+N44+9.P93J MU6Y&(2K>MD2SH"9X"\,@Z$6]7%*A8?U&Q]%A]W'I M$/Z=(\.B+;.-,R]$]X"5?9+(FU'-('8LDM:O5'_#_HX*R/MA583\3CI7U.$L M;AD4D]7$C"378P^] M()!??SZJ'=%G&.90?2Z8_S=_"CK4[]ZU]36:.N'B:*]]-YV\[W:K[5JW<=+Z M\<, L9WCXV$4!,XL\=ZK/Y;V!0<%IR!%IP8.(OSYB"#X4A?_%>M?94S\(MO^ M\8.Z:.FWU3\U.ZM_:Z]Y8GWU;VN>:#>SWPIF0M;VT ED,5B=4^NF(IZS&XMP MNJP?:O3/AQPAU!=T/_.S/,'\BG0K^D;>(O9C]@>AJ[R>^"]2V"Q;- MZN\"T\RO8+DXY>(\<'$T^V@>/62AEF?QY MEL$2Z?R>)'XO]#M&/$E%"@!F_ M+UC*E\NJ'B-_9J%#!TOUE4+]\4<01M62-QPXXWQ\*CK+@$3W=L&>G$=B!+-< M#;T:$L4M5V0M\W_-"W+!35[/0*G82(^ V3WVU'?CQ[5K57N#;7^,N>V%X'RL MC5OCL*(]=;%E%"5.O:?D"'1Z? "]/XK?TU&ZN,B[>3P^L=J9-4G3V?MW[ZZO MKZMP674<7;WKQ<,)PA2]\]RQ$[]SG=1Y9S?KG4:C_0Z>:-NU9KO5M;NUQDFW M??+.L;O'=KW6;/V][MW47;LZ2:<;P-+HM&)JZ!9P@$/5TW%"@R.P[J''^U-O MJPC"0# $IQ'"CIF! [X2HP=&0;[Q+;_.P8990Q6$N)P/.-ZP[(1;NS/;.XZ? M[0SMG#]TCO_K4*<&1^"XT6ZU.XL/:=3XT K>LG^_>N/V1V,V.W>P:$KOMW=@U%MD_B"YOU_YN_]VV&[6&_7":6RZW,R4W!_XE M!S8#E5\OM#%QDLJ14 \@$&PN8Y.H-*$T1=( DWNZ8,(E5AV9&;"8(56Q?J_V M^(D+V"X$0*/S61(JH,1MD5=QJ@N]^].[OO41\8WB_-O6:@H[/]KK0]Q/\;K# MD0BEHO)R)[A'1NCN<3KS65*'K:LT[*K]?_9D)P]:67ELY40^-VS[>.A%C5K] MA@!2-W()]'%)%#B02G_^HJ$CEOOS?C&*%W(=,(V.XDVLK-0],_$3*00]-YJA MHF(^XE(:/*R.7^]27,G)_"+B<7SF_/9C?(M7^]Q]>X1X>K)"L MDR'9K;6?RY"T.]:?UX4B##B4B"^4H9:SN]ES^^P!&*]%(@' M)1#):GQ4@;C>:BP%8LE0R_F]JOD=D$"T:W;UX^^7KW 37_[>_;_3KY^LCR&B M=@T]RXV&^=*2Z^.3=1&$UOK60X\:;84"3\3LCT2HZ4.US.KYS?7LWOP,1(O_?I M%6[BR]^[0C$"\QA*^]12EI3S*^>WY_,[,%ER=G[Q"C?QY>]=H2QQO1%UCRE% M23F_J>O+T _<)6XT.<8DL;"N3 M=2N2KEO_]D.G;I]\2*P_YDZ<>G%P:WWUL&66I5JTVK7C/ZAU%M[U3[Y*]?.B M'IJZF=<(VXBD*??>- 36ZHY:6\]NG\"7]H(.R_F5\]N#^9&@>T?-@_3WBX=_ M73L]Z?ZU/$3C_MP:[6&+HZD3C_V0A^?,TTA]P?M#WTC?GUIMN_Y'C:/5^@6_ MHK%1^Z-N^R$-B9Y =5D$)N\\3&CPY25,R+/JFQOMV06UYT8T22/E\>?<[CT$\FKX9&RZ+9ET>C8 DFJ.<8U:U;@6 M57>D)\0C#8D$QN/43Q+=*5T>PDV8_:QUF)OK'89F(39Z'G$;$.K>[(T):#A, MK:GS'5Y#U;^+[Y8:6+O;:#! \93LSXH5+5V:0VWB>YH5RX^S1N+<&OK6&GNA M%SN!,5SRHL+-]SY]^_7\CS\_ M?ON?BO7Q]_[>&@>[B0UA@[?WP(1G*9:'QU9W)4K[RY_KZ>W[TA;*[]MS="]< MN,7>A:;Q+GEGG3GQ\-;Z#9[Z]$&LU\3^GWQ^.V<$OX-56K*"%[IYJXYY>0Y? MEC3^YJ=!>0I?ZBG,L&;_VQ\BYIZ7^*YJ/M:?^-YH&7WO-3KFNCMUS/W+?[P; M1.[M+__Z'^\FZ33XY?\#4$L! A0#% @ O8(I3W0"G>[!" X3D !H M ( ! &5X:&EB:70S,3$M8V5O,S R>#(P,3DN:'1M4$L! M A0#% @ O8(I3PQ"%\_)" 9CD !H ( !^0@ &5X M:&EB:70S,3(M8V9O,S R>#(P,3DN:'1M4$L! A0#% @ O8(I3V=E.X%A M!0 +1X !H ( !^A$ &5X:&EB:70S,C$M8V5O.3 V>#(P M,3DN:'1M4$L! A0#% @ O8(I3XK[@CMQ!0 71X !H M ( !DQ< &5X:&EB:70S,C(M8V9O.3 V>#(P,3DN:'1M4$L! A0#% @ MO8(I3ZDJ,Y/T#0 QY@ ! ( !/!T &AQ>2TR,#$Y,#*P :'%Y+3(P,3DP-S,Q7V-A;"YX;6Q02P$"% ,4 " "]@BE/!"#; M7PE# #53 , % @ %>1 :'%Y+3(P,3DP-S,Q7V1E9BYX M;6Q02P$"% ,4 " "]@BE/KO[]63.K "I70D % @ &9 MAP :'%Y+3(P,3DP-S,Q7VQA8BYX;6Q02P$"% ,4 " "]@BE/CA_)HUEM M "XIP4 % @ '^,@$ :'%Y+3(P,3DP-S,Q7W!R92YX;6Q0 M2P$"% ,4 " "]@BE/'0N97OBH 0":EQ4 % @ &)H $ J:'%Y+3(P,3EX-W@S,3$P<2YH=&U02P4& H "@"H @ LTD# end